

10/720,600

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	6	NOV 10	CA/CAPLUS F-Term thesaurus enhanced
NEWS	7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	8	NOV 20	CA/CAPLUS to MARPAT accession number crossover limit increased to 50,000
NEWS	9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	13	DEC 18	CA/CAPLUS pre-1967 chemical substance index entries enhanced with preparation role
NEWS	14	DEC 18	CA/CAPLUS patent kind codes updated
NEWS	15	DEC 18	MARPAT to CA/CAPLUS accession number crossover limit increased to 50,000
NEWS	16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	17	DEC 27	CA/CAPLUS enhanced with more pre-1907 records
NEWS	18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	19	JAN 16	CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS	20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	22	JAN 22	CA/CAPLUS updated with revised CAS roles
NEWS	23	JAN 22	CA/CAPLUS enhanced with patent applications from India
NEWS	24	JAN 29	PHAR reloaded with new search and display fields
NEWS	25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	26	FEB 13	CASREACT coverage to be extended
NEWS	27	Feb 15	PATDPASPC enhanced with Drug Approval numbers
NEWS	28	Feb 15	RUSSIAPAT enhanced with pre-1994 records
NEWS	29	Feb 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS	30	Feb 26	MEDLINE reloaded with enhancements
NEWS	31	Feb 26	EMBASE enhanced with Clinical Trial Number field
NEWS	32	Feb 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS	33	Feb 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS	34	Feb 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),

10/720,600

AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 07:45:00 ON 04 MAR 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 07:45:15 ON 04 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 2 MAR 2007 HIGHEST RN 924584-96-3

DICTIONARY FILE UPDATES: 2 MAR 2007 HIGHEST RN 924584-96-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10720600.str

10/720,600



chain nodes :  
10 11 12 13 17  
ring nodes :  
1 2 3 4 5 6 7 8 9  
chain bonds :  
2-11 4-10 9-17 10-12 12-13  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9  
exact/norm bonds :  
2-11 4-10 6-9 8-9 9-17 12-13  
exact bonds :  
5-7 7-8 10-12  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6  
isolated ring systems :  
containing 1 :

G1:H,CH3

Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS  
11:CLASS 12:CLASS 13:Atom 17:CLASS


10/720,600

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 H,Me

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 07:45:35 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 791 TO ITERATE

100.0% PROCESSED 791 ITERATIONS

36 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 14133 TO 17507

PROJECTED ANSWERS: 360 TO 1080


L2 36 SEA SSS SAM L1

=> d scan



10/720,600

L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-(2-quinolinyl)-  
3-piperidinyl]- (9CI)  
MF C22 H24 N6



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):29

10/720,600

L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-N-[2-[4-(1-methylethyl)-1-piperazinyl]ethyl]-  
(9CI)

MF C28 H35 N9 O S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/720,600

L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN Benzamide, 2-fluoro-N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidiny]sulfonyl]ethyl]- (9CI)


MF C22 H27 F N6 O3 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/720,600

L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN 3-Piperidinamine, 1-[(4-fluorophenoxy)acetyl]-N,4-dimethyl-N-1H-  
pyrrolo[2,3-d]pyrimidin-4-yl- (9CI)  
MF C21 H24 F N5 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/720,600

L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 1(2H)-Pyridinecarboxylic acid, 4-[4-[[2,6-bis(4-methyl-1-piperazinyl)-4-pyridinyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-,  
1,1-dimethylethyl ester (9CI)

MF C31 H44 N10 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/720,600

L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN Carbamic acid, methyl[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]-, phenylmethyl ester (9CI)

MF C24 H32 N6 O4 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/720,600

L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-(chloromethyl)phenyl]-N-[(6-methoxy-3-pyridinyl)methyl]- (9CI)


MF C20 H18 Cl N5 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/720,600

L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN 1(2H)-Pyridinecarboxylic acid, 4-[4-[[7-[2-(dimethylamino)ethyl]-1H-indazol-5-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-,  
1,1-dimethylethyl ester (9CI)  
MF C27 H34 N8 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*



10/720,600

L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN 3-Piperidinamine, N,4-dimethyl-1-(oxophenylacetyl)-N-1H-pyrrolo[2,3-  
d]pyrimidin-4-yl- (9CI)  
MF C21 H23 N5 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/720,600

L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN Pyridine, 1-[4-(dimethylamino)-1-oxobutyl]-1,2,3,6-tetrahydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI)


MF C24 H28 N8 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/720,600

L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Pyridine, 1,2,3,6-tetrahydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-  
d]pyrimidin-6-yl]-1-(4-pyridinylcarbonyl)- (9CI)  
MF C24 H20 N8 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/720,600

L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN Benzoic acid, 4-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-  
1-piperidinyl]methyl]- (9CI)


MF C21 H25 N5 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/720,600


L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Piperazine, 1-[[4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-1(2H)-pyridinyl]carbonyl]-4-ethyl- (9CI)  
MF C25 H28 N8 O S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/720,600


L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Carbamic acid, [3-[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidiny]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI)  
MF C21 H32 N6 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/720,600

L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN 3-Piperidinamine, N,4-dimethyl-1-[(2-methyl-4-thiazolyl)carbonyl]-N-1H-  
pyrrolo[2,3-d]pyrimidin-4-yl- (9CI)  
MF C18 H22 N6 O S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/720,600

L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-[3-(diethylamino)-1-oxopropyl]-1,2,3,6-tetrahydro- (9CI)

MF C25 H29 N7 O S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*




10/720,600

L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN


IN 3-Piperidinamine, 1-(3-azetidiny carbonyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-

MF C17 H24 N6 O . C2 H F3 O2

CM 1




CM 2



10/720,600

L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-[[4-(methylsulfonyl)phenyl]methyl]-3-piperidinyl]- (9CI)  
MF C21 H27 N5 O2 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/720,600

L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 1(2H)-Pyridinecarboxamide, 4-[4-[[7-[2-(dimethylamino)ethyl]-1H-indazol-5-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-(1,1-dimethylethyl)-3,6-dihydro- (9CI)

MF C27 H35 N9 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/720,600

L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 3-Piperidinamine, N,4-dimethyl-1-[(3-oxocyclopentyl)carbonyl]-N-1H-  
pyrrolo[2,3-d]pyrimidin-4-yl- (9CI)


MF C19 H25 N5 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/720,600

L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-(4-isoquinolinylamino)-1H-  
pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI)  
MF C25 H26 N6 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/720,600

L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 1(2H)-Pyridinecarboxamide, N-[1,1-dimethyl-2-(1-pyrrolidinyl)ethyl]-3,6-dihydro-4-[4-[(1-methyl-1H-indazol-5-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI)

MF C28 H35 N9 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/720,600

L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 1-Piperidinecarboxamide, 4-methyl-N-(5-methyl-3-isoxazolyl)-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI)


MF C18 H23 N7 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/720,600

L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN 1(2H)-Pyridinecarboxamide, N-(1,1-dimethylethyl)-3,6-dihydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI)  
MF C23 H26 N8 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*



10/720,600

L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN 3-Piperidinamine, 1-(butylsulfonyl)-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-  
4-yl- (9CI)  
MF C16 H25 N5 O2 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/720,600

L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 3-Piperidinamine, N,4-dimethyl-1-(oxo-1-pyrrolidinylacetyl)-N-1H-  
pyrrolo[2,3-d]pyrimidin-4-yl- (9CI)


MF C19 H26 N6 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/720,600

L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-  
1,2,3,6-tetrahydro-1-[(4-methyl-1-piperazinyl)acetyl]- (9CI)  
MF C25 H28 N8 O S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/720,600

L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN Cyclopropanecarboxamide, N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-  
d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]- (9CI)

MF C19 H28 N6 O3 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/720,600

L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 3-Piperidinamine, N,4-dimethyl-1-(3-nitro-1-oxopropyl)-N-1H-pyrrolo[2,3-  
d]pyrimidin-4-yl- (9CI)


MF C16 H22 N6 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/720,600

L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN 1(2H)-Pyridinecarboxylic acid, 4-[4-[[3-[2-(acetylamino)ethyl]imidazo[1,2-  
a]pyridin-6-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-,  
1,1-dimethylethyl ester (9CI)  
MF C27 H32 N8 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):39

10/720,600

L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN 3-Piperidinamine, 1-(cyclobutylcarbonyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-  
d]pyrimidin-4-yl- (9CI)  
MF C18 H25 N5 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/720,600

L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5,6-diphenyl-N-[(tetrahydro-2H-pyran-2-yl)methyl]- (9CI)

MF C24 H24 N4 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*




10/720,600

L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 1(2H)-Pyridinecarboxylic acid, 4-[4-[[7-[2-(dimethylamino)ethyl]-1-methyl-1H-indazol-5-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-,  
1,1-dimethylethyl ester (9CI)


MF C28 H36 N8 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/720,600


L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-[6-(methylamino)-4-pyrimidinyl]-3-piperidinyl]- (9CI)  
MF C18 H24 N8



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/720,600


L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-6-benzothiazolyl-6-(1,2,3,6-  
tetrahydro-4-pyridinyl)-, trihydrochloride (9CI)  
MF C18 H16 N6 S . 3 Cl H



● 3 HCl

10/720,600

L2 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN 7H-Pyrrolo[2,3-d]pyrimidine, 4-(methyl-2-pyridylamino)- (7CI)  
MF C12 H11 N5



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

10/720,600

=> s 11 sss ful

FULL SEARCH INITIATED 07:46:26 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 16380 TO ITERATE

100.0% PROCESSED 16380 ITERATIONS

787 ANSWERS

SEARCH TIME: 00.00.01

L3 787 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.55

172.76

FILE 'CAPLUS' ENTERED AT 07:46:34 ON 04 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Mar 2007 VOL 146 ISS 11

FILE LAST UPDATED: 2 Mar 2007 (20070302/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13

L4 41 L3

=> s 14 and (organ(1)trnasplant(1)rejection)

129168 ORGAN



0 TRNASPLANT

36009 REJECTION

0 ORGAN(L)TRNASPLANT(L)REJECTION

L5 0 L4 AND (ORGAN(L)TRNASPLANT(L)REJECTION)

=> d 14 1-41 bib hitstr



chain nodes :

10 11 12 13 17

ring nodes :

1 2 3 4 5 6 7 8 9

chain bonds :

2-11 4-10 9-17 10-12 12-13

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9

exact/norm bonds :

2-11 4-10 6-9 8-9 9-17 12-13

exact bonds :

5-7 7-8 10-12

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

G1:H,CH3

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS11:CLASS12:CLASS  
13:Atom 17:CLASS




10/720,600

L4 ANSWER 1 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2007:117374 CAPLUS  
DN 146:206328  
TI Process for preparation of piperidinylaminopyrrolopyrimidines from  
activated pyrrolopyrimidines and piperidinylamines.  
IN Ruggeri, Sally Gut; Hawkins, Joel Michael; Makowski, Teresa Margaret;  
Rutherford, Jennifer Lea; Urban, Frank John  
PA Pfizer Products Inc., USA  
SO PCT Int. Appl., 33pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007012953	A2	20070201	WO 2006-IB2048	20060717
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	JP 2007039455	A	20070215	JP 2006-206218	20060728
PRAI	US 2005-704011P	P	20050729		
IT	477600-73-0P 477600-74-1P				
	RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of piperidinylaminopyrrolopyrimidines from activated pyrrolopyrimidines and piperidinylamines)				
RN	477600-73-0 CAPLUS				
CN	1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[(3R,4R)-4-methyl-1-(phenylmethyl)-3-piperidinyl]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




RN 477600-74-1 CAPLUS  
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[(3R,4R)-4-methyl-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/720,600



IT 477600-75-2P 540737-29-9P


RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of piperidinylaminopyrrolopyrimidines from activated pyrrolopyrimidines and piperidinylamines)

RN 477600-75-2 CAPLUS

CN 3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 540737-29-9 CAPLUS

CN 3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-, (3R,4R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 477600-75-2

CMF C16 H20 N6 O

Absolute stereochemistry.


10/720,600



CM 2

CRN 77-92-9

CMF C6 H8 O7



10/720,600

L4 ANSWER 2 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:1357142 CAPLUS

DN 146:75599

TI Use of GIP, vitamin D3, or their analogs for enhancing stem or progenitor cell differentiation into insulin producing cells

IN Austen, Matthias; Burk, Ulrike

PA Develogen Aktiengesellschaft, Germany

SO PCT Int. Appl., 39pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006136374	A2	20061228	WO 2006-EP5912	20060620
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	EP 2005-13255	A	20050620		
	EP 2005-15366	A	20050714		
	EP 2005-22528	A	20051014		
IT	477600-75-2, CP-690550				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(addnl. therapeutic agent; use of GIP, vitamin D3, or their analogs for enhancing stem or progenitor cell differentiation into insulin producing cells)				
RN	477600-75-2 CAPLUS				
CN	3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-, (3R,4R)- (9CI) (CA INDEX NAME)				


Absolute stereochemistry.



10/720,600

L4 ANSWER 3 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2006:1352280 CAPLUS  
DN 146:198229  
TI Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy  
AU Rousvoal, Geraldine; Si, Ming-Sing; Lau, Macy; Zhang, Sally; Berry, Gerald  
J.; Flores, Mona G.; Changelian, Paul S.; Reitz, Bruce A.; Borie, Dominic  
C.  
CS Transplantation Immunology Laboratory, Department of Cardiothoracic  
Surgery, Falk Cardiovascular Research Center, Stanford University School  
of Medicine, Stanford, CA, USA  
SO Transplant International (2006), 19(12), 1014-1021  
CODEN: TRINE5; ISSN: 0934-0874  
PB Blackwell Publishing Ltd.  
DT Journal  
LA English  
IT 477600-75-2, CP-690550  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(CP-690 and 550 inhibit Janus kinase 3 and prevented allograft  
vasculopathy in rat model of aorta transplantation)  
RN 477600-75-2 CAPLUS  
CN 3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-  
d]pyrimidin-4-yl-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/720,600

L4 ANSWER 4 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2006:1176630 CAPLUS  
DN 145:489215  
TI Azapaulones as immunomodulators, their preparation, pharmaceutical compositions, and use for preventing and treating pancreatic autoimmune disorders  
IN Mussmann, Rainer; Kunick, Conrad; Stukenbrock, Hendrik; Geese, Marcus; Kegel, Simone; Burk, Ulrike  
PA Develogen Aktiengesellschaft, Germany; Technische Universitaet Carolo-Wilhelmina zu Braunschweig  
SO PCT Int. Appl., 83pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006117221	A1	20061109	WO 2006-EP4186	20060504
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	EP 2005-9846	A	20050504		
	EP 2005-15986	A	20050722		
	EP 2005-23168	A	20051024		
	EP 2006-1327	A	20060123		
OS	MARPAT 145:489215				
IT	477600-75-2, CP-690550				
	RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(preparation of azapaulones for treatment and prevention of pancreatic autoimmune disorders)				
RN	477600-75-2 CAPLUS				
CN	3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-, (3R,4R)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/720,600

10/720,600

L4 ANSWER 5 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2006:1176629 CAPLUS  
DN 145:483725  
TI Use of GSK-3 inhibitors for preventing and treating pancreatic autoimmune disorders  
IN Mussmann, Rainer; Austen, Matthias; Kelter, Arndt-Rene; Harder, Friedrich; Aicher, Babette; Lomow, Alexander  
PA Develogen Aktiengesellschaft, Germany  
SO PCT Int. Appl., 84pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006117212	A2	20061109	WO 2006-EP4170	20060504
	WO 2006117212	A3	20070215		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	EP 1728873	A1	20061206	EP 2005-11599	20050530
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			
PRAI	EP 2005-9846	A	20050504		
	EP 2005-11599	A	20050530		
	EP 2005-15986	A	20050722		
	EP 2005-23168	A	20051024		
OS	MARPAT 145:483725				
IT	477600-75-2, CP-690550				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(use of GSK3 inhibitors for preventing and treating pancreatic autoimmune disorders)				
RN	477600-75-2 CAPLUS				
CN	3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-, (3R,4R)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



10/720,600



10/720,600


L4 ANSWER 6 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2006:513675 CAPLUS  
DN 145:34151  
TI Combinations of JAK kinase inhibitors  
IN Cooke, Nigel Graham; Manley, Paul W.  
PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.  
SO PCT Int. Appl., 61 pp.  
CODEN: PIXXD2

DT Patent  
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006056399	A2	20060601	WO 2005-EP12480	20051122
	WO 2006056399	A3	20060831		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2004-630713P	P	20041124		
IT	477600-75-2, CP 690550				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(combinations of JAK kinase inhibitors with other protein kinase inhibitors for treatment or prevention of proliferative disease)				
RN	477600-75-2 CAPLUS				
CN	3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-, (3R,4R)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



L4 ANSWER 7 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:152715 CAPLUS

DN 144:233089

TI Preparation of aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds as antiproliferative, particularly antitumor agents

IN Ahmed, Saleh; Barba, Oscar; Bloxham, Jason; Dawson, Graham; Gattrell, William; Kitchin, John; Pegg, Neil Anthony; Saba, Imaad; Shadiq, Shazia; Smith, Colin Peter Sambrook; Smyth, Don; Steinig, Arno G.; Wilkes, Robin; Foreman, Kenneth; Weng, Qinghua Felix; Stolz, Kathryn; Tavares, Paula; Panicker, Bijoy; Li, An-Hu; Dong, Hanqing; Ma, Lifu; Cox, Matthew

PA Osi Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 253 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006017443	A2	20060216	WO 2005-US27274	20050801
	WO 2006017443	A3	20070118		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2006211678	A1	20060921	US 2005-194158	20050801
---------------	----	----------	----------------	----------

PRAI US 2004-598173P P 20040802

US 2005-698516P P 20050712


OS MARPAT 144:233089

IT 876339-20-7P, 4-[4-[(1H-Indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 876339-21-8P, (1H-Indazol-5-yl)[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine trihydrochloride 876339-55-8P, (Benzothiazol-6-yl)[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine trihydrochloride 876339-56-9P, 3-[[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]carbonyl]benzoic acid methyl ester 876339-86-5P, 6-[1-(3-Hydroxy-2,2-dimethylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]-N-(1,3-benzothiazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine 876340-03-3P, [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl](1-hydroxymethylcyclopropyl)methanone 876340-20-4P, 4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid 4-nitrophenyl ester 876340-31-7P, [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]piperazin-1-ylmethanone 876340-68-0P, 4-[4-[(3-Chloro-1H-indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 876340-70-4P, 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-2-chloroethanone 876340-84-0P, 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-3-chloropropan-1-one 876340-85-1P, 1-[4-[4-[(Benzothiazol-6-

yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]propenone 876341-16-1P, 4-[4-[(6-Methoxypyridin-3-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 876341-18-3P, 4-[4-[(1-Methyl-6-oxo-1,6-dihydropyridin-3-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 876341-59-2P, tert-Butyl 4-[4-[(benzothiazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylate 876341-60-5P, 4-[4-[(3-Methyl-1H-indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 876341-62-7P, (3-Methyl-1H-indazol-5-yl)[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine trihydrochloride 876341-66-1P, 4-[4-[(1-Methyl-1H-indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 876341-67-2P, (1-Methyl-1H-indazol-5-yl)[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine trihydrochloride  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidate; preparation of pyrrolopyrimidines multi-kinase inhibiting compds. as antitumor agents)

RN 876339-20-7 CAPLUS


CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 876339-21-8 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-1H-indazol-5-yl-6-(1,2,3,6-tetrahydro-4-pyridinyl)-, trihydrochloride (9CI) (CA INDEX NAME)


10/720,600



● 3 HCl

RN 876339-55-8 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-6-benzothiazolyl-6-(1,2,3,6-tetrahydro-4-pyridinyl)-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 876339-56-9 CAPLUS


CN Benzoic acid, 3-[[4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-1(2H)-pyridinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 876339-86-5 CAPLUS


CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1,2,3,6-tetrahydro-1-(3-hydroxy-2,2-dimethyl-1-oxopropyl)- (9CI) (CA INDEX NAME)

10/720,600




RN 876340-03-3 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1,2,3,6-tetrahydro-1-[[1-(hydroxymethyl)cyclopropyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 876340-20-4 CAPLUS


CN 1(2H)-Pyridinecarboxylic acid, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 4-nitrophenyl ester (9CI) (CA INDEX NAME)



RN 876340-31-7 CAPLUS


CN Piperazine, 1-[[4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-1(2H)-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)

10/720,600




RN 876340-68-0 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[(3-chloro-1H-indazol-5-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI)  
(CA INDEX NAME)




RN 876340-70-4 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-(chloroacetyl)-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)




RN 876340-84-0 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-(3-chloro-1-oxopropyl)-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)




RN 876340-85-1 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1,2,3,6-tetrahydro-1-(1-oxo-2-propenyl)- (9CI) (CA INDEX NAME)



RN 876341-16-1 CAPLUS


CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-[(6-methoxy-3-pyridinyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 876341-18-3 CAPLUS


CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[(1,6-dihydro-1-methyl-6-oxo-3-pyridinyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/720,600




RN 876341-59-2 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-(5-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME).



RN 876341-60-5 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-[(3-methyl-1H-indazol-5-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 876341-62-7 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-methyl-1H-indazol-5-yl)-6-(1,2,3,6-tetrahydro-4-pyridinyl)-, trihydrochloride (9CI) (CA INDEX NAME)




10/720,600



● 3 HCl


RN 876341-66-1 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-[(1-methyl-1H-indazol-5-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI)  
(CA INDEX NAME)



RN 876341-67-2 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(1-methyl-1H-indazol-5-yl)-6-(1,2,3,6-tetrahydro-4-pyridinyl)-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

IT 876338-77-1P 876338-85-1P 876338-86-2P

876338-97-5P 876338-98-6P 876339-01-4P  
876339-02-5P 876339-03-6P 876339-05-8P  
876339-07-0P 876339-08-1P 876339-10-5P  
876339-11-6P 876339-13-8P 876339-17-2P  
876339-22-9P, (1H-Indazol-5-yl)[6-(1-methylsulfonyl-1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine  
876339-23-0P, 2-Dimethylamino-1-[4-[4-[(1H-indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]ethanone  
876339-24-1P, 1-[4-[4-[(1H-Indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]ethanone  
876339-25-2P, 2,2,2-Trifluoro-1-[4-[4-[(1H-indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]ethanone  
876339-26-3P, 4-[4-[(1H-Indol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 876339-27-4P 876339-28-5P 876339-29-6P  
876339-30-9P 876339-31-0P 876339-32-1P  
876339-33-2P 876339-34-3P 876339-35-4P  
876339-36-5P 876339-37-6P 876339-38-7P  
876339-39-8P, [6-[1-(2-Chloropyrimidin-4-yl)-1,2,3,6-tetrahydropyridin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl](1H-indazol-5-yl)amine 876339-40-1P 876339-41-2P  
876339-42-3P 876339-43-4P 876339-44-5P  
876339-45-6P 876339-46-7P 876339-47-8P  
876339-48-9P 876339-49-0P 876339-50-3P  
876339-51-4P 876339-52-5P, 4-[4-[(1H-Indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]piperidine-1-carboxylic acid tert-butyl ester 876339-53-6P, 4-[4-[(1H-Indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-(2-methoxyethyl)-1H-pyridin-2-one  
876339-57-0P, 3-[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]carbonylbenzoic acid  
876339-58-1P, 1-[4-[4-[(1H-Indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-2-phenylethanone  
876339-59-2P, Phenyl 4-[4-[(1H-indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylate  
876339-60-5P, N-Methyl-N-phenyl-4-[4-[(1H-indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxamide  
876339-61-6P, N-Phenyl 4-[4-[(1H-Indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxythioamide  
876339-62-7P, N-(tert-Butyl) 4-[4-[(1H-indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxamide  
876339-63-8P, N-Ethyl 4-[4-[(1H-indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxamide  
876339-64-9P, 4-[4-[(1H-Indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid  
N-(2-fluorophenyl)amide 876339-65-0P, 4-[4-[(1H-Indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid N-(3-fluorophenyl)amide 876339-66-1P, 4-[4-[(1H-Indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid N-(4-fluorophenyl)amide 876339-67-2P, 4-[4-[(1H-Indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid N-(2-methoxyphenyl)amide  
876339-68-3P, 4-[4-[(1H-Indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid  
N-(3-methoxyphenyl)amide 876339-69-4P, 4-[4-[(1H-Indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid N-(4-methoxyphenyl)amide 876339-70-7P, 4-[4-[(1H-Indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid phenylamide 876339-71-8P, 4-[4-[(1H-Indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid benzylamide 876339-72-9P, 4-[4-[(1H-Indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-

2H-pyridine-1-carboxamide 876339-73-0P, 4-[4-[(1H-Indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid N-(pyridin-3-yl)amide 876339-74-1P, N-(2-Pyridinyl) 4-[4-[(1H-indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxamide 876339-75-2P, N-(4-Pyridinyl) 4-[4-[(1H-indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxamide 876339-76-3P, 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-2-(pyridin-3-yl)ethanone 876339-77-4P, 4-[4-[(1,3-Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-(4-fluorophenyl)-3,6-dihydropyridine-1(2H)-carboxamide 876339-78-5P, 4-[4-[(1,3-Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-(2-fluorophenyl)-3,6-dihydropyridine-1(2H)-carboxamide 876339-79-6P, 4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid phenylamide 876339-80-9P, 4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxamide 876339-81-0P, 4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butylamide 876339-82-1P, 4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid isopropylamide 876339-83-2P 876339-84-3P, 4-[4-[(1,3-Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-N,N-dimethyl-3,6-dihydropyridine-1(2H)-carboxamide 876339-85-4P, 6-[1-[4-(Dimethylamino)butanoyl]-1,2,3,6-tetrahydropyridin-4-yl]-N-(1,3-benzothiazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine 876339-87-6P, 6-[1-[2,2-Dimethyl-3-oxopropanoyl]-1,2,3,6-tetrahydropyridin-4-yl]-N-(1,3-benzothiazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine 876339-88-7P, 6-[1-[2,2-Dimethyl-3-(4-methylpiperazin-1-yl)propanoyl]-1,2,3,6-tetrahydropyridin-4-yl]-N-(1,3-benzothiazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine 876339-89-8P, 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-3-chloro-2,2-dimethylpropan-1-one 876339-90-1P, 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-2,2-dimethyl-3-(pyrrolidin-1-yl)propan-1-one 876339-91-2P, 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-3-diethylamino-2,2-dimethylpropan-1-one 876339-92-3P, 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-3-tert-butylamino-2,2-dimethylpropan-1-one 876339-93-4P, 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-3-dimethylamino-2,2-dimethylpropan-1-one 876339-94-5P, 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-3-(3-hydroxypyrrolidin-1-yl)-2,2-dimethylpropan-1-one 876339-95-6P, 3-(Azepan-1-yl)-1-[4-[4-[(benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-2,2-dimethylpropan-1-one 876339-96-7P, 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-3-(4-hydroxypiperidin-1-yl)-2,2-dimethylpropan-1-one 876339-97-8P, 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-3-(4-isopropylpiperazin-1-yl)-2,2-dimethylpropan-1-one 876339-98-9P, 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-2,2-dimethyl-3-(morpholin-4-yl)propan-1-one 876339-99-0P, 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-3-(4,4-difluoropiperidin-1-yl)-2,2-dimethylpropan-1-one 876340-00-0P, 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-3-(3,5-dimethylpiperazin-1-yl)-2,2-dimethylpropan-1-one 876340-01-1P, 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-2-(2-methoxyethoxy)ethanone

876340-02-2P, [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl](morpholin-4-yl)methanone  
 876340-04-4P, [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl][1-[(piperidin-1-yl)methyl]cyclopropyl]methanone 876340-05-5P,  
 [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl][1-[(4-methylpiperazin-1-yl)methyl]cyclopropyl]methanone 876340-06-6P,  
 [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl][1-[(pyrrolidin-1-yl)methyl]cyclopropyl]methanone  
 876340-08-8P, [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl][1-[(diethylamino)methyl]cyclopropyl]methanone 876340-10-2P,  
 [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl][1-[(tert-butylamino)methyl]cyclopropyl]methanone  
 876340-12-4P, [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl][1-[(dimethylamino)methyl]cyclopropyl]methanone 876340-13-5P,  
 [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl][1-[(3-hydroxypyrrolidin-1-yl)methyl]cyclopropyl]methanone 876340-14-6P,  
 [1-[(Azepan-1-yl)methyl]cyclopropyl][4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]methanone  
 876340-15-7P, [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl][1-[(4-hydroxypiperidin-1-yl)methyl]cyclopropyl]methanone 876340-16-8P,  
 [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl][1-[(4-isopropylpiperazin-1-yl)methyl]cyclopropyl]methanone 876340-17-9P,  
 [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl][1-[(morpholin-4-yl)methyl]cyclopropyl]methanone  
 876340-18-0P, [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl][1-[(4,4-difluoropiperidin-1-yl)methyl]cyclopropyl]methanone 876340-19-1P,  
 [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl][1-[(3,5-dimethylpiperidin-1-yl)methyl]cyclopropyl]methanone 876340-21-5P,  
 4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid (2-dimethylaminoethyl)amide  
 876340-22-6P, 4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid (2-diethylaminoethyl)amide 876340-23-7P, 4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid (2-isopropylaminoethyl)amide 876340-24-8P,  
 4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid [2-(piperazin-1-yl)ethyl]amide  
 876340-25-9P, 4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid [2-(diisopropylamino)ethyl]amide 876340-26-0P,  
 4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid (2-methoxyethyl)amide  
 876340-27-1P, 4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid N,N-bis(2-methoxyethyl)amide 876340-28-2P, 4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid [2-(piperidin-1-yl)ethyl]amide 876340-29-3P,  
 4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid [2-(morpholin-4-yl)ethyl]amide  
 876340-30-6P, 4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid [2-(pyrrolidin-1-yl)ethyl]amide 876340-32-8P,

[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl](4-ethylpiperazin-1-yl)methanone 876340-33-9P, [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl](4-isopropylpiperazin-1-yl)methanone 876340-34-0P, [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl](3,5-dimethylpiperazin-1-yl)methanone 876340-35-1P, [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl](4-cyclopentylpiperazin-1-yl)methanone 876340-36-2P, [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl](1-methylazepan-4-yl)methanone 876340-37-3P, [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl][4-(2-methoxyethyl)piperazin-1-yl]methanone 876340-38-4P, [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl][4-(2-dimethylaminoethyl)piperazin-1-yl]methanone 876340-39-5P, 4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid N-methyl-N-(1-methylpiperidin-4-yl)amide 876340-40-8P, [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]thiomorpholin-4-ylmethanone 876340-41-9P, [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl](cis-2,6-dimethylmorpholin-4-yl)methanone 876340-42-0P, [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl](4-hydroxypiperidin-1-yl)methanone 876340-43-1P, [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl](3-hydroxypyrrolidin-1-yl)methanone 876340-44-2P, 4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid diethylamide 876340-45-3P, (Azetidin-1-yl)[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]methanone 876340-46-4P, [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]pyrrolidin-1-ylmethanone 876340-47-5P, [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl](4,4-difluoropiperidin-1-yl)methanone 876340-48-6P, [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl](4-propylpiperazin-1-yl)methanone 876340-49-7P, [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl](4-isobutylpiperazin-1-yl)methanone 876340-50-0P, [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl][4-(1-ethylpropyl)piperazin-1-yl]methanone 876340-51-1P, [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl](4-cyclobutylmethylpiperazin-1-yl)methanone 876340-52-2P, 4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid (2-bromoethyl)amide 876340-53-3P, 4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid [2-(4-methylpiperazin-1-yl)ethyl]amide 876340-54-4P, 4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid (2-tert-butylaminoethyl)amide 876340-55-5P, 4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid [2-(3-hydroxypyrrolidin-1-yl)ethyl]amide 876340-56-6P, 4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid [2-(azepan-1-yl)ethyl]amide 876340-57-7P, 4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid [2-(4-hydroxypiperidin-1-yl)ethyl]amide 876340-58-8P, 4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-

d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid  
 [2-(4-isopropylpiperazin-1-yl)ethyl]amide 876340-59-9P,  
 4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-  
 dihydro-2H-pyridine-1-carboxylic acid [2-(4,4-difluoropiperidin-1-  
 yl)ethyl]amide 876340-60-2P, 4-[4-[(Benzothiazol-6-yl)amino]-7H-  
 pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid  
 [2-(3,5-dimethylpiperazin-1-yl)ethyl]amide 876340-61-3P,  
 (Benzothiazol-6-yl)[6-[1-(3-chloropropyl)-1,2,3,6-tetrahydropyridin-4-yl]-  
 7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine 876340-62-4P,  
 (Benzothiazol-6-yl)[6-[1-[3-(4-methylpiperazin-1-yl)propyl]-1,2,3,6-  
 tetrahydropyridin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine  
 876340-63-5P, (Benzothiazol-6-yl)[6-[1-[3-(piperidin-1-yl)propyl]-  
 1,2,3,6-tetrahydropyridin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine  
 876340-64-6P, 4-[4-[(1-Ethyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-  
 d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl  
 ester 876340-65-7P, 4-[4-[(1-Phenethyl-1H-pyrazol-3-yl)amino]-7H-  
 pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid  
 tert-butyl ester 876340-66-8P, 4-[4-[(1-Phenethyl-1H-pyrazol-4-  
 yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-  
 carboxylic acid tert-butyl ester 876340-69-1P,  
 1-[4-[4-[(3-Chloro-1H-indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-  
 3,6-dihydro-2H-pyridin-1-yl]-3-(piperidin-1-yl)propan-1-one  
 876340-71-5P, 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-  
 d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-2-(4-methylpiperazin-1-  
 yl)ethanone 876340-72-6P, 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-  
 pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-2-(pyrrolidin-1-  
 yl)ethanone 876340-73-7P, 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-  
 pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-2-  
 diethylaminoethanone 876340-74-8P, 1-[4-[4-[(Benzothiazol-6-  
 yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-2-  
 (piperidin-1-yl)ethanone 876340-75-9P, 1-[4-[4-[(Benzothiazol-6-  
 yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-2-  
 tert-butylaminoethanone 876340-76-0P, 1-[4-[4-[(Benzothiazol-6-  
 yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-2-  
 dimethylaminoethanone 876340-77-1P, 1-[4-[4-[(Benzothiazol-6-  
 yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-2-  
 (3-hydroxypyrrolidin-1-yl)ethanone 876340-78-2P,  
 2-(Azepan-1-yl)-1-[4-[4-[(benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-  
 d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]ethanone  
 876340-79-3P  
 , 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-  
 dihydro-2H-pyridin-1-yl]-2-(4-hydroxypiperidin-1-yl)ethanone  
 876340-80-6P, 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-  
 d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-2-(4-isopropylpiperazin-1-  
 yl)ethanone 876340-81-7P, 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-  
 pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-2-(morpholin-4-  
 yl)ethanone 876340-82-8P, 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-  
 pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-2-(4,4-  
 difluoropiperidin-1-yl)ethanone 876340-83-9P,  
 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-  
 dihydro-2H-pyridin-1-yl]-2-(3,5-dimethylpiperazin-1-yl)ethanone  
 876340-86-2P, 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-  
 d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-3-(4-methylpiperazin-1-  
 yl)propan-1-one 876340-87-3P, 1-[4-[4-[(Benzothiazol-6-yl)amino]-  
 7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-3-  
 (pyrrolidin-1-yl)propan-1-one 876340-88-4P, 1-[4-[4-  
 [(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-  
 pyridin-1-yl]-3-diethylaminopropan-1-one 876340-89-5P,  
 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-  
 dihydro-2H-pyridin-1-yl]-3-diisopropylaminopropan-1-one  
 876340-90-8P, 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-


d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-3-tert-butylaminopropan-1-one 876340-91-9P, 3-(Azetidin-1-yl)-1-[4-[4-[(benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]propan-1-one 876340-92-0P, 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-3-(3-hydroxypyrrolidin-1-yl)propan-1-one 876340-93-1P, 3-(Azepan-1-yl)-1-[4-[4-[(benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]propan-1-one 876340-94-2P, 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-3-(4-hydroxypiperidin-1-yl)propan-1-one 876340-95-3P, 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-3-(4-isopropylpiperazin-1-yl)propan-1-one 876340-96-4P, 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-3-(morpholin-4-yl)propan-1-one 876340-97-5P, 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-3-(4,4-difluoropiperidin-1-yl)propan-1-one 876340-98-6P, 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-3-(3,5-dimethylpiperazin-1-yl)propan-1-one 876340-99-7P, 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-3-(piperidin-1-yl)propan-1-one 876341-00-3P, 1-[4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-3-dimethylaminopropan-1-one 876341-01-4P, (Benzothiazol-6-yl)[6-(1-methylsulfonyl-1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine 876341-02-5P, (Benzothiazol-6-yl)[6-(1-ethylsulfonyl-1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine 876341-03-6P, (Benzothiazol-6-yl)[6-[1-[(propan-1-yl)sulfonyl]-1,2,3,6-tetrahydropyridin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine 876341-04-7P, (Benzothiazol-6-yl)[6-[1-[(propan-2-yl)sulfonyl]-1,2,3,6-tetrahydropyridin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine 876341-05-8P, (Benzothiazol-6-yl)[6-[1-(cyclopropylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine 876341-06-9P, 4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-sulfonic acid dimethylamide 876341-07-0P, (Benzothiazol-6-yl)[6-[1-[(butan-2-yl)sulfonyl]-1,2,3,6-tetrahydropyridin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine 876341-08-1P, [6-(1-Phenylsulfonyl-1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl](benzothiazol-6-yl)amine 876341-09-2P, 1-[4-[4-[(1H-Indol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-3-(piperidin-1-yl)propan-1-one 876341-12-7P, 4-[4-[[2-(4-Methylpiperazin-1-yl)pyridin-4-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 876341-13-8P, 4-[4-[[2-Chloro-6-(4-methylpiperazin-1-yl)pyridin-4-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 876341-14-9P, 4-[4-[[2,6-Bis(4-methylpiperazin-1-yl)pyridin-4-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 876341-15-0P, 4-[4-[(6-Carbamoylpyridin-3-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 876341-17-2P, 4-[4-[(6-Oxo-1,6-dihydropyridin-3-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 876341-19-4P, 4-[4-[(1-Methyl-6-oxo-1,6-dihydropyridin-3-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butylamide 876341-21-8P, 4-[4-[(1-Oxo-2,3-dihydro-1H-isoidol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 876341-23-0P, 4-[4-[(2-Aminobenzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid

tert-butyl ester 876341-24-1P 876341-41-2P, tert-Butyl  
 4-[4-[(1H-indol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-  
 2H-pyridine-1-carboxylate 876341-44-5P, 4-[4-[(6-Oxo-1-phenyl-  
 1,6-dihydropyridin-3-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-  
 dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester  
 876341-45-6P, 4-[4-[(6-Oxo-1-phenyl-1,6-dihydropyridin-3-yl)amino]-  
 7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid  
 tert-butylamide 876341-46-7P, tert-Butyl 4-[4-[[6-hydroxy-5-  
 (thiazol-5-yl)pyridin-3-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-  
 dihydro-2H-pyridine-1-carboxylate 876341-47-8P, tert-Butyl  
 4-[4-[[1-methyl-6-oxo-5-(thiazol-5-yl)-1,6-dihydropyridin-3-yl]amino]-7H-  
 pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylate  
 876341-56-9P 876341-57-0P 876341-58-1P,  
 N-tert-Butyl-4-[4-[(benzothiazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-  
 yl]-3,6-dihydro-2H-pyridine-1-carboxamide. 876341-61-6P,  
 1-[4-[4-[(3-Methyl-1H-indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-  
 3,6-dihydro-2H-pyridin-1-yl]-3-(piperidin-1-yl)propan-1-one  
 876341-63-8P, 3-Dimethylamino-1-[4-[4-[(3-methyl-1H-indazol-5-  
 yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-  
 yl]propan-1-one 876341-64-9P, 3-(Imidazol-1-yl)-1-[4-[4-[(3-  
 methyl-1H-indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-  
 2H-pyridin-1-yl]propan-1-one 876341-65-0P, 4-[4-[(3-Methoxy-1H-  
 indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-  
 pyridine-1-carboxylic acid tert-butyl ester 876341-68-3P,  
 4-[4-[(1-Methyl-1H-indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-  
 3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butylamide  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(drug candidate; preparation of pyrrolopyrimidines multi-kinase inhibiting  
 compds. as antitumor agents)

RN 876338-77-1 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-  
 d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX  
 NAME)




RN 876338-85-1 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[(3-amino-1H-indazol-5-yl)amino]-1H-  
 pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI)  
 (CA INDEX NAME)




10/720,600




RN 876338-86-2 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-(1H-indazol-6-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 876338-97-5 CAPLUS


CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-(4-isoquinolinylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 876338-98-6 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-(1H-indazol-3-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


10/720,600



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 876339-01-4 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-(1,3-benzodioxol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI)  
(CA INDEX NAME)




RN 876339-02-5 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-(1H-benzotriazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI)  
(CA INDEX NAME)




RN 876339-03-6 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-(1H-indol-6-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 876339-05-8 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-(1,2-benzisoxazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI)  
(CA INDEX NAME)




RN 876339-07-0 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-[(6-methyl-1H-indazol-5-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI)  
(CA INDEX NAME)




RN 876339-08-1 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 876339-10-5 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-(6-quinoxalinylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 876339-11-6 CAPLUS


CN 1(2H)-Pyridinecarboxylic acid, 4-[4-(1H-benzimidazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 876339-13-8 CAPLUS


CN 1(2H)-Pyridinecarboxylic acid, 4-[4-(6-benzoxazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/720,600




RN 876339-17-2 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-(1,2-benzisothiazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI)  
(CA INDEX NAME)



RN 876339-22-9 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-1H-indazol-5-yl-6-[1,2,3,6-tetrahydro-1-(methylsulfonyl)-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 876339-23-0 CAPLUS


CN Pyridine, 1-[(dimethylamino)acetyl]-1,2,3,6-tetrahydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)

CN(C)CC(=O)N1CC=CC=C1c2c[nH]c3cc4c(c2n3)N=C5C=CC=CC=C5N4

CN    Pyridine, 1-acetyl-1,2,3,6-tetrahydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI)    (CA INDEX NAME)




CN    Pyridine, 1,2,3,6-tetrahydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-(trifluoroacetyl)- (9CI)    (CA INDEX NAME)




CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-(1H-indol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/720,600




RN 876339-27-4 CAPLUS

CN Pyridine, 1,2,3,6-tetrahydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-(methoxyacetyl)- (9CI) (CA INDEX NAME)




RN 876339-28-5 CAPLUS

CN Morpholine, 4-[[3,6-dihydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1(2H)-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 876339-29-6 CAPLUS

CN Pyridine, 1-[(1-acetyl-4-piperidinyl)carbonyl]-1,2,3,6-tetrahydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)




RN 876339-30-9 CAPLUS

CN Pyridine, 1-[(1,2-dimethyl-1H-imidazol-5-yl)sulfonyl]-1,2,3,6-tetrahydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)



RN 876339-31-0 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)




RN 876339-32-1 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, methyl ester (9CI) (CA INDEX NAME)




10/720,600




RN 876339-33-2 CAPLUS

CN 1(2H)-Pyridinesulfonamide, 3,6-dihydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 876339-34-3 CAPLUS


CN Pyridine, 1,2,3,6-tetrahydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-[1-oxo-3-(1-piperidiny)propyl]- (9CI) (CA INDEX NAME)



RN 876339-35-4 CAPLUS


CN Pyridine, 1-[4-(dimethylamino)-1-oxobutyl]-1,2,3,6-tetrahydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)

10/720,600




RN 876339-36-5 CAPLUS

CN Pyridine, 1,2,3,6-tetrahydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-(3-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 876339-37-6 CAPLUS


CN Pyridine, 1-benzoyl-1,2,3,6-tetrahydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)



RN 876339-38-7 CAPLUS


CN Pyridine, 1-(2,2-dimethyl-1-oxopropyl)-1,2,3,6-tetrahydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)

10/720,600




RN 876339-39-8 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[1-(2-chloro-4-pyrimidinyl)-1,2,3,6-tetrahydro-4-pyridinyl]-N-1H-indazol-5-yl- (9CI) (CA INDEX NAME)



RN 876339-40-1 CAPLUS


CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1,2,3,6-tetrahydro-1-(4-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 876339-41-2 CAPLUS


CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-benzoyl-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

10/720,600




RN 876339-42-3 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-(3,3-dimethyl-1-oxobutyl)-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)




RN 876339-43-4 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-butyl-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 876339-44-5 CAPLUS


CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-cyclopentyl-3,6-dihydro- (9CI) (CA INDEX NAME)



10/720,600


RN 876339-45-6 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)




RN 876339-46-7 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-cyclobutyl-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 876339-47-8 CAPLUS


CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-cyclohexyl-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 876339-48-9 CAPLUS


CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)

10/720,600




RN 876339-49-0 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 876339-50-3 CAPLUS


CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-(4-cyanophenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 876339-51-4 CAPLUS


CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-(3-chlorophenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)

10/720,600




RN 876339-52-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 876339-53-6 CAPLUS


CN 2(1H)-Pyridinone, 4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 876339-57-0 CAPLUS


CN Benzoic acid, 3-[[4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-1(2H)-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)

10/720,600




RN 876339-58-1 CAPLUS

CN Pyridine, 1,2,3,6-tetrahydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-(phenylacetyl)- (9CI) (CA INDEX NAME)



RN 876339-59-2 CAPLUS


CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 876339-60-5 CAPLUS


CN 1(2H)-Pyridinecarboxamide, 3,6-dihydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-methyl-N-phenyl- (9CI) (CA INDEX NAME)






RN 876339-61-6 CAPLUS

CN 1(2H)-Pyridinecarbothioamide, 3,6-dihydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 876339-62-7 CAPLUS


CN 1(2H)-Pyridinecarboxamide, N-(1,1-dimethylethyl)-3,6-dihydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)



RN 876339-63-8 CAPLUS


CN 1(2H)-Pyridinecarboxamide, N-ethyl-3,6-dihydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)

10/720,600




RN 876339-64-9 CAPLUS

CN 1(2H)-Pyridinecarboxamide, N-(2-fluorophenyl)-3,6-dihydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)



RN 876339-65-0 CAPLUS


CN 1(2H)-Pyridinecarboxamide, N-(3-fluorophenyl)-3,6-dihydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)



RN 876339-66-1 CAPLUS


CN 1(2H)-Pyridinecarboxamide, N-(4-fluorophenyl)-3,6-dihydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)

10/720,600




RN 876339-67-2 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 3,6-dihydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 876339-68-3 CAPLUS


CN 1(2H)-Pyridinecarboxamide, 3,6-dihydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 876339-69-4 CAPLUS


CN 1(2H)-Pyridinecarboxamide, 3,6-dihydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

10/720,600




RN 876339-70-7 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 3,6-dihydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 876339-71-8 CAPLUS


CN 1(2H)-Pyridinecarboxamide, 3,6-dihydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 876339-72-9 CAPLUS


CN 1(2H)-Pyridinecarboxamide, 3,6-dihydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)

10/720,600




RN 876339-73-0 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 3,6-dihydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 876339-74-1 CAPLUS


CN 1(2H)-Pyridinecarboxamide, 3,6-dihydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-2-pyridinyl- (9CI) (CA INDEX NAME)



RN 876339-75-2 CAPLUS


CN 1(2H)-Pyridinecarboxamide, 3,6-dihydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-4-pyridinyl- (9CI) (CA INDEX NAME)

10/720,600




RN 876339-76-3 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1,2,3,6-tetrahydro-1-(3-pyridinylacetyl)- (9CI) (CA INDEX NAME)



RN 876339-77-4 CAPLUS


CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-(4-fluorophenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 876339-78-5 CAPLUS


CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-(2-fluorophenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)

10/720,600




RN 876339-79-6 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-N-phenyl- (9CI) (CA INDEX NAME)



RN 876339-80-9 CAPLUS


CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 876339-81-0 CAPLUS


CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-(1,1-dimethylethyl)-3,6-dihydro- (9CI) (CA INDEX NAME)

10/720,600




RN 876339-82-1 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 876339-83-2 CAPLUS

CN Piperazine, 1-[[4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-1(2H)-pyridinyl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 876339-84-3 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-N,N-dimethyl- (9CI) (CA INDEX NAME)




10/720,600




RN 876339-85-4 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-[4-(dimethylamino)-1-oxobutyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 876339-87-6 CAPLUS


CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-(2,2-dimethyl-1,3-dioxopropyl)-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 876339-88-7 CAPLUS


CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-[2,2-dimethyl-3-(4-methyl-1-piperazinyl)-1-oxopropyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

10/720,600




RN 876339-89-8 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-(3-chloro-2,2-dimethyl-1-oxopropyl)-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 876339-90-1 CAPLUS


CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-[2,2-dimethyl-1-oxo-3-(1-pyrrolidinyl)propyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 876339-91-2 CAPLUS


CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-[3-(diethylamino)-2,2-dimethyl-1-oxopropyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

10/720,600




RN 876339-92-3 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-[3-[(1,1-dimethylethyl)amino]-2,2-dimethyl-1-oxopropyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)




RN 876339-93-4 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-[3-(dimethylamino)-2,2-dimethyl-1-oxopropyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 876339-94-5 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1,2,3,6-tetrahydro-1-[3-(3-hydroxy-1-pyrrolidinyl)-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 876339-95-6 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-


10/720,600

[3-(hexahydro-1H-azepin-1-yl)-2,2-dimethyl-1-oxopropyl]-1,2,3,6-tetrahydro-  
(9CI) (CA INDEX NAME)




RN 876339-96-7 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1,2,3,6-tetrahydro-1-[3-(4-hydroxy-1-piperidiny1)-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 876339-97-8 CAPLUS


CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-[2,2-dimethyl-3-[4-(1-methylethyl)-1-piperazinyl]-1-oxopropyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 876339-98-9 CAPLUS


CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-[2,2-dimethyl-3-(4-morpholinyl)-1-oxopropyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

10/720,600




RN 876339-99-0 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-[3-(4,4-difluoro-1-piperidinyl)-2,2-dimethyl-1-oxopropyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 876340-00-0 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-[3-(3,5-dimethyl-1-piperazinyl)-2,2-dimethyl-1-oxopropyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)




RN 876340-01-1 CAPLUS


CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1,2,3,6-tetrahydro-1-[(2-methoxyethoxy)acetyl]- (9CI) (CA INDEX NAME)

COC(=O)N1CCCCC1C2=CN3C(=N2)N(C4=CC=C5N=CN=C4S5)C(=N3)N

CN Morpholine, 4-[[4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-1(2H)-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)




CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-  
1,2,3,6-tetrahydro-1-[[1-(1-piperidinylmethyl)cyclopropyl]carbonyl]- (9CI)  
(CA INDEX NAME)




CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-  
1,2,3,6-tetrahydro-1-[[1-[(4-methyl-1-piperazinyl)methyl]cyclopropyl]carbo  
nyl]- (9CI) (CA INDEX NAME)

10/720,600




RN 876340-06-6 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1,2,3,6-tetrahydro-1-[[1-(1-pyrrolidinylmethyl)cyclopropyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 876340-08-8 CAPLUS


CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-[[1-[(diethylamino)methyl]cyclopropyl]carbonyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 876340-10-2 CAPLUS


CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-[[1-[(1,1-dimethylethyl)amino]methyl]cyclopropyl]carbonyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

10/720,600




RN 876340-12-4 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-  
[[1-[(dimethylamino)methyl]cyclopropyl]carbonyl]-1,2,3,6-tetrahydro- (9CI)  
(CA INDEX NAME)



RN 876340-13-5 CAPLUS


CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-  
1,2,3,6-tetrahydro-1-[[1-[(3-hydroxy-1-pyrrolidinyl)methyl]cyclopropyl]car  
bonyl]- (9CI) (CA INDEX NAME)



RN 876340-14-6 CAPLUS


CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-  
[[1-[(hexahydro-1H-azepin-1-yl)methyl]cyclopropyl]carbonyl]-1,2,3,6-  
tetrahydro- (9CI) (CA INDEX NAME)






RN 876340-15-7 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1,2,3,6-tetrahydro-1-[[1-[(4-hydroxy-1-piperidyl)methyl]cyclopropyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 876340-16-8 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1,2,3,6-tetrahydro-1-[[1-[[4-(1-methylethyl)-1-piperazinyl]methyl]cyclopropyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 876340-17-9 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1,2,3,6-tetrahydro-1-[[1-(4-morpholinylmethyl)cyclopropyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 876340-18-0 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-[[1-[(4,4-difluoro-1-piperidinyl)methyl]cyclopropyl]carbonyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 876340-19-1 CAPLUS


CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-[[1-[(3,5-dimethyl-1-piperidinyl)methyl]cyclopropyl]carbonyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 876340-21-5 CAPLUS


CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-[2-(dimethylamino)ethyl]-3,6-dihydro- (9CI) (CA INDEX NAME)

10/720,600




RN 876340-22-6 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-[2-(diethylamino)ethyl]-3,6-dihydro- (9CI) (CA INDEX NAME)




RN 876340-23-7 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-N-[2-[(1-methylethyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 876340-24-8 CAPLUS


CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-N-[2-(1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)



10/720,600


RN 876340-25-9 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-[2-[bis(1-methylethyl)amino]ethyl]-3,6-dihydro- (9CI)  
(CA INDEX NAME)




RN 876340-26-0 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 876340-27-1 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-N,N-bis(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 876340-28-2 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 876340-29-3 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 876340-30-6 CAPLUS


CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 876340-32-8 CAPLUS


CN Piperazine, 1-[[4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-1(2H)-pyridinyl]carbonyl]-4-ethyl- (9CI) (CA INDEX NAME)

10/720,600




RN 876340-33-9 CAPLUS

CN Piperazine, 1-[[4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-1(2H)-pyridinyl]carbonyl]-4-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 876340-34-0 CAPLUS

CN Piperazine, 1-[[4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-1(2H)-pyridinyl]carbonyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 876340-35-1 CAPLUS

CN Piperazine, 1-[[4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-


10/720,600

yl]-3,6-dihydro-1(2H)-pyridinyl]carbonyl]-4-cyclopentyl- (9CI) (CA INDEX NAME)




RN 876340-36-2 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-[(hexahydro-1-methyl-1H-azepin-4-yl)carbonyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 876340-37-3 CAPLUS


CN Piperazine, 1-[[4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-1(2H)-pyridinyl]carbonyl]-4-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 876340-38-4 CAPLUS


CN 1-Piperazineethanamine, 4-[[4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-1(2H)-pyridinyl]carbonyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

10/720,600




RN 876340-39-5 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-N-methyl-N-(1-methyl-4-piperidiny)- (9CI)  
(CA INDEX NAME)



RN 876340-40-8 CAPLUS

CN Thiomorpholine, 4-[[4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-1(2H)-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 876340-41-9 CAPLUS


CN Morpholine, 4-[[4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-1(2H)-pyridinyl]carbonyl]-2,6-dimethyl-, (2R,6S)-rel- (9CI) (CA INDEX NAME)




Relative stereochemistry.



CN    Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-  
1,2,3,6-tetrahydro-1-[(4-hydroxy-1-piperidiny)l carbonyl]- (9CI)    (CA INDEX  
NAME)




CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-  
1,2,3,6-tetrahydro-1-[(3-hydroxy-1-pyrrolidinyl)carbonyl]- (9CI) (CA  
INDEX NAME)




CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N,N-diethyl-3,6-dihydro- (9CI) (CA INDEX NAME)

10/720,600




RN 876340-45-3 CAPLUS

CN Pyridine, 1-(1-azetidinyldicarbonyl)-4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 876340-46-4 CAPLUS


CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1,2,3,6-tetrahydro-1-(1-pyrrolidinyldicarbonyl)- (9CI) (CA INDEX NAME)



RN 876340-47-5 CAPLUS


CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-[(4,4-difluoro-1-piperidinyldicarbonyl)-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

10/720,600




RN 876340-48-6 CAPLUS

CN Piperazine, 4-[[4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-1(2H)-pyridinyl]carbonyl]-4-propyl- (9CI) (CA INDEX NAME)



RN 876340-49-7 CAPLUS


CN Piperazine, 4-[[4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-1(2H)-pyridinyl]carbonyl]-4-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 876340-50-0 CAPLUS


CN Piperazine, 4-[[4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-1(2H)-pyridinyl]carbonyl]-4-(1-ethylpropyl)- (9CI) (CA INDEX NAME)

10/720,600




RN 876340-51-1 CAPLUS

CN Piperazine, 4-[[4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-1(2H)-pyridinyl]carbonyl]-4-(cyclobutylmethyl)- (9CI) (CA INDEX NAME)




RN 876340-52-2 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-(2-bromoethyl)-3,6-dihydro- (9CI) (CA INDEX NAME)




RN 876340-53-3 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 876340-54-4 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-[2-[(1,1-dimethylethyl)amino]ethyl]-3,6-dihydro- (9CI)  
(CA INDEX NAME)



RN 876340-55-5 CAPLUS


CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-N-[2-(3-hydroxy-1-pyrrolidinyl)ethyl]- (9CI)  
(CA INDEX NAME)



RN 876340-56-6 CAPLUS


CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-[2-(hexahydro-1H-azepin-1-yl)ethyl]-3,6-dihydro- (9CI)  
(CA INDEX NAME)

10/720,600




RN 876340-57-7 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-N-[2-(4-hydroxy-1-piperidinyl)ethyl]- (9CI)  
(CA INDEX NAME)




RN 876340-58-8 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-N-[2-[4-(1-methylethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 876340-59-9 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-[2-(4,4-difluoro-1-piperidinyl)ethyl]-3,6-dihydro- (9CI) (CA INDEX NAME)




RN 876340-60-2 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-3,6-dihydro-(9CI) (CA INDEX NAME)



RN 876340-61-3 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-6-benzothiazolyl-6-[1-(3-chloropropyl)-1,2,3,6-tetrahydro-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 876340-62-4 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-6-benzothiazolyl-6-[1,2,3,6-tetrahydro-1-[3-(4-methyl-1-piperazinyl)propyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)

10/720,600




RN 876340-63-5 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-6-benzothiazolyl-6-[1,2,3,6-tetrahydro-1-[3-(1-piperidinyl)propyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 876340-64-6 CAPLUS


CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[(1-ethyl-1H-pyrazol-4-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 876340-65-7 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-[[1-(2-phenylethyl)-1H-pyrazol-3-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)






ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 876340-66-8 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-[[1-(2-phenylethyl)-1H-pyrazol-4-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 876340-69-1 CAPLUS


CN Pyridine, 4-[4-[(3-chloro-1H-indazol-5-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1,2,3,6-tetrahydro-1-[1-oxo-3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 876340-71-5 CAPLUS


CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1,2,3,6-tetrahydro-1-[(4-methyl-1-piperazinyl)acetyl]- (9CI) (CA INDEX NAME)

10/720,600




RN 876340-72-6 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1,2,3,6-tetrahydro-1-(1-pyrrolidinylacetyl)- (9CI) (CA INDEX NAME)



RN 876340-73-7 CAPLUS


CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-[(diethylamino)acetyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 876340-74-8 CAPLUS


CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1,2,3,6-tetrahydro-1-(1-piperidiny lacetyl)- (9CI) (CA INDEX NAME)

10/720,600




RN 876340-75-9 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-  
[[ (1,1-dimethylethyl) amino] acetyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX  
NAME)



RN 876340-76-0 CAPLUS


CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-  
[(dimethylamino) acetyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 876340-77-1 CAPLUS


CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-  
1,2,3,6-tetrahydro-1-[(3-hydroxy-1-pyrrolidinyl)acetyl]- (9CI) (CA INDEX  
NAME)

10/720,600




RN 876340-78-2 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-  
[(hexahydro-1H-azepin-1-yl)acetyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX  
NAME)




RN 876340-79-3 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-  
1,2,3,6-tetrahydro-1-[(4-hydroxy-1-piperidinyl)acetyl]- (9CI) (CA INDEX  
NAME)




RN 876340-80-6 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-  
1,2,3,6-tetrahydro-1-[[4-(1-methylethyl)-1-piperazinyl]acetyl]- (9CI) (CA  
INDEX NAME)




RN 876340-81-7 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1,2,3,6-tetrahydro-1-(4-morpholinylacetyl)- (9CI) (CA INDEX NAME)



RN 876340-82-8 CAPLUS


CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-[(4,4-difluoro-1-piperidinyl)acetyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 876340-83-9 CAPLUS


CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-[(3,5-dimethyl-1-piperazinyl)acetyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

10/720,600




RN 876340-86-2 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1,2,3,6-tetrahydro-1-[3-(4-methyl-1-piperazinyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 876340-87-3 CAPLUS


CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1,2,3,6-tetrahydro-1-[1-oxo-3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 876340-88-4 CAPLUS


CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-[3-(diethylamino)-1-oxopropyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

10/720,600




RN 876340-89-5 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-[3-[bis(1-methylethyl)amino]-1-oxopropyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)




RN 876340-90-8 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-[3-[(1,1-dimethylethyl)amino]-1-oxopropyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)




RN 876340-91-9 CAPLUS

CN Pyridine, 1-[3-(1-azetidiny)-1-oxopropyl]-4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)




RN 876340-92-0 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1,2,3,6-tetrahydro-1-[3-(3-hydroxy-1-pyrrolidiny)-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 876340-93-1 CAPLUS


CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-[3-(hexahydro-1H-azepin-1-yl)-1-oxopropyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 876340-94-2 CAPLUS


CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1,2,3,6-tetrahydro-1-[3-(4-hydroxy-1-piperidiny)-1-oxopropyl]- (9CI) (CA INDEX NAME)






RN 876340-95-3 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1,2,3,6-tetrahydro-1-[3-[4-(1-methylethyl)-1-piperazinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 876340-96-4 CAPLUS


CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1,2,3,6-tetrahydro-1-[3-(4-morpholinyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 876340-97-5 CAPLUS


CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-[3-(4,4-difluoro-1-piperidinyl)-1-oxopropyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

10/720,600




RN 876340-98-6 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-[3-(3,5-dimethyl-1-piperazinyl)-1-oxopropyl]-1,2,3,6-tetrahydro- (9CI)  
(CA INDEX NAME)



RN 876340-99-7 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1,2,3,6-tetrahydro-1-[1-oxo-3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 876341-00-3 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-


10/720,600

[3-(dimethylamino)-1-oxopropyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)




RN 876341-01-4 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-6-benzothiazolyl-6-[1,2,3,6-tetrahydro-1-(methanesulfonyl)-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 876341-02-5 CAPLUS


CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-(ethanesulfonyl)-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 876341-03-6 CAPLUS


CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-(propylsulfonyl)-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

10/720,600




RN 876341-04-7 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1,2,3,6-tetrahydro-1-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 876341-05-8 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-(cyclopropylsulfonyl)-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 876341-06-9 CAPLUS


CN 1(2H)-Pyridinesulfonamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-N,N-dimethyl- (9CI) (CA INDEX NAME)



10/720,600


RN 876341-07-0 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1,2,3,6-tetrahydro-1-[(1-methylpropyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 876341-08-1 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1,2,3,6-tetrahydro-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 876341-09-2 CAPLUS

CN Pyridine, 1,2,3,6-tetrahydro-4-[4-(1H-indol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-[1-oxo-3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 876341-12-7 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-[[2-(4-methyl-1-piperazinyl)-4-pyridinyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 876341-13-8 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[[2-chloro-6-(4-methyl-1-piperazinyl)-4-pyridinyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 876341-14-9 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[[2,6-bis(4-methyl-1-piperazinyl)-4-pyridinyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 876341-15-0 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[[6-(aminocarbonyl)-3-pyridinyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 876341-17-2 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[(1,6-dihydro-6-oxo-3-pyridinyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 876341-19-4 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-[(1,6-dihydro-1-methyl-6-oxo-3-pyridinyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-(1,1-dimethylethyl)-3,6-dihydro- (9CI) (CA INDEX NAME)




RN 876341-21-8 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[(2,3-dihydro-1-oxo-1H-isoindol-5-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 876341-23-0 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[(2-amino-6-benzothiazolyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI)  
(CA INDEX NAME)



RN 876341-24-1 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[(2-amino-1H-benzimidazol-5-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester  
(9CI) (CA INDEX NAME)




RN 876341-41-2 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-(1H-indol-4-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




10/720,600




RN 876341-44-5 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[(1,6-dihydro-6-oxo-1-phenyl-3-pyridinyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 876341-45-6 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-[(1,6-dihydro-6-oxo-1-phenyl-3-pyridinyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-(1,1-dimethylethyl)-, 3,6-dihydro- (9CI) (CA INDEX NAME)




RN 876341-46-7 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[[1,6-dihydro-6-oxo-5-(5-thiazolyl)-3-pyridinyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 876341-47-8 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[[1,6-dihydro-1-methyl-6-oxo-5-(5-thiazolyl)-3-pyridinyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 876341-56-9 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-[(1-methyl-1H-benzimidazol-6-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 876341-57-0 CAPLUS


CN 1(2H)-Pyridinecarboxamide, N-(1,1-dimethylethyl)-3,6-dihydro-4-[4-[(1-methyl-1H-benzimidazol-6-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)

CN1C=NC2=C1C=CC=C2C3=CC=CC=C3NC4=NC=CC5=C4C(=C3)N=C5C6=CC=CC=C6N(C7=CC=CC=C7)C(=O)NCC


CN 1(2H)-Pyridinecarboxamide, 4-[4-(5-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-(1,1-dimethylethyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



CN    Pyridine, 1,2,3,6-tetrahydro-4-[4-[(3-methyl-1H-indazol-5-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-[1-oxo-3-(1-piperidinyl)propyl]- (9CI)  
(CA INDEX NAME)




CN    Pyridine, 1-[3-(dimethylamino)-1-oxopropyl]-1,2,3,6-tetrahydro-4-[4-[(3-methyl-1H-indazol-5-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI)    (CA INDEX NAME)




RN 876341-64-9 CAPLUS

CN Pyridine, 1,2,3,6-tetrahydro-1-[3-(1H-imidazol-1-yl)-1-oxopropyl]-4-[4-[(3-methyl-1H-indazol-5-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)




RN 876341-65-0 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-[(3-methoxy-1H-indazol-5-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 876341-68-3 CAPLUS

CN 1(2H)-Pyridinecarboxamide, N-(1,1-dimethylethyl)-3,6-dihydro-4-[4-[(1-methyl-1H-indazol-5-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)



IT 876341-69-4P, 1-[4-[4-[(1-Methyl-1H-indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-3-(piperidin-1-yl)propan-1-one 876341-70-7P, 2-(2-Methoxyethoxy)-1-[4-[4-[(1-methyl-1H-indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]ethanone 876341-71-8P, [4-[4-[(1-Methyl-1H-indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl](4-methylpiperazin-1-yl)methanone 876341-72-9P, 4-[4-[2-[(2-Dimethylaminoethyl)amino]benzothiazol-6-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 876341-73-0P, 4-[4-[2-(Benzylamino)benzothiazol-6-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 876341-74-1P, 4-[4-[2-(Phenethylaminobenzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 876341-75-2P, 4-[4-[2-(2-Methoxyethylamino)benzothiazol-6-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 876342-00-6P, [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl](2,2,4-trimethylpiperazin-1-yl)methanone 876342-01-7P, [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl](2,4,5-trimethylpiperazin-1-yl)methanone 876342-02-8P, [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl](3,4,5-trimethylpiperazin-1-yl)methanone 876342-03-9P, [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl][4-(2,2,2-trifluoroethyl)piperazin-1-yl]methanone 876342-04-0P, [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl](4-tert-butylpiperazin-1-yl)methanone 876342-05-1P 876342-06-2P, (Benzothiazol-6-yl)[6-[1-(thiazol-2-yl)-1,2,3,6-tetrahydropyridin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine 876342-07-3P, (Benzothiazol-6-yl)[6-[1-(oxazol-2-yl)-1,2,3,6-tetrahydropyridin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine 876342-08-4P, 4-[4-[(3-Phenyl-3H-benzimidazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 876342-09-5P, 4-[4-[(3-Phenyl-3H-benzimidazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butylamide 876342-10-8P 876342-11-9P 876342-12-0P, 4-[4-[(3-(2-Aminoethyl)-3H-benzimidazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butylamide 876342-13-1P, 4-[4-[(3-(2-Aminoethyl)-3H-benzimidazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 876342-14-2P 876342-15-3P 876342-16-4P 876342-17-5P 876342-18-6P, 4-[4-[(Imidazo[1,2-a]pyridin-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-

carboxylic acid tert-butylamide 876342-19-7P,  
 4-[4-[(Imidazo[1,2-a]pyridin-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-  
 3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester  
 876342-20-0P, 4-[4-[(3-Methylimidazo[1,2-a]pyridin-6-yl)amino]-7H-  
 pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid  
 tert-butylamide 876342-21-1P, 4-[4-[(3-Methylimidazo[1,2-  
 a]pyridin-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-  
 pyridine-1-carboxylic acid tert-butyl ester 876342-22-2P,  
 4-[4-[(3-Phenylimidazo[1,2-a]pyridin-6-yl)amino]-7H-pyrrolo[2,3-  
 d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid  
 tert-butylamide 876342-23-3P, 4-[4-[(3-Phenylimidazo[1,2-  
 a]pyridin-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-  
 pyridine-1-carboxylic acid tert-butyl ester 876342-24-4P,  
 4-[4-[(3-(2-Carbamoylphenyl)imidazo[1,2-a]pyridin-6-yl)amino]-7H-  
 pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid  
 tert-butylamide 876342-25-5P, 4-[4-[(3-(2-  
 Carbamoylphenyl)imidazo[1,2-a]pyridin-6-yl)amino]-7H-pyrrolo[2,3-  
 d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl  
 ester 876342-26-6P, 4-[4-[(3-(2-Dimethylaminoethyl)imidazo[1,2-  
 a]pyridin-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-  
 pyridine-1-carboxylic acid tert-butylamide 876342-27-7P,  
 4-[4-[(3-(2-Dimethylaminoethyl)imidazo[1,2-a]pyridin-6-yl)amino]-7H-  
 pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid  
 tert-butyl ester 876342-28-8P, 4-[4-[(3-(2-  
 Acetylaminoethyl)imidazo[1,2-a]pyridin-6-yl)amino]-7H-pyrrolo[2,3-  
 d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid  
 tert-butylamide 876342-29-9P, 4-[4-[(3-(2-  
 Acetylaminoethyl)imidazo[1,2-a]pyridin-6-yl)amino]-7H-pyrrolo[2,3-  
 d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl  
 ester 876342-30-2P, 4-[4-[(3-[(Dimethylamino)methyl]imidazo[1,2-  
 a]pyridin-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-  
 pyridine-1-carboxylic acid tert-butylamide 876342-31-3P,  
 4-[4-[(3-[(Dimethylamino)methyl]imidazo[1,2-a]pyridin-6-yl)amino]-7H-  
 pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid  
 tert-butyl ester 876342-32-4P, 4-[4-[(7-Aminomethyl-1H-indazol-5-  
 yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-  
 carboxylic acid tert-butylamide 876342-33-5P,  
 4-[4-[(7-Aminomethyl-1H-indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-  
 yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester  
 876342-34-6P, 4-[4-[(7-Aminomethyl-1-methyl-1H-indazol-5-yl)amino]-  
 7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid  
 tert-butylamide 876342-35-7P, 4-[4-[(7-Aminomethyl-1-methyl-1H-  
 indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-  
 pyridine-1-carboxylic acid tert-butyl ester 876342-36-8P,  
 4-[4-[(7-[(Dimethylamino)methyl]-1-methyl-1H-indazol-5-yl)amino]-7H-  
 pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid  
 tert-butylamide 876342-37-9P, 4-[4-[(7-[(Dimethylamino)methyl]-1-  
 methyl-1H-indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-  
 2H-pyridine-1-carboxylic acid tert-butyl ester 876342-38-0P,  
 4-[4-[(7-[(Dimethylamino)methyl]-1H-indazol-5-yl)amino]-7H-pyrrolo[2,3-  
 d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid  
 tert-butylamide 876342-39-1P, 4-[4-[(7-[(Dimethylamino)methyl]-  
 1H-indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-  
 pyridine-1-carboxylic acid tert-butyl ester 876342-40-4P,  
 4-[4-[(7-(2-Dimethylaminoethyl)-1H-indazol-5-yl)amino]-7H-pyrrolo[2,3-  
 d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid  
 tert-butylamide 876342-41-5P, 4-[4-[(7-(2-Dimethylaminoethyl)-1H-  
 indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-  
 pyridine-1-carboxylic acid tert-butyl ester 876342-42-6P,  
 4-[4-[(7-(2-Dimethylaminoethyl)-1-methyl-1H-indazol-5-yl)amino]-7H-  
 pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid

tert-butylamide 876342-43-7P, 4-[4-[[7-(2-Dimethylaminoethyl)-1-methyl-1H-indazol-5-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 876342-44-8P, 4-[4-[(Imidazo[1,5-a]pyridin-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butylamide 876342-45-9P, 4-[4-[(Imidazo[1,5-a]pyridin-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 876342-46-0P, 4-[4-[(3-Methylimidazo[1,5-a]pyridin-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butylamide 876342-47-1P, 4-[4-[(3-Methylimidazo[1,5-a]pyridin-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 876342-48-2P, 4-[4-[(1-Methylimidazo[1,5-a]pyridin-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butylamide 876342-49-3P, 4-[4-[(1-Methylimidazo[1,5-a]pyridin-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 876342-50-6P, 4-[4-[(Imidazo[1,5-a]pyridin-7-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butylamide 876342-51-7P, 4-[4-[(Imidazo[1,5-a]pyridin-7-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 876342-52-8P, 4-[4-[(3-Methylimidazo[1,5-a]pyridin-7-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butylamide 876342-53-9P, 4-[4-[(3-Methylimidazo[1,5-a]pyridin-7-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 876342-54-0P, 4-[4-[(1-Methylimidazo[1,5-a]pyridin-7-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butylamide 876342-55-1P, 4-[4-[(1-Methylimidazo[1,5-a]pyridin-7-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 876342-56-2P, 4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid (2-hydroxy-1,1-dimethylethyl)amide 876342-57-3P, 4-[4-[(1-Methyl-1H-indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid (2-hydroxy-1,1-dimethylethyl)amide 876342-58-4P, 4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid (2-methoxy-1,1-dimethylethyl)amide 876342-59-5P, 4-[4-[(1-Methyl-1H-indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid (2-methoxy-1,1-dimethylethyl)amide 876342-60-8P, 4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid (2-dimethylamino-1,1-dimethylethyl)amide 876342-61-9P, 4-[4-[(1-Methyl-1H-indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid (2-dimethylamino-1,1-dimethylethyl)amide 876342-62-0P, 4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid [1,1-dimethyl-2-(pyrrolidin-1-yl)ethyl]amide 876342-63-1P, 4-[4-[(1-Methyl-1H-indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid [1,1-dimethyl-2-(pyrrolidin-1-yl)ethyl]amide 876342-64-2P, 4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid [1,1-dimethyl-2-(morpholin-4-yl)ethyl]amide 876342-65-3P, 4-[4-[(1-Methyl-1H-indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid [1,1-dimethyl-2-(morpholin-4-yl)ethyl]amide 876342-66-4P, 4-[4-[(1H-Indol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butylamide 876342-67-5P, 4-[4-[(Quinolin-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid


tert-butylamide 876342-68-6P, (Hexahydropyrrolo[1,2-a]pyrazin-2-yl)[4-[4-[(imidazo[1,2-a]pyridin-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]methanone 876342-69-7P, (Hexahydropyrrolo[1,2-a]pyrazin-2-yl)[4-[4-[(3-methyl-3H-benzimidazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]methanone 876342-70-0P, (Hexahydropyrrolo[1,2-a]pyrazin-2-yl)[4-[4-[(1-methyl-1H-indazol-5-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]methanone 876342-71-1P, [4-[4-[(Benzothiazol-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl](hexahydropyrrolo[1,2-a]pyrazin-2-yl)methanone 876342-72-2P 876342-74-4P 876342-75-5P 876342-76-6P 876342-78-8P 876342-79-9P 876342-80-2P 876342-81-3P 876342-82-4P 876342-83-5P 876342-84-6P 876342-85-7P 876342-86-8P 876342-87-9P 876342-88-0P 876342-89-1P 876342-91-5P 876342-92-6P 876342-95-9P 876342-96-0P 876342-97-1P 876342-98-2P 876342-99-3P 876343-00-9P 876343-01-0P 876343-02-1P 876343-03-2P 876343-04-3P 876343-05-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrrolopyrimidines multi-kinase inhibiting compds. as antitumor agents)

RN 876341-69-4 CAPLUS

CN Pyridine, 1,2,3,6-tetrahydro-4-[4-[(1-methyl-1H-indazol-5-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-[1-oxo-3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 876341-70-7 CAPLUS

CN Pyridine, 1,2,3,6-tetrahydro-1-[(2-methoxyethoxy)acetyl]-4-[4-[(1-methyl-1H-indazol-5-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)




10/720,600




RN 876341-71-8 CAPLUS

CN Piperazine, 1-[[3,6-dihydro-4-[4-[(1-methyl-1H-indazol-5-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1(2H)-pyridinyl]carbonyl]-4-methyl- (9CI)  
(CA INDEX NAME)



RN 876341-72-9 CAPLUS


CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[[2-[[2-(dimethylamino)ethyl]amino]-6-benzothiazolyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 876341-73-0 CAPLUS


CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-[[2-[(phenylmethyl)amino]-6-benzothiazolyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/720,600




RN 876341-74-1 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-[[2-[(2-phenylethyl)amino]-6-benzothiazolyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 876341-75-2 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-[[2-[(2-methoxyethyl)amino]-6-benzothiazolyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 876342-00-6 CAPLUS

CN Piperazine, 1-[[4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-1(2H)-pyridinyl]carbonyl]-2,2,4-trimethyl- (9CI) (CA INDEX NAME)




RN 876342-01-7 CAPLUS

CN Piperazine, 1-[[4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-1(2H)-pyridinyl]carbonyl]-2,4,5-trimethyl- (9CI) (CA INDEX NAME)



RN 876342-02-8 CAPLUS

CN Piperazine, 4-[[4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-1(2H)-pyridinyl]carbonyl]-1,2,6-trimethyl- (9CI) (CA INDEX NAME)




RN 876342-03-9 CAPLUS

CN Piperazine, 1-[[4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-1(2H)-pyridinyl]carbonyl]-4-(2,2,2-trifluoroethyl)- (9CI)


10/720,600

(CA INDEX NAME)




RN 876342-04-0 CAPLUS

CN Piperazine, 1-[[4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-1(2H)-pyridinyl]carbonyl]-4-(1,1-dimethylethyl)- (9CI)  
(CA INDEX NAME)



RN 876342-05-1 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-6-benzothiazolyl-6-(3,6-dihydro[1(2H),2'-bipyridin]-4-yl)- (9CI) (CA INDEX NAME)



RN 876342-06-2 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-6-benzothiazolyl-6-[1,2,3,6-tetrahydro-1-(2-thiazolyl)-4-pyridinyl]- (9CI) (CA INDEX NAME)

10/720,600




RN 876342-07-3 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-6-benzothiazolyl-6-[1,2,3,6-tetrahydro-1-(2-oxazolyl)-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 876342-08-4 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-[(1-phenyl-1H-benzimidazol-6-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 876342-09-5 CAPLUS


CN 1(2H)-Pyridinecarboxamide, N-(1,1-dimethylethyl)-3,6-dihydro-4-[4-[(1-phenyl-1H-benzimidazol-6-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)



10/720,600


RN 876342-10-8 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-[[1-[2-(aminocarbonyl)phenyl]-1H-benzimidazol-6-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-(1,1-dimethylethyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 876342-11-9 CAPLUS


CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[[1-[2-(aminocarbonyl)phenyl]-1H-benzimidazol-6-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 876342-12-0 CAPLUS


CN 1(2H)-Pyridinecarboxamide, 4-[4-[[1-(2-aminoethyl)-1H-benzimidazol-6-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-(1,1-dimethylethyl)-3,6-dihydro- (9CI) (CA INDEX NAME)

10/720,600




RN 876342-13-1 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[[1-(2-aminoethyl)-1H-benzimidazol-6-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 876342-14-2 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-[[1-[2-(dimethylamino)ethyl]-1H-benzimidazol-6-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-(1,1-dimethylethyl)-3,6-dihydro- (9CI) (CA INDEX NAME)




RN 876342-15-3 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[[1-[2-(dimethylamino)ethyl]-1H-benzimidazol-6-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 876342-16-4 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-[[1-[2-(acetylamino)ethyl]-1H-benzimidazol-6-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-(1,1-dimethylethyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 876342-17-5 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[[1-[2-(acetylamino)ethyl]-1H-benzimidazol-6-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 876342-18-6 CAPLUS

CN 1(2H)-Pyridinecarboxamide, N-(1,1-dimethylethyl)-3,6-dihydro-4-[4-(imidazo[1,2-a]pyridin-6-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)




CN(CCCC(=O)N1CCCCC1)c2ccccc2Nc3nc4c(ncn4C5=CC=CC=C5)C(=N1)N=CN=C1

CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-(imidazo[1,2-a]pyridin-6-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI)  
(CA INDEX NAME)




CN 1(2H)-Pyridinecarboxamide, N-(1,1-dimethylethyl)-3,6-dihydro-4-[4-[(3-methylimidazo[1,2-a]pyridin-6-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-  
(9CI) (CA INDEX NAME)




CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-[(3-methylimidazo[1,2-a]pyridin-6-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/720,600




RN 876342-22-2 CAPLUS

CN 1(2H)-Pyridinecarboxamide, N-(1,1-dimethylethyl)-3,6-dihydro-4-[4-[(3-phenylimidazo[1,2-a]pyridin-6-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)




RN 876342-23-3 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-[(3-phenylimidazo[1,2-a]pyridin-6-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 876342-24-4 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-[[3-[2-(aminocarbonyl)phenyl]imidazo[1,2-a]pyridin-6-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-(1,1-dimethylethyl)-3,6-dihydro- (9CI) (CA INDEX NAME)




RN 876342-25-5 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[[3-[2-(aminocarbonyl)phenyl]imidazo[1,2-a]pyridin-6-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 876342-26-6 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-[[3-[2-(dimethylamino)ethyl]imidazo[1,2-a]pyridin-6-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-(1,1-dimethylethyl)-3,6-dihydro- (9CI) (CA INDEX NAME)




RN 876342-27-7 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[[3-[2-(dimethylamino)ethyl]imidazo[1,2-a]pyridin-6-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 876342-28-8 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-[[3-[2-(acetylamino)ethyl]imidazo[1,2-a]pyridin-6-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-(1,1-dimethylethyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 876342-29-9 CAPLUS


CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[[3-[2-(acetylamino)ethyl]imidazo[1,2-a]pyridin-6-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 876342-30-2 CAPLUS


CN 1(2H)-Pyridinecarboxamide, 4-[4-[[3-[(dimethylamino)methyl]imidazo[1,2-a]pyridin-6-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-(1,1-dimethylethyl)-3,6-dihydro- (9CI) (CA INDEX NAME)

10/720,600




RN 876342-31-3 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[[3-[(dimethylamino)methyl]imidazo[1,2-a]pyridin-6-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 876342-32-4 CAPLUS


CN 1(2H)-Pyridinecarboxamide, 4-[4-[[7-(aminomethyl)-1H-indazol-5-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-(1,1-dimethylethyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 876342-33-5 CAPLUS


CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[[7-(aminomethyl)-1H-indazol-5-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/720,600




RN 876342-34-6 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-[[7-(aminomethyl)-1-methyl-1H-indazol-5-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-(1,1-dimethylethyl)-3,6-dihydro- (9CI) (CA INDEX NAME)




RN 876342-35-7 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[[7-(aminomethyl)-1-methyl-1H-indazol-5-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 876342-36-8 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-[[7-[(dimethylamino)methyl]-1-methyl-1H-indazol-5-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-(1,1-dimethylethyl)-3,6-dihydro- (9CI) (CA INDEX NAME)




RN 876342-37-9 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[[7-[(dimethylamino)methyl]-1-methyl-1H-indazol-5-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 876342-38-0 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-[[7-[(dimethylamino)methyl]-1H-indazol-5-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-(1,1-dimethylethyl)-3,6-dihydro- (9CI) (CA INDEX NAME)




RN 876342-39-1 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[[7-[(dimethylamino)methyl]-1H-indazol-5-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-,


10/720,600

1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 876342-40-4 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-[[7-[2-(dimethylamino)ethyl]-1H-indazol-5-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-(1,1-dimethylethyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 876342-41-5 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[[7-[2-(dimethylamino)ethyl]-1H-indazol-5-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 876342-42-6 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-[[7-[2-(dimethylamino)ethyl]-1-methyl-1H-indazol-5-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-(1,1-dimethylethyl)-3,6-dihydro- (9CI) (CA INDEX NAME)




10/720,600




RN 876342-43-7 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[[7-[2-(dimethylamino)ethyl]-1-methyl-1H-indazol-5-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 876342-44-8 CAPLUS


CN 1(2H)-Pyridinecarboxamide, N-(1,1-dimethylethyl)-3,6-dihydro-4-[4-(imidazo[1,5-a]pyridin-6-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)



RN 876342-45-9 CAPLUS


CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-(imidazo[1,5-a]pyridin-6-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/720,600




RN 876342-46-0 CAPLUS

CN 1(2H)-Pyridinecarboxamide, N-(1,1-dimethylethyl)-3,6-dihydro-4-[4-[(3-methylimidazo[1,5-a]pyridin-6-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-(9CI) (CA INDEX NAME)




RN 876342-47-1 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-[(3-methylimidazo[1,5-a]pyridin-6-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 876342-48-2 CAPLUS

CN 1(2H)-Pyridinecarboxamide, N-(1,1-dimethylethyl)-3,6-dihydro-4-[4-[(1-methylimidazo[1,5-a]pyridin-6-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-(9CI) (CA INDEX NAME)




RN 876342-49-3 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-[(1-methylimidazo[1,5-a]pyridin-6-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 876342-50-6 CAPLUS


CN 1(2H)-Pyridinecarboxamide, N-(1,1-dimethylethyl)-3,6-dihydro-4-[4-(imidazo[1,5-a]pyridin-7-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)



RN 876342-51-7 CAPLUS


CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-(imidazo[1,5-a]pyridin-7-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/720,600




RN 876342-52-8 CAPLUS

CN 1(2H)-Pyridinecarboxamide, N-(1,1-dimethylethyl)-3,6-dihydro-4-[4-[(3-methylimidazo[1,5-a]pyridin-7-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)



RN 876342-53-9 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-[(3-methylimidazo[1,5-a]pyridin-7-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 876342-54-0 CAPLUS


CN 1(2H)-Pyridinecarboxamide, N-(1,1-dimethylethyl)-3,6-dihydro-4-[4-[(1-methylimidazo[1,5-a]pyridin-7-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)

Cc1nc2ccccc2n1Nc3nc4c(ncn4C5=CC=CC=C5N5C(=O)NCC)cc6ccccc36

CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-[(1-methylimidazo[1,5-a]pyridin-7-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-N-(2-hydroxy-1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




CN 1(2H)-Pyridinecarboxamide, 3,6-dihydro-N-(2-hydroxy-1,1-dimethylethyl)-4-[4-[(1-methyl-1H-indazol-5-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-  
(9CI) (CA INDEX NAME)

CN1C=NC2=C1C=CC=C2C(=N3C=CC=C4C(=N5C=CC=CC=C5N(C)C(=O)NC(C)(C)CO)C6=CC=CC=C6N3)N4

CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-N-(2-methoxy-1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




CN 1(2H)-Pyridinecarboxamide, 3,6-dihydro-N-(2-methoxy-1,1-dimethylethyl)-4-[4-[(1-methyl-1H-indazol-5-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-  
(9CI) (CA INDEX NAME)




CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-[2-(dimethylamino)-1,1-dimethylethyl]-3,6-dihydro-  
(9CI) (CA INDEX NAME)

10/720,600




RN 876342-61-9 CAPLUS

CN 1(2H)-Pyridinecarboxamide, N-[2-(dimethylamino)-1,1-dimethylethyl]-3,6-dihydro-4-[4-[(1-methyl-1H-indazol-5-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)



RN 876342-62-0 CAPLUS


CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-[1,1-dimethyl-2-(1-pyrrolidinyl)ethyl]-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 876342-63-1 CAPLUS


CN 1(2H)-Pyridinecarboxamide, N-[1,1-dimethyl-2-(1-pyrrolidinyl)ethyl]-3,6-dihydro-4-[4-[(1-methyl-1H-indazol-5-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)

10/720,600




RN 876342-64-2 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-[1,1-dimethyl-2-(4-morpholinyl)ethyl]-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 876342-65-3 CAPLUS

CN 1(2H)-Pyridinecarboxamide, N-[1,1-dimethyl-2-(4-morpholinyl)ethyl]-3,6-dihydro-4-[4-[(1-methyl-1H-indazol-5-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)




RN 876342-66-4 CAPLUS

CN 1(2H)-Pyridinecarboxamide, N-(1,1-dimethylethyl)-3,6-dihydro-4-[4-(1H-indol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)




10/720,600




RN 876342-67-5 CAPLUS

CN 1(2H)-Pyridinecarboxamide, N-(1,1-dimethylethyl)-3,6-dihydro-4-[4-(6-quinolinylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)




RN 876342-68-6 CAPLUS

CN Pyrrolo[1,2-a]pyrazine, 2-[[3,6-dihydro-4-[4-(imidazo[1,2-a]pyridin-6-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1(2H)-pyridinyl]carbonyl]octahydro- (9CI) (CA INDEX NAME)




RN 876342-69-7 CAPLUS

CN Pyrrolo[1,2-a]pyrazine, 2-[[3,6-dihydro-4-[4-[(1-methyl-1H-benzimidazol-6-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1(2H)-pyridinyl]carbonyl]octahydro- (9CI) (CA INDEX NAME)




RN 876342-70-0 CAPLUS

CN Pyrrolo[1,2-a]pyrazine, 2-[[3,6-dihydro-4-[4-[(1-methyl-1H-indazol-5-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1(2H)-pyridinyl]carbonyl]hexahydro- (9CI) (CA INDEX NAME)




RN 876342-71-1 CAPLUS

CN Pyrrolo[1,2-a]pyrazine, 2-[[4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-1(2H)-pyridinyl]carbonyl]octahydro- (9CI) (CA INDEX NAME)




RN 876342-72-2 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-[[1-(2-phenylethyl)-1H-benzimidazol-6-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 876342-74-4 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-[[1-(2-hydroxyethyl)-1H-benzimidazol-6-yl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 876342-75-5 CAPLUS


CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[(3-bromoimidazo[1,2-a]pyridin-6-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 876342-76-6 CAPLUS


CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-[(1-methyl-1H-indazol-6-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/720,600




RN 876342-78-8 CAPLUS

CN Pyridine, 1,2,3,6-tetrahydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-(4-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 876342-79-9 CAPLUS


CN Pyridine, 1,2,3,6-tetrahydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-(3-pyridinylacetyl)- (9CI) (CA INDEX NAME)



RN 876342-80-2 CAPLUS


CN Pyridine, 1,2,3,6-tetrahydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-(4-pyridinylacetyl)- (9CI) (CA INDEX NAME)

10/720,600




RN 876342-81-3 CAPLUS

CN Pyridine, 1,2,3,6-tetrahydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-(2-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 876342-82-4 CAPLUS


CN Pyridine, 1,2,3,6-tetrahydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-[(2-methoxyethoxy)acetyl]- (9CI) (CA INDEX NAME)



RN 876342-83-5 CAPLUS


CN Pyridine, 1-(3,3-dimethyl-1-oxobutyl)-1,2,3,6-tetrahydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)

10/720,600




RN 876342-84-6 CAPLUS

CN Pyridine, 1,2,3,6-tetrahydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-(propylsulfonyl)- (9CI) (CA INDEX NAME)



RN 876342-85-7 CAPLUS


CN Pyridine, 1-(ethylsulfonyl)-1,2,3,6-tetrahydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)



RN 876342-86-8 CAPLUS


CN Pyridine, 1,2,3,6-tetrahydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)

10/720,600




RN 876342-87-9 CAPLUS

CN Pyridine, 1,2,3,6-tetrahydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 876342-88-0 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-ethyl-3,6-dihydro- (9CI) (CA INDEX NAME)




RN 876342-89-1 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[(3-ethyl-1H-indazol-5-yl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 876342-91-5 CAPLUS

CN Pyridine, 1-[3-(dimethylamino)-1-oxopropyl]-1,2,3,6-tetrahydro-4-[4-(1H-indazol-5-ylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)



RN 876342-92-6 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[(2,6-dichloro-4-pyridinyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 876342-95-9 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-ethyl-3,6-dihydro-N-methyl- (9CI) (CA INDEX NAME)




10/720,600



RN 876342-96-0 CAPLUS


CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-(1,1-dimethylethyl)-3,6-dihydro-N-methyl- (9CI) (CA INDEX NAME)



RN 876342-97-1 CAPLUS

CN Piperazine, 1-[[4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-1(2H)-pyridinyl]carbonyl]-2,5-dimethyl-4-(2-propenyl)-, (2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876342-98-2 CAPLUS

CN Piperazine, 1-[[4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-1(2H)-pyridinyl]carbonyl]-2,5-dimethyl-, (2S,5R)- (9CI) (CA INDEX NAME)


10/720,600

Absolute stereochemistry.




RN 876342-99-3 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-[2-(diethylamino)-1,1-dimethylethyl]-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 876343-00-9 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-[2-(3,5-dimethyl-1-piperazinyl)-1,1-dimethylethyl]-3,6-dihydro- (9CI) (CA INDEX NAME)




RN 876343-01-0 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1,2,3,6-tetrahydro-1-[[1-[(methylsulfonyl)oxy]methyl]cyclopropyl]carbonyl

10/720,600


] - (9CI) (CA INDEX NAME)



RN 876343-02-1 CAPLUS


CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1,2,3,6-tetrahydro-1-[[ (3S)-3-hydroxy-1-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876343-03-2 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1,2,3,6-tetrahydro-1-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 876343-04-3 CAPLUS

CN Pyridine, 4-[4-(6-benzothiazolylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-1-[2-(dimethylamino)-2-methyl-1-oxopropyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 876343-05-4 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-6-benzothiazolyl-6-(1,2,3,6-tetrahydro-4-pyridinyl)- (9CI) (CA INDEX NAME)



IT 876343-12-3P, (Benzothiazol-6-yl)(6-iodo-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amine 876343-27-0P, (3-Chloro-1H-indazol-5-yl)[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine 876343-28-1P, (3-Chloro-1H-indazol-5-yl)[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine monotrifluoroacetate 876343-29-2P, (3-Chloro-1H-indazol-5-yl)[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine trihydrochloride 876343-64-5P, (Benzothiazol-5-yl)[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine trihydrochloride 876343-69-0P, N-(2-Dimethylaminoethyl)-N'-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]benzothiazole-2,6-diamine 876343-70-3P, N-Benzyl-N'-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]benzothiazole-2,6-diamine 876343-72-5P, N-Phenethyl-N'-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]benzothiazole-2,6-diamine 876343-74-7P, N-(2-Methoxyethyl)-N'-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]benzothiazole-2,6-diamine


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyrrolopyrimidines multi-kinase inhibiting compds. as antitumor agents)

RN 876343-12-3 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-6-benzothiazolyl-6-iodo- (9CI) (CA INDEX NAME)

10/720,600




RN 876343-27-0 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-1H-indazol-5-yl)-6-(1,2,3,6-tetrahydro-4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 876343-28-1 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-1H-indazol-5-yl)-6-(1,2,3,6-tetrahydro-4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 876343-29-2 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-chloro-1H-indazol-5-yl)-6-(1,2,3,6-tetrahydro-4-pyridinyl)-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 876343-64-5 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-5-benzothiazolyl-6-(1,2,3,6-tetrahydro-4-pyridinyl)-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 876343-69-0 CAPLUS

CN 2,6-Benzothiazolodiamine, N2-[2-(dimethylamino)ethyl]-N6-[6-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 876343-70-3 CAPLUS

CN 2,6-Benzothiazolodiamine, N2-(phenylmethyl)-N6-[6-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 876343-72-5 CAPLUS

CN 2,6-Benzothiazol-2-amine, N2-(2-phenylethyl)-N6-[6-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)



RN 876343-74-7 CAPLUS

CN 2,6-Benzothiazol-2-amine, N2-(2-methoxyethyl)-N6-[6-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)



IT 876343-15-6, (1H-Indazol-5-yl)[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine 876343-16-7,

(1H-Indazol-5-yl)(6-iodo-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amine


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrrolopyrimidines multi-kinase inhibiting compds. as antitumor agents)

RN 876343-15-6 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-1H-indazol-5-yl-6-(1,2,3,6-tetrahydro-4-pyridinyl)- (9CI) (CA INDEX NAME)

10/720,600



RN 876343-16-7 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-1H-indazol-5-yl-6-iodo- (9CI) (CA  
INDEX NAME)






10/720,600

L4 ANSWER 8 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2006:120142 CAPLUS  
DN 144:205775  
TI Use of secreted proteinase inhibitor TIMP-2 for preventing and treating  
pancreatic disease, obesity and metabolic syndrome  
IN Onichtchouk, Daria; Burk, Ulrike; Hoffmann, Ursula  
PA Develogen Aktiengesellschaft, Germany  
SO PCT Int. Appl., 74 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006013114	A1	20060209	WO 2005-EP8578	20050808
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	EP 2004-18751	A	20040806		
IT	477600-75-2, Cp-690550				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(use of secreted proteinase inhibitor TIMP-2 for preventing and treating pancreatic disease, obesity and metabolic syndrome)				
RN	477600-75-2 CAPLUS				
CN	3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-, (3R,4R)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/720,600

L4 ANSWER 9 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:31415 CAPLUS

DN 144:108353

TI Preparation of pyrrolo[2,3-d]pyrimidines that modulate ACK1 and LCK activity for use against cancer

IN Farthing, Christopher N.; Faulder, Paul; Frenkel, Alexander David; Harrison, Martin James; Jiao, Xianyun; Kayser, Frank; Kopecky, David J.; Liu, Jinqian; Lively, Sarah E.; Sharma, Rajiv; Shuttleworth, Stephen Joseph

PA Amgen Inc., USA

SO PCT Int. Appl., 79 pp.  
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006004703	A2	20060112	WO 2005-US22836	20050629
	WO 2006004703	A3	20060309		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 2006040965	A1	20060223	US 2005-169313	20050629
PRAI	US 2004-583682P	P	20040629		


OS MARPAT 144:108353

IT 873078-84-3P, N-Allyl-4-[5-phenyl-4-[[[(S)-tetrahydrofuran-2-yl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]benzenesulfonamide  
873078-85-4P, [[4-[5-Phenyl-4-[[[(S)-tetrahydrofuran-2-yl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]sulfonyl]amino]acetic acid tert-butyl ester 873078-86-5P  
, [[(Ethoxycarbonyl)methyl][4-[5-phenyl-4-[[[(S)-tetrahydrofuran-2-yl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]sulfonyl]amino]acetic acid ethyl ester  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(drug candidate; preparation of pyrrolo[2,3-d]pyrimidines that modulate ACK1 and LCK activity for use against cancer)

RN 873078-84-3 CAPLUS

CN Benzenesulfonamide, 4-[5-phenyl-4-[[[(2S)-tetrahydro-2-furanyl)methyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-N-2-propenyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 873078-85-4 CAPLUS

CN Glycine, N-[[4-[5-phenyl-4-[[[(2S)-tetrahydro-2-furanyl]methyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 873078-86-5 CAPLUS

CN Glycine, N-(2-ethoxy-2-oxoethyl)-N-[[4-[5-phenyl-4-[[[(2S)-tetrahydro-2-furanyl]methyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 873078-70-7P, (5,6-Diphenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl) [2-

(morpholin-4-yl)ethyl]amine 873078-71-8P, (5,6-Diphenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)[(tetrahydrofuran-2-yl)methyl]amine 873078-72-9P, (5,6-Diphenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)[(tetrahydrothiophen-2-yl)methyl]amine 873078-73-0P, (5,6-Diphenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)[(tetrahydropyran-2-yl)methyl]amine 873078-74-1P, N,N-Dimethyl-4-[5-phenyl-4-[[[(S)-tetrahydrofuran-2-yl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]benzenesulfonamide 873078-78-5P, N-Methyl-4-[5-phenyl-4-[[[(S)-tetrahydrofuran-2-yl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]benzenesulfonamide 873078-79-6P, N,N-Diethyl-4-[5-phenyl-4-[[[(S)-tetrahydrofuran-2-yl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]benzenesulfonamide 873078-80-9P, N,N-Bis(2-methoxyethyl)-4-[5-phenyl-4-[[[(S)-tetrahydrofuran-2-yl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]benzenesulfonamide 873078-81-0P, N-(2-Methoxyethyl)-4-[5-phenyl-4-[[[(S)-tetrahydrofuran-2-yl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]benzenesulfonamide 873078-82-1P, [6-[4-[(Morpholin-4-yl)sulfonyl]phenyl]-5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl][[(S)-tetrahydrofuran-2-yl)methyl]amine 873078-83-2P, N-[2-(Morpholin-4-yl)ethyl]-4-[5-phenyl-4-[[[(S)-tetrahydrofuran-2-yl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]benzenesulfonamide 873078-87-6P, 4-[5-Phenyl-4-[[[(S)-tetrahydrofuran-2-yl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]benzenesulfonamide 873078-88-7P, N-(2,3-Dihydroxypropyl)-4-[5-phenyl-4-[[[(S)-tetrahydrofuran-2-yl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]benzenesulfonamide 873078-89-8P, [[4-[5-Phenyl-4-[[[(S)-tetrahydrofuran-2-yl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]sulfonyl]amino]acetic acid 873078-90-1P, N-(2-Hydroxyethyl)-4-[5-phenyl-4-[[[(S)-tetrahydrofuran-2-yl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]benzenesulfonamide 873078-91-2P, N,N-Bis(2-hydroxyethyl)-4-[5-phenyl-4-[[[(S)-tetrahydrofuran-2-yl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]benzenesulfonamide 873078-92-3P 873078-94-5P, [6-[4-[2-(Morpholin-4-yl)ethoxy]phenyl]-5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl][[(S)-tetrahydrofuran-2-yl)methyl]amine 873078-95-6P, [5-Phenyl-6-[4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl][[(S)-tetrahydrofuran-2-yl)methyl]amine 873078-96-7P, 1-[2-[4-[5-Phenyl-4-[[[(S)-tetrahydrofuran-2-yl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenoxy]ethyl]pyrrolidin-2-one 873078-97-8P, [6-[4-[2-(1-Methylpyrrolidin-2-yl)ethoxy]phenyl]-5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl][[(S)-tetrahydrofuran-2-yl)methyl]amine 873078-99-0P, [4-[5-Phenyl-4-[[[(S)-tetrahydrofuran-2-yl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenoxy]acetonitrile 873079-00-6P, N-Methyl-4-[5-phenyl-4-[[[(S)-tetrahydrofuran-2-yl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]benzamide 873079-02-8P, N,N-Dimethyl-4-[5-phenyl-4-[[[(S)-tetrahydrofuran-2-yl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]benzamide 873079-03-9P, (Morpholin-4-yl)[4-[5-phenyl-4-[[[(S)-tetrahydrofuran-2-yl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methanone 873079-04-0P, N-Cyclopropyl-4-[5-phenyl-4-[[[(S)-tetrahydrofuran-2-yl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]benzamide 873079-05-1P, N-(2-Methoxyethyl)-4-[5-phenyl-4-[[[(S)-tetrahydrofuran-2-yl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]benzamide 873079-06-2P, N-[2-(Morpholin-4-yl)ethyl]-4-[5-phenyl-4-[[[(S)-tetrahydrofuran-2-yl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]benzamide 873079-07-3P, N-(2-Dimethylaminoethyl)-4-[5-phenyl-4-[[[(S)-tetrahydrofuran-2-yl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]benzamide 873079-08-4P, N-[6-[4-(2-Dimethylaminoethoxy)phenyl]-5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-N-([1,3]dithiolan-2-yl)methyl]amine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU


10/720,600

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(drug candidate; preparation of pyrrolo[2,3-d]pyrimidines that modulate ACK1  
and LCK activity for use against cancer)


RN 873078-70-7 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[2-(4-morpholinyl)ethyl]-5,6-  
diphenyl- (9CI) (CA INDEX NAME)



RN 873078-71-8 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5,6-diphenyl-N-[(tetrahydro-2-  
furanyl)methyl]- (9CI) (CA INDEX NAME)



RN 873078-72-9 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5,6-diphenyl-N-[(tetrahydro-2-  
thienyl)methyl]- (9CI) (CA INDEX NAME)

10/720,600



RN 873078-73-0 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5,6-diphenyl-N-[(tetrahydro-2H-pyran-2-yl)methyl]- (9CI) (CA INDEX NAME)



RN 873078-74-1 CAPLUS

CN Benzenesulfonamide, N,N-dimethyl-4-[5-phenyl-4-[[[(2S)-tetrahydro-2-furanyl)methyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 873078-78-5 CAPLUS

CN Benzenesulfonamide, N-methyl-4-[5-phenyl-4-[[[(2S)-tetrahydro-2-furanyl)methyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)

10/720,600


Absolute stereochemistry.



RN 873078-79-6 CAPLUS

CN Benzenesulfonamide, N,N-diethyl-4-[5-phenyl-4-[[[(2S)-tetrahydro-2-furanyl]methyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 873078-80-9 CAPLUS

CN Benzenesulfonamide, N,N-bis(2-methoxyethyl)-4-[5-phenyl-4-[[[(2S)-tetrahydro-2-furanyl]methyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/720,600

RN 873078-81-0 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-4-[5-phenyl-4-[[[(2S)-tetrahydro-2-furanyl]methyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 873078-82-1 CAPLUS

CN Morpholine, 4-[[4-[5-phenyl-4-[[[(2S)-tetrahydro-2-furanyl]methyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 873078-83-2 CAPLUS

CN Benzenesulfonamide, N-[2-(4-morpholinyl)ethyl]-4-[5-phenyl-4-[[[(2S)-tetrahydro-2-furanyl]methyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/720,600



RN 873078-87-6 CAPLUS

CN Benzenesulfonamide, 4-[5-phenyl-4-[[[(2S)-tetrahydro-2-furanyl]methyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 873078-88-7 CAPLUS

CN Benzenesulfonamide, N-(2,3-dihydroxypropyl)-4-[5-phenyl-4-[[[(2S)-tetrahydro-2-furanyl]methyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/720,600



RN 873078-89-8 CAPLUS

CN Glycine, N-[[4-[5-phenyl-4-[[[(2S)-tetrahydro-2-furanyl]methyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 873078-90-1 CAPLUS

CN Benzenesulfonamide, N-(2-hydroxyethyl)-4-[5-phenyl-4-[[[(2S)-tetrahydro-2-furanyl]methyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 873078-91-2 CAPLUS

CN Benzenesulfonamide, N,N-bis(2-hydroxyethyl)-4-[5-phenyl-4-[[[(2S)-

10/720,600

tetrahydro-2-furanyl]methyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 873078-92-3 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[2-(dimethylamino)ethoxy]phenyl]-  
5-phenyl-N-[[2S]-tetrahydro-2-furanyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 873078-94-5 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[2-(4-morpholinyl)ethoxy]phenyl]-  
5-phenyl-N-[[2S]-tetrahydro-2-furanyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/720,600



RN 873078-95-6 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-phenyl-6-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-N-[[ (2S)-tetrahydro-2-furanyl]methyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 873078-96-7 CAPLUS

CN 2-Pyrrolidinone, 1-[2-[4-[5-phenyl-4-[[ (2S)-tetrahydro-2-furanyl]methyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/720,600



RN 873078-97-8 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[2-(1-methyl-2-pyrrolidinyl)ethoxy]phenyl]-5-phenyl-N-[[ (2S)-tetrahydro-2-furanyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 873078-99-0 CAPLUS

CN Acetonitrile, [4-[5-phenyl-4-[[[(2S)-tetrahydro-2-furanyl]methyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/720,600



RN 873079-00-6 CAPLUS

CN Benzamide, N-methyl-4-[5-phenyl-4-[[[(2S)-tetrahydro-2-furanyl]methyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 873079-02-8 CAPLUS

CN Benzamide, N,N-dimethyl-4-[5-phenyl-4-[[[(2S)-tetrahydro-2-furanyl]methyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 873079-03-9 CAPLUS

10/720,600

CN Morpholine, 4-[4-[5-phenyl-4-[[[(2S)-tetrahydro-2-furanyl]methyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]benzoyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 873079-04-0 CAPLUS

CN Benzamide, N-cyclopropyl-4-[5-phenyl-4-[[[(2S)-tetrahydro-2-furanyl]methyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 873079-05-1 CAPLUS

CN Benzamide, N-(2-methoxyethyl)-4-[5-phenyl-4-[[[(2S)-tetrahydro-2-furanyl]methyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/720,600




RN 873079-06-2 CAPLUS


CN Benzamide, N-[2-(4-morpholinyl)ethyl]-4-[5-phenyl-4-[[[(2S)-tetrahydro-2-furanyl]methyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 873079-07-3 CAPLUS



10/720,600


CN Benzamide, N-[2-(dimethylamino)ethyl]-4-[5-phenyl-4-[[[(2S)-tetrahydro-2-furanyl]methyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 873079-08-4 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[2-(dimethylamino)ethoxy]phenyl]-N-(1,3-dithiolan-2-ylmethyl)-5-phenyl- (9CI) (CA INDEX NAME)



IT 873078-76-3P, [5-Phenyl-6-(triethylsilyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl][[(S)-tetrahydrofuran-2-yl]methyl]amine

873078-77-4P, (6-Iodo-5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)[[(S)-tetrahydrofuran-2-yl]methyl]amine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of pyrrolo[2,3-d]pyrimidines that modulate ACK1 and LCK activity for use against cancer)

RN 873078-76-3 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-phenyl-N-[[[(2S)-tetrahydro-2-furanyl]methyl]-6-(triethylsilyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/720,600



RN 873078-77-4 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-iodo-5-phenyl-N-[[ (2S)-tetrahydro-2-furanyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/720,600

L4 ANSWER 10 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2005:1347233 CAPLUS  
DN 144:480633  
TI Combined Use of the JAK3 Inhibitor CP-690,550 with Mycophenolate Mofetil  
to Prevent Kidney Allograft Rejection in Nonhuman Primates  
AU Borie, Dominic C.; Larson, Michael J.; Flores, Mona G.; Campbell, Andrew;  
Rousvoal, Geraldine; Zhang, Sally; Higgins, John P.; Ball, Douglas J.;  
Kudlacz, Elizabeth M.; Brissette, William H.; Elliott, Eileen A.; Reitz,  
Bruce A.; Changelian, Paul S.  
CS Transplantation Immunology Laboratory, Department of Cardiothoracic  
Surgery, Falk Cardiovascular Research Center, Stanford University School  
of Medicine, Stanford, CA, USA  
SO Transplantation (2005), 80(12), 1756-1764  
CODEN: TRPLAU; ISSN: 0041-1337  
PB Lippincott Williams & Wilkins  
DT Journal  
LA English  
IT 477600-75-2, CP-690550  
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
(combined CP-690,550 with mycophenolate mofetil significantly improved  
allograft survival and delayed onset of acute cellular rejection  
following renal transplantation in nonhuman primate)  
RN 477600-75-2 CAPLUS  
CN 3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-  
d]pyrimidin-4-yl-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/720,600

L4 ANSWER 11 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2005:1258976 CAPLUS  
DN 145:81867  
TI Effects of JAK3 Inhibition with CP-690,550 on Immune Cell Populations and  
Their Functions in Nonhuman Primate Recipients of Kidney Allografts  
AU Paniagua, Ricardo; Si, Ming-Sing; Flores, Mona G.; Rousvoal, Geraldine;  
Zhang, Sally; Aalami, Oliver; Campbell, Andrew; Changelian, Paul S.;  
Reitz, Bruce A.; Borie, Dominic C.  
CS Transplantation Immunology Laboratory, Department of Cardiothoracic  
Surgery, Stanford University School of Medicine, Stanford, CA, USA  
SO Transplantation (2005), 80(9), 1283-1292  
CODEN: TRPLAU; ISSN: 0041-1337  
PB Lippincott Williams & Wilkins  
DT Journal  
LA English  
IT 477600-75-2  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(JAK3 inhibition with CP-690,550 in cynomolgus monkey with kidney  
allograft resulted in significant reduction of NK cells, IL-2 enhanced  
IFN- $\gamma$  production, proliferation, CD25 and CD71 expression of T cells)  
RN 477600-75-2 CAPLUS  
CN 3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-  
d]pyrimidin-4-yl-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/720,600

L4 ANSWER 12 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2005:1200417 CAPLUS  
DN 143:432653  
TI Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor  
for treatment of autoimmune disease  
IN Lake, Philip  
PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.  
SO PCT Int. Appl., 39 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005105146	A1	20051110	WO 2005-EP4758	20050502
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005237254	A1	20051110	AU 2005-237254	20050502
	CA 2563569	A1	20051110	CA 2005-2563569	20050502
	EP 1755680	A1	20070228	EP 2005-741179	20050502
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRAI	US 2004-567677P	P	20040503		
	US 2004-590061P	P	20040721		
	WO 2005-EP4758	W	20050502		
OS	MARPAT 143:432653				
IT	477600-75-2				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combinations comprising S1P receptor agonist and JAK3 kinase inhibitor)				
RN	477600-75-2 CAPLUS				
CN	3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-, (3R,4R)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD


10/720,600

ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/720,600

L4 ANSWER 13 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2005:1015847 CAPLUS  
DN 144:141871  
TI Quantitative Analysis of the Immunosuppressant CP-690,550 in Whole Blood  
by Column-Switching High-Performance Liquid Chromatography and Mass  
Spectrometry Detection  
AU Paniagua, Ricardo; Campbell, Andrew; Changelian, Paul S.; Reitz, Bruce A.;  
Prakash, Chandra; Borie, Dominic C.  
CS Transplantation Immunology Laboratory, Department of Cardiothoracic  
Surgery, Stanford University School of Medicine, Stanford, CA, 94305-5407,  
USA  
SO Therapeutic Drug Monitoring (2005), 27(5), 608-616  
CODEN: TDMODV; ISSN: 0163-4356  
PB Lippincott Williams & Wilkins  
DT Journal  
LA English  
IT 477600-75-2  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(column-switching high-performance liquid chromatog. coupled with mass  
spectrometry was effective and sensitive assay technique in monitoring  
CP-690, 550 in whole blood of allograft transplanted monkey model)  
RN 477600-75-2 CAPLUS  
CN 3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-  
d]pyrimidin-4-yl-, (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/720,600

L4 ANSWER 14 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2005:963932 CAPLUS  
DN 143:422564  
TI Adenosine Kinase Inhibitors. 5. Synthesis, Enzyme Inhibition, and  
Analgesic Activity of Diaryl-erythro-furanosyltubercidin Analogs  
AU Boyer, Serge H.; Ugarkar, Bheemaroo G.; Solbach, Joel; Kopcho, Joseph;  
Matelich, Michael C.; Ollis, Kristin; Gomez-Galeno, Jorge E.; Mendonca,  
Rohan; Tsuchiya, Megumi; Nagahisa, Atsushi; Nakane, Masami; Wiesner, James  
B.; Erion, Mark D.  
CS Metabasis Therapeutics Inc., San Diego, CA, 92121, USA  
SO Journal of Medicinal Chemistry (2005), 48(20), 6430-6441  
CODEN: JMCMAR; ISSN: 0022-2623  
PB American Chemical Society  
DT Journal  
LA English  
OS CASREACT 143:422564  
IT 868274-25-3P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT.  
(Reactant or reagent)  
(preparation, structure-activity, and analgesic activity of  
diaryl-erythro-furanosyltubercidin analogs as adenosine kinase  
inhibitors)  
RN 868274-25-3 CAPLUS  
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-  
phenyl- (9CI) (CA INDEX NAME)



RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



10/720,600

L4 ANSWER 15 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2005:588671 CAPLUS  
DN 143:97394  
TI Preparation of pyrrolopyrimidines as method of treatment of transplant rejection  
IN Changelian, Paul Steven  
PA Pfizer Products Inc., USA  
SO PCT Int. Appl., 92 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005060972	A2	20050707	WO 2004-IB4034	20041206
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004305317	A1	20050707	AU 2004-305317	20041206
	CA 2549485	A1	20050707	CA 2004-2549485	20041206
	EP 1734967	A2	20061227	EP 2004-801340	20041206
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	CN 1893952	A	20070110	CN 2004-80037758	20041206
	US 2005159433	A1	20050721	US 2004-11474	20041213
	NO 2006002292	A	20060614	NO 2006-2292	20060519
PRAI	US 2003-531180P	P	20031217		
	WO 2004-IB4034	W	20041206		
OS	MARPAT 143:97394				
IT	344418-61-7P, 1-[4-Methyl-3-[(methyl)(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]ethanone 344418-63-9P, [1-(2-Aminoethanesulfonyl)-4-methylpiperidin-3-yl](methyl)(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amine 344418-65-1P, (1-(Ethanesulfonyl)-4-methylpiperidin-3-yl)(methyl)(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amine 344418-67-3P, [1-(Butanesulfonyl)-4-methylpiperidin-3-yl](methyl)(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amine 344418-73-1P, N-[2-[4-Methyl-3-[(methyl)(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-sulfonyl]ethyl]propionamide 344418-75-3P, [2-[4-Methyl-3-[(methyl)(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-sulfonyl]ethyl]carbamic acid methyl ester 344418-77-5P, N-[2-[4-Methyl-3-[(methyl)(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-sulfonyl]ethyl]isobutyramide 344418-79-7P, (1-(Methanesulfonyl)piperidin-3-yl)(methyl)(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amine 344418-82-2P, (1-(Ethanesulfonyl)piperidin-3-yl)(methyl)(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amine 344418-86-6P, Methyl[1-(propanesulfonyl)piperidin-3-yl](7H-pyrrolo[2,3-d]pyrimidin-4-yl)amine 344418-88-8P, [1-(Butanesulfonyl)piperidin-3-yl](methyl)(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amine 344418-90-2P, 2,2-Dimethyl-N-[2-[4-methyl-3-[(methyl)(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-sulfonyl]ethyl]propionamide 344418-92-4P, 3-[4-Methyl-3-[(methyl)(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile 344418-94-6P, [3-[4-Methyl-3-[(methyl)(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropyl]carbamic				

acid tert-butyl ester 344418-96-8P, Methyl[4-methyl-1-(propanesulfonyl)piperidin-3-yl](7H-pyrrolo[2,3-d]pyrimidin-4-yl)amine 344418-98-0P, 3-Amino-1-[4-methyl-3-[(methyl)(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]propan-1-one 344419-00-7P, 2-Methoxy-1-[4-methyl-3-[(methyl)(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]ethanone 344419-02-9P, 2-Dimethylamino-1-[4-methyl-3-[(methyl)(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]ethanone 344419-05-2P, 3,3,3-Trifluoro-1-[4-methyl-3-[(methyl)(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]propan-1-one 344419-07-4P, N-[2-[4-Methyl-3-[(methyl)(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-2-oxoethyl]acetamide 344419-10-9P, 3-Ethoxy-1-[4-methyl-3-[(methyl)(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]propan-1-one 344419-13-2P, 4-Methyl-3-[(methyl)(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxylic acid methylamide 344419-15-4P, 4-Methyl-3-[(methyl)(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxylic acid diethylamide 344419-17-6P, Methyl[4-methyl-1-((2-(methylamino)ethane)sulfonyl)piperidin-3-yl](7H-pyrrolo[2,3-d]pyrimidin-4-yl)amine 344419-66-5P, 4-Methyl-3-[(methyl)(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxylic acid methyl ester 344419-70-1P, [[4-Methyl-3-[(methyl)(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]amino]acetic acid ethyl ester 344419-71-2P, 3,3,3-Trifluoro-1-[4-methyl-3-[(methyl)(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]propan-1-one 344419-73-4P, 1-[4-Methyl-3-[(methyl)(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]butan-3-yn-1-one 344419-74-5P, 1-[3-[(5-Chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)methylamino]-4-methylpiperidin-1-yl]propan-1-one 344419-75-6P 344419-76-7P 344419-77-8P, 1-[3-[(5-Fluoro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)methylamino]-4-methylpiperidin-1-yl]propan-1-one 384338-43-6P, 4-Methyl-3-[(methyl)(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxylic acid dimethylamide 477600-75-2P 477600-77-4P 477600-78-5P, (3R,4R)-4-Methyl-3-[(methyl)(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxylic acid methyl ester 477600-79-6P 477600-80-9P, (3R,4R)-4-Methyl-3-[(methyl)(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxylic acid dimethylamide 477600-81-0P 477600-82-1P 477600-83-2P 477600-86-5P 477600-87-6P 701913-17-9P, 4-Methyl-3-[(methyl)(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxylic acid isobutyl ester 701913-26-0P 701913-27-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolopyrimidines as method of treatment of transplant rejection)

RN 344418-61-7 CAPLUS


CN 3-Piperidinamine, 1-acetyl-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-(9CI) (CA INDEX NAME)

10/720,600




RN 344418-63-9 CAPLUS

CN 3-Piperidinamine, 1-[(2-aminoethyl)sulfonyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 344418-65-1 CAPLUS

CN 3-Piperidinamine, 1-(ethylsulfonyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 344418-67-3 CAPLUS


CN 3-Piperidinamine, 1-(butylsulfonyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)

CC1(CCN(C1)C2=CN3C=CC=CC3=N2)S(=O)(=O)CCCC

CN Propanamide, N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)




CN Carbamic acid, [2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)




CN Propanamide, 2-methyl-N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)

10/720,600




RN 344418-79-7 CAPLUS

CN 3-Piperidinamine, N-methyl-1-(methanesulfonyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 344418-82-2 CAPLUS


CN 3-Piperidinamine, 1-(ethanesulfonyl)-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 344418-86-6 CAPLUS


CN 3-Piperidinamine, N-methyl-1-(propylsulfonyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)

10/720,600




RN 344418-88-8 CAPLUS

CN 3-Piperidinamine, 1-(butylsulfonyl)-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 344418-90-2 CAPLUS


CN Propanamide, 2,2-dimethyl-N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)



RN 344418-92-4 CAPLUS


CN 3-Piperidinamine, 1-(cyanoacetyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)

10/720,600




RN 344418-94-6 CAPLUS

CN Carbamic acid, [3-[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 344418-96-8 CAPLUS


CN 3-Piperidinamine, N,4-dimethyl-1-(propylsulfonyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 344418-98-0 CAPLUS


CN 3-Piperidinamine, 1-(3-amino-1-oxopropyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)

10/720,600




RN 344419-00-7 CAPLUS

CN 3-Piperidinamine, 1-(methoxyacetyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 344419-02-9 CAPLUS

CN 3-Piperidinamine, 1-[(dimethylamino)acetyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 344419-05-2 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-1-(3,3,3-trifluoro-1-oxopropyl)- (9CI) (CA INDEX NAME)




10/720,600




RN 344419-07-4 CAPLUS

CN Acetamide, N-[2-[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 344419-10-9 CAPLUS


CN 3-Piperidinamine, 1-(3-ethoxy-1-oxopropyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 344419-13-2 CAPLUS


CN 1-Piperidinecarboxamide, N,4-dimethyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)

10/720,600




RN 344419-15-4 CAPLUS

CN 1-Piperidinecarboxamide, N,N-diethyl-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



RN 344419-17-6 CAPLUS


CN 3-Piperidinamine, N,4-dimethyl-1-[[2-(methylamino)ethyl]sulfonyl]-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 344419-66-5 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-, methyl ester (9CI) (CA INDEX NAME)

10/720,600




RN 344419-70-1 CAPLUS

CN Glycine, N-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 344419-71-2 CAPLUS


CN 3-Piperidinamine, N,4-dimethyl-N-(5-methyl-1H-pyrrolo[2,3-d]pyrimidin-4-yl)-1-(3,3,3-trifluoro-1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 344419-73-4 CAPLUS


CN 3-Piperidinamine, N,4-dimethyl-1-(1-oxo-3-butynyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)

10/720,600




RN 344419-74-5 CAPLUS

CN 3-Piperidinamine, N-(5-chloro-1H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-methyl-N-methyl-1-(1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 344419-75-6 CAPLUS


CN 1-Piperidinecarboximidamide, N'-cyano-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N'-propyl- (9CI) (CA INDEX NAME)



RN 344419-76-7 CAPLUS


CN 1-Piperidinecarboximidamide, N'-cyano-N,N,4-trimethyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)

10/720,600




RN 344419-77-8 CAPLUS

CN 3-Piperidinamine, N-(5-fluoro-1H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-methyl-N-methyl-1-(1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 384338-43-6 CAPLUS

CN 1-Piperidinecarboxamide, N,N,4-trimethyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)




RN 477600-75-2 CAPLUS

CN 3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/720,600



RN 477600-77-4 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-1-(propylsulfonyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-, (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477600-78-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-, methyl ester, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477600-79-6 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-1-(3,3,3-trifluoro-1-oxopropyl)-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/720,600



RN 477600-80-9 CAPLUS

CN 1-Piperidinecarboxamide, N,N,4-trimethyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-, (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477600-81-0 CAPLUS

CN Glycine, N-[[[(3R,4R)-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidiny]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477600-82-1 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-N-(5-methyl-1H-pyrrolo[2,3-d]pyrimidin-4-yl)-1-(3,3,3-trifluoro-1-oxopropyl)-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/720,600



RN 477600-83-2 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-1-(1-oxo-3-butynyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-, (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477600-86-5 CAPLUS

CN 1-Piperidinecarboximidamide, N-cyano-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N'-propyl-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477600-87-6 CAPLUS


CN 1-Piperidinecarboximidamide, N'-cyano-N,N,4-trimethyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




10/720,600



RN 701913-17-9 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-, 2-methylpropyl ester (9CI) (CA INDEX NAME)



RN 701913-26-0 CAPLUS

CN 3-Piperidinamine, N-(5-chloro-1H-pyrrolo[2,3-d]pyrimidin-4-yl)-N,4-dimethyl-1-(1-oxopropyl)-, (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 701913-27-1 CAPLUS

CN 3-Piperidinamine, N-(5-fluoro-1H-pyrrolo[2,3-d]pyrimidin-4-yl)-N,4-dimethyl-1-(1-oxopropyl)-, (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 384336-73-6P, Methyl (4-methylpiperidin-3-yl) (7H-pyrrolo[2,3-d]pyrimidin-4-yl)amine 384337-90-0P, (1-Benzyl-4-methylpiperidin-3-yl) (methyl) (7H-pyrrolo[2,3-d]pyrimidin-4-yl)amine  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of pyrrolopyrimidines as method of treatment of transplant rejection)  
 RN 384336-73-6 CAPLUS  
 CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-(4-methyl-3-piperidinyl)-(9CI) (CA INDEX NAME)



RN 384337-90-0 CAPLUS  
 CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-(phenylmethyl)-3-piperidinyl]- (9CI) (CA INDEX NAME)



10/720,600

L4 ANSWER 16 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2005:450935 CAPLUS  
DN 142:476227  
TI Method of treatment of atherosclerosis using pyrrolo[2,3-d]pyrimidine  
compounds inhibiting JAK3 kinase  
IN Changelian, Paul S.  
PA Pfizer Inc., USA  
SO U.S. Pat. Appl. Publ., 17 pp.  
CODEN: USXXCO

DT Patent  
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005113395	A1	20050526	US 2004-993052	20041118
	CA 2545192	A1	20050609	CA 2004-2545192	20041115
	WO 2005051393	A1	20050609	WO 2004-IB3788	20041115
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				
	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				
	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,				
	AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				
	EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,				
	SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,				
	NE, SN, TD, TG				
	EP 1689407	A1	20060816	EP 2004-798912	20041115
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	BR 2004016909	A	20070116	BR 2004-16909	20041115
PRAI	US 2003-525496P	P	20031125		
	WO 2004-IB3788	W	20041115		

OS MARPAT 142:476227


IT 344419-05-2P

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);  
RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL  
(Biological study); PREP (Preparation); RACT (Reactant or reagent); USES  
(Uses)

(pyrrolo[2,3-d]pyrimidine compds. inhibiting JAK3 kinase for treatment  
of atherosclerosis)


RN 344419-05-2 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-1-(3,3,3-  
trifluoro-1-oxopropyl)- (9CI) (CA INDEX NAME)




10/720,600

IT 344418-92-4P 344418-96-8P  
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);  
SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological  
study); PREP (Preparation); USES (Uses)  
(pyrrolo[2,3-d]pyrimidine compds. inhibiting JAK3 kinase for treatment  
of atherosclerosis)  
RN 344418-92-4 CAPLUS  
CN 3-Piperidinamine, 1-(cyanoacetyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-  
d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 344418-96-8 CAPLUS  
CN 3-Piperidinamine, N,4-dimethyl-1-(propylsulfonyl)-N-1H-pyrrolo[2,3-  
d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




IT 344419-66-5 344419-70-1 344419-71-2  
344419-74-5 344419-75-6 344419-76-7  
344419-77-8 384338-43-6 477600-75-2  
477600-77-4 477600-78-5 477600-79-6  
477600-80-9 477600-81-0 477600-82-1  
477600-86-5 477600-87-6 701913-26-0  
701913-27-1  
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);  
THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(pyrrolo[2,3-d]pyrimidine compds. inhibiting JAK3 kinase for treatment  
of atherosclerosis)  
RN 344419-66-5 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-  
4-ylamino)-, methyl ester (9CI) (CA INDEX NAME)

10/720,600




RN 344419-70-1 CAPLUS

CN Glycine, N-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 344419-71-2 CAPLUS


CN 3-Piperidinamine, N,4-dimethyl-N-(5-methyl-1H-pyrrolo[2,3-d]pyrimidin-4-yl)-1-(3,3,3-trifluoro-1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 344419-74-5 CAPLUS


CN 3-Piperidinamine, N-(5-chloro-1H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-methyl-N-methyl-1-(1-oxopropyl)- (9CI) (CA INDEX NAME)

10/720,600




RN 344419-75-6 CAPLUS

CN 1-Piperidinecarboximidamide, N-cyano-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N'-propyl- (9CI) (CA INDEX NAME)



RN 344419-76-7 CAPLUS


CN 1-Piperidinecarboximidamide, N'-cyano-N,N,4-trimethyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



RN 344419-77-8 CAPLUS


CN 3-Piperidinamine, N-(5-fluoro-1H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-methyl-N-methyl-1-(1-oxopropyl)- (9CI) (CA INDEX NAME)

10/720,600



RN 384338-43-6 CAPLUS


CN 1-Piperidinecarboxamide, N,N,4-trimethyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



RN 477600-75-2 CAPLUS

CN 3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477600-77-4 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-1-(propylsulfonyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/720,600



RN 477600-78-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-, methyl ester, (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477600-79-6 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-1-(3,3,3-trifluoro-1-oxopropyl)-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477600-80-9 CAPLUS

CN 1-Piperidinecarboxamide, N,N,4-trimethyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/720,600



RN 477600-81-0 CAPLUS

CN Glycine, N-[[ (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477600-82-1 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-N-(5-methyl-1H-pyrrolo[2,3-d]pyrimidin-4-yl)-1-(3,3,3-trifluoro-1-oxopropyl)-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477600-86-5 CAPLUS

CN 1-Piperidinecarboximidamide, N-cyano-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N'-propyl-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/720,600



RN 477600-87-6 CAPLUS

CN 1-Piperidinecarboximidamide, N'-cyano-N,N,4-trimethyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-, (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 701913-26-0 CAPLUS

CN 3-Piperidinamine, N-(5-chloro-1H-pyrrolo[2,3-d]pyrimidin-4-yl)-N,4-dimethyl-1-(1-oxopropyl)-, (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 701913-27-1 CAPLUS

CN 3-Piperidinamine, N-(5-fluoro-1H-pyrrolo[2,3-d]pyrimidin-4-yl)-N,4-dimethyl-1-(1-oxopropyl)-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 344418-61-7P 344418-63-9P 344418-65-1P  
 344418-67-3P 344418-73-1P 344418-75-3P  
 344418-77-5P 344418-79-7P 344418-82-2P  
 344418-86-6P 344418-88-8P 344418-90-2P  
 344418-94-6P 344418-98-0P 344419-00-7P  
 344419-02-9P 344419-07-4P 344419-10-9P  
 344419-13-2P 344419-15-4P 344419-17-6P  
 701913-17-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(pyrrolo[2,3-d]pyrimidine compds. inhibiting JAK3 kinase for treatment of atherosclerosis)

RN 344418-61-7 CAPLUS


CN 3-Piperidinamine, 1-acetyl-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 344418-63-9 CAPLUS


CN 3-Piperidinamine, 1-[(2-aminoethyl)sulfonyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)

10/720,600




RN 344418-65-1 CAPLUS

CN 3-Piperidinamine, 1-(ethylsulfonyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 344418-67-3 CAPLUS


CN 3-Piperidinamine, 1-(butylsulfonyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 344418-73-1 CAPLUS


CN Propanamide, N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)

10/720,600




RN 344418-75-3 CAPLUS

CN Carbamic acid, [2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 344418-77-5 CAPLUS


CN Propanamide, 2-methyl-N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)



RN 344418-79-7 CAPLUS


CN 3-Piperidinamine, N-methyl-1-(methanesulfonyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)

10/720,600




RN 344418-82-2 CAPLUS

CN 3-Piperidinamine, 1-(ethylsulfonyl)-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 344418-86-6 CAPLUS


CN 3-Piperidinamine, N-methyl-1-(propylsulfonyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 344418-88-8 CAPLUS


CN 3-Piperidinamine, 1-(butylsulfonyl)-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)

10/720,600




RN 344418-90-2 CAPLUS

CN Propanamide, 2,2-dimethyl-N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)




RN 344418-94-6 CAPLUS

CN Carbamic acid, [3-[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 344418-98-0 CAPLUS

CN 3-Piperidinamine, 1-(3-amino-1-oxopropyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 344419-00-7 CAPLUS

CN 3-Piperidinamine, 1-(methoxyacetyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 344419-02-9 CAPLUS

CN 3-Piperidinamine, 1-[(dimethylamino)acetyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 344419-07-4 CAPLUS

CN Acetamide, N-[2-[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)




10/720,600




RN 344419-10-9 CAPLUS

CN 3-Piperidinamine, 1-(3-ethoxy-1-oxopropyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 344419-13-2 CAPLUS


CN 1-Piperidinecarboxamide, N,4-dimethyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



RN 344419-15-4 CAPLUS


CN 1-Piperidinecarboxamide, N,N-diethyl-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)

10/720,600




RN 344419-17-6 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-1-[[2-(methylamino)ethyl]sulfonyl]-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 701913-17-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




IT 384336-73-6P 384337-90-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(pyrrolo[2,3-d]pyrimidine compds. inhibiting JAK3 kinase for treatment of atherosclerosis)

RN 384336-73-6 CAPLUS


10/720,600

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-(4-methyl-3-piperidinyl)-  
(9CI) (CA INDEX NAME)



RN 384337-90-0 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-(phenylmethyl)-  
3-piperidinyl]- (9CI) (CA INDEX NAME)



10/720,600

L4 ANSWER 17 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2005:307059 CAPLUS  
DN 143:146136  
TI Immunosuppression by the JAK3 Inhibitor CP-690,550 Delays Rejection and Significantly Prolongs Kidney Allograft Survival in Nonhuman Primates  
AU Borie, Dominic C.; Changelian, Paul S.; Larson, Michael J.; Si, Ming-Sing; Paniagua, Ricardo; Higgins, John P.; Holm, Bari; Campbell, Andrew; Lau, Macy; Zhang, Sally; Flores, Mona G.; Rousvoal, Geraldine; Hawkins, Jennifer; Ball, Douglas A.; Kudlacz, Elizabeth M.; Brissette, William H.; Elliott, Eileen A.; Reitz, Bruce A.; Morris, Randall E.  
CS Transplantation Immunology Laboratory, Department of Cardiothoracic Surgery, Falk Cardiovascular Research Center, Stanford University School of Medicine, Stanford, CA, USA  
SO Transplantation (2005), 79(7), 791-801  
CODEN: TRPLAU; ISSN: 0041-1337  
PB Lippincott Williams & Wilkins  
DT Journal  
LA English  
IT 477600-75-2, CP-690550  
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (CP-690,550 prolonged survival and delayed onset of rejection of allograft with persistent anemia, polyoma virus-like nephritis and urinary calcium carbonate accretions side effect in monkey model of renal allograft transplantation)  
RN 477600-75-2 CAPLUS  
CN 3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/720,600

L4 ANSWER 18 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2004:1101576 CAPLUS  
DN 142:148191  
TI The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers  
in cynomolgus monkey blood following chronic oral dosing  
AU Conklyn, Maryrose; Andresen, Catharine; Changelian, Paul; Kudlacz,  
Elizabeth  
CS Department of Antibacterials, Immunology and Cancer, Pfizer Global  
Research and Development, Groton, CT, USA  
SO Journal of Leukocyte Biology (2004), 76(6), 1248-1255  
CODEN: JLBIE7; ISSN: 0741-5400  
PB Federation of American Societies for Experimental Biology  
DT Journal  
LA English  
IT 477600-75-2, CP-690550  
RL: PAC (Pharmacological activity); BIOL (Biological study)  
(JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell nos. in  
cynomolgus monkey blood following chronic oral dosing)  
RN 477600-75-2 CAPLUS  
CN 3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-  
d]pyrimidin-4-yl-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/720,600

L4 ANSWER 19 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2004:1060779 CAPLUS  
DN 142:38274  
TI Preparation of 7H-pyrrolo[2,3-d]pyrimidines as protein tyrosine kinase inhibitors  
IN Bold, Guido; Capraro, Hans-Georg; Caravatti, Giorgio; Traxler, Peter  
PA Switz.  
SO U.S. Pat. Appl. Publ., 41 pp., Cont.-in-part of U.S. Ser. No. 485,747.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004248911	A1	20041209	US 2004-783000	20040220
	WO 2003013541	A1	20030220	WO 2002-EP8780	20020806
	WO 2003013541	A8	20040226		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW

RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR

	US 2004242600	A1	20041202	US 2004-485747	20040203
PRAI	GB 2001-19249	A	20010807		
	WO 2002-EP8780	W	20020806		
	US 2004-485747	A2	20040203		


OS MARPAT 142:38274

IT 497840-89-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(claimed compound; preparation of pyrrolopyrimidines as protein tyrosine kinase inhibitors)

RN 497840-89-8 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(6-methoxy-3-pyridinyl)-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



IT 497840-85-4P 497840-86-5P 497840-87-6P  
497840-88-7P 497840-90-1P 497840-91-2P  
497840-92-3P 497840-93-4P 497840-94-5P  
497840-95-6P 497840-96-7P 497840-97-8P

10/720,600


497840-98-9P 497840-99-0P 497841-00-6P  
497841-01-7P 497841-02-8P 497841-04-0P  
497841-05-1P 497841-06-2P 497841-07-3P  
497841-08-4P 497841-09-5P 497841-10-8P  
497841-11-9P 497841-12-0P 497841-13-1P  
497841-14-2P 497841-15-3P 497841-16-4P  
497841-17-5P 497841-18-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(claimed compound; preparation of pyrrolopyrimidines as protein tyrosine  
kinase inhibitors)


RN 497840-85-4 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-1,3-benzodioxol-5-yl-6-[4-[(4-methyl-  
1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-86-5 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-1,3-benzodioxol-5-yl-6-[4-[(4-ethyl-  
1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-87-6 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-1,3-benzodioxol-5-yl-6-[4-  
[(dimethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)

10/720,600




RN 497840-88-7 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-1,3-benzodioxol-5-yl-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-90-1 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(6-methoxy-3-pyridinyl)-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 497840-91-2 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(dimethylamino)methyl]phenyl]-N-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)




10/720,600




RN 497840-92-3 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 497840-93-4 CAPLUS


CN 2(1H)-Pyridinone, 5-[[6-[4-(4-morpholinylmethyl)phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



10/720,600


RN 497840-94-5 CAPLUS

CN 2(1H)-Pyridinone, 5-[[6-[4-[(dimethylamino)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497840-95-6 CAPLUS


CN 2(1H)-Pyridinone, 5-[[6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497840-96-7 CAPLUS


CN 2(1H)-Pyridinone, 5-[[6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)

10/720,600



RN 497840-97-8 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(6-methoxy-3-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 497840-98-9 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(6-methoxy-3-pyridinyl)methyl]-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)

10/720,600



RN 497840-99-0 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(dimethylamino)methyl]phenyl]-N-[(6-methoxy-3-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 497841-00-6 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(2-methoxy-4-pyridinyl)methyl]- (9CI) (CA INDEX NAME)

10/720,600




RN 497841-01-7 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2-methoxy-4-pyridinyl)methyl]-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497841-02-8 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(dimethylamino)methyl]phenyl]-N-[(2-methoxy-4-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



10/720,600


RN 497841-04-0 CAPLUS

CN 2(1H)-Pyridinone, 5-[[[6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 497841-05-1 CAPLUS

CN 2(1H)-Pyridinone, 5-[[[6-[4-[(dimethylamino)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 497841-06-2 CAPLUS

CN 2(1H)-Pyridinone, 5-[[[6-[4-(4-morpholinylmethyl)phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 497841-07-3 CAPLUS


CN 2(1H)-Pyridinone, 4-[[[6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 497841-08-4 CAPLUS


CN 2(1H)-Pyridinone, 4-[[[6-[4-(4-morpholinylmethyl)phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)

10/720,600



RN 497841-09-5 CAPLUS

CN 2(1H)-Pyridinone, 4-[[[6-[4-[(dimethylamino)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 497841-10-8 CAPLUS

CN 2(1H)-Pyridinone, 4-[[[6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)




10/720,600




RN 497841-11-9 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(2-methoxy-4-pyridinyl)-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497841-12-0 CAPLUS


CN 2(1H)-Pyridinone, 4-[[6-[4-(4-morpholinylmethyl)phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



10/720,600


RN 497841-13-1 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(2-methoxy-4-pyridinyl)-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497841-14-2 CAPLUS


CN 2(1H)-Pyridinone, 4-[[6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497841-15-3 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-(2-methoxy-4-pyridinyl)- (9CI) (CA INDEX NAME)

10/720,600




RN 497841-16-4 CAPLUS

CN 2(1H)-Pyridinone, 4-[[6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497841-17-5 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(dimethylamino)methyl]phenyl]-N-(2-methoxy-4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 497841-18-6 CAPLUS

CN 2(1H)-Pyridinone, 4-[[6-[4-[(dimethylamino)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)

10/720,600




IT 497841-49-3P 497841-50-6P 497841-51-7P  
497841-52-8P 497841-53-9P 497841-54-0P  
497841-55-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation of pyrrolopyrimidines as protein tyrosine kinase inhibitors)


RN 497841-49-3 CAPLUS

CN Benzenemethanol, 4-[4-(1,3-benzodioxol-5-ylamino)-1H-pyrrolo[2,3-  
d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)



RN 497841-50-6 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-1,3-benzodioxol-5-yl-6-[4-  
(chloromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497841-51-7 CAPLUS


CN Benzoic acid, 4-[4-[(6-methoxy-3-pyridinyl)methyl]amino]-1H-pyrrolo[2,3-  
d]pyrimidin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)

10/720,600




RN 497841-52-8 CAPLUS

CN Benzenemethanol, 4-[4-[(6-methoxy-3-pyridinyl)methyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)



RN 497841-53-9 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-(chloromethyl)phenyl]-N-[(6-methoxy-3-pyridinyl)methyl]- (9CI) (CA INDEX NAME)




RN 497841-54-0 CAPLUS

CN Benzenemethanol, 4-[4-[(2-methoxy-4-pyridinyl)amino]-1H-pyrrolo[2,3-


10/720,600

d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)



RN 497841-55-1 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-(chloromethyl)phenyl]-N-(2-methoxy-4-pyridinyl)- (9CI) (CA INDEX NAME)



10/720,600

L4 ANSWER 20 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2004:1020436 CAPLUS  
DN 142:347762  
TI Targeting the jak/STAT pathway for immunosuppression  
AU O'Shea, J. J.  
CS Molecular Immunology and Inflammation Branch, National Institute of  
Arthritis and Musculoskeletal and Skin Diseases, National Institute of  
Health, Bethesda, MD, USA  
SO Annals of the Rheumatic Diseases (2004), 63(Suppl. 2), ii67-ii71  
CODEN: ARDIAO; ISSN: 0003-4967  
PB BMJ Publishing Group  
DT Journal; General Review  
LA English  
IT 477600-75-2, CP-690550  
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological  
activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(targeting the jak/STAT pathway for immunosuppression)  
RN 477600-75-2 CAPLUS  
CN 3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-  
d]pyrimidin-4-yl-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/720,600

L4 ANSWER 21 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:927019 CAPLUS

DN 141:388734

TI Kinase-modulating heterocyclic compounds that induce neuronal differentiation in embryonic stem cells, and useful in the treatment of kinase signalling-associated diseases

IN Ding, Sheng; Wu, Tom; Gray, Nathanael; Schultz, Peter

PA IRM LLC, Bermuda; The Scripps Research Institute

SO PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004093812	A2	20041104	WO 2004-US12399	20040422
	WO 2004093812	A3	20050303		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005038049	A1	20050217	US 2004-829804	20040422
---------------	----	----------	----------------	----------

PRAI US 2003-465018P P 20030422

US 2003-489178P P 20030721

OS MARPAT 141:388734


IT 784150-26-1P 784150-27-2P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(kinase-modulating heterocyclic compds. that induce neuronal differentiation in embryonic stem cells, and useful in treatment of kinase signalling-associated diseases)

RN 784150-26-1 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-(3-aminophenyl)-N-3-pyridinyl- (9CI)  
(CA INDEX NAME)




RN 784150-27-2 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-(3-aminophenyl)-N-1H-indazol-6-yl- (9CI) (CA INDEX NAME)



10/720,600



10/720,600

L4 ANSWER 22 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:467744 CAPLUS

DN 141:38624

TI Treatment of transplant rejection using pyrrolo[2,3-d]pyrimidin-4-ylamines.

IN Changelian, Paul Steven

PA Pfizer Products Inc., USA

SO PCT Int. Appl., 52 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004047843	A1	20040610	WO 2003-IB5229	20031117
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2507392	A1	20040610	CA 2003-2507392	20031117
	AU 2003276591	A1	20040618	AU 2003-276591	20031117
	EP 1572213	A1	20050914	EP 2003-811831	20031117
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003016487	A	20051011	BR 2003-16487	20031117
	CN 1717236	A	20060104	CN 2003-80104237	20031117
	JP 2006509000	T	20060316	JP 2004-554807	20031117
	US 2004116449	A1	20040617	US 2003-720600	20031124
PRAI	US 2002-429784P	P	20021126		
	WO 2003-IB5229	W	20031117		
OS	MARPAT 141:38624				
IT	344418-61-7P 344418-63-9P 344418-65-1P 344418-67-3P 344418-73-1P 344418-75-3P 344418-77-5P 344418-79-7P 344418-82-2P 344418-86-6P 344418-88-8P 344418-90-2P 344418-92-4P 344418-94-6P 344418-96-8P 344418-98-0P 344419-00-7P 344419-02-9P 344419-07-4P 344419-10-9P 344419-13-2P 344419-15-4P 344419-17-6P 701913-17-9P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(treatment of transplant rejection using pyrrolopyrimidinylamines)				
RN	344418-61-7 CAPLUS				
CN	3-Piperidinamine, 1-acetyl-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-(9CI) (CA INDEX NAME)				

10/720,600




RN 344418-63-9 CAPLUS

CN 3-Piperidinamine, 1-[(2-aminoethyl)sulfonyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 344418-65-1 CAPLUS

CN 3-Piperidinamine, 1-(ethylsulfonyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 344418-67-3 CAPLUS

CN 3-Piperidinamine, 1-(butylsulfonyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 344418-73-1 CAPLUS

CN Propanamide, N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)



RN 344418-75-3 CAPLUS


CN Carbamic acid, [2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 344418-77-5 CAPLUS


CN Propanamide, 2-methyl-N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)

10/720,600




RN 344418-79-7 CAPLUS

CN 3-Piperidinamine, N-methyl-1-(methanesulfonyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 344418-82-2 CAPLUS


CN 3-Piperidinamine, 1-(ethanesulfonyl)-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 344418-86-6 CAPLUS


CN 3-Piperidinamine, N-methyl-1-(propylsulfonyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)

10/720,600




RN 344418-88-8 CAPLUS

CN 3-Piperidinamine, 1-(butylsulfonyl)-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 344418-90-2 CAPLUS


CN Propanamide, 2,2-dimethyl-N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)



RN 344418-92-4 CAPLUS


CN 3-Piperidinamine, 1-(cyanoacetyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)

10/720,600




RN 344418-94-6 CAPLUS

CN Carbamic acid, [3-[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 344418-96-8 CAPLUS


CN 3-Piperidinamine, N,4-dimethyl-1-(propylsulfonyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 344418-98-0 CAPLUS


CN 3-Piperidinamine, 1-(3-amino-1-oxopropyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)

10/720,600




RN 344419-00-7 CAPLUS

CN 3-Piperidinamine, 1-(methoxyacetyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 344419-02-9 CAPLUS

CN 3-Piperidinamine, 1-[(dimethylamino)acetyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 344419-07-4 CAPLUS

CN Acetamide, N-[2-[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)




10/720,600




RN 344419-10-9 CAPLUS

CN 3-Piperidinamine, 1-(3-ethoxy-1-oxopropyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 344419-13-2 CAPLUS


CN 1-Piperidinecarboxamide, N,4-dimethyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



RN 344419-15-4 CAPLUS


CN 1-Piperidinecarboxamide, N,N-diethyl-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)

10/720,600




RN 344419-17-6 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-1-[[2-(methylamino)ethyl]sulfonyl]-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 701913-17-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-, 2-methylpropyl ester (9CI) (CA INDEX NAME)



IT 344419-05-2 344419-66-5 344419-70-1  
344419-71-2 344419-73-4 344419-74-5  
344419-75-6 344419-76-7 344419-77-8  
384338-43-6 477600-75-2 477600-77-4  
477600-78-5 477600-79-6 477600-80-9  
477600-81-0 477600-82-1 477600-83-2

10/720,600


477600-86-5 477600-87-6 701913-26-0  
701913-27-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(treatment of transplant rejection using pyrrolopyrimidinylamines)


RN 344419-05-2 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-1-(3,3,3-trifluoro-1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 344419-66-5 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-, methyl ester (9CI) (CA INDEX NAME)



RN 344419-70-1 CAPLUS


CN Glycine, N-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

10/720,600




RN 344419-71-2 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-N-(5-methyl-1H-pyrrolo[2,3-d]pyrimidin-4-yl)-1-(3,3,3-trifluoro-1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 344419-73-4 CAPLUS


CN 3-Piperidinamine, N,4-dimethyl-1-(1-oxo-3-butynyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 344419-74-5 CAPLUS


CN 3-Piperidinamine, N-(5-chloro-1H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-methyl-N-methyl-1-(1-oxopropyl)- (9CI) (CA INDEX NAME)

10/720,600




RN 344419-75-6 CAPLUS

CN 1-Piperidinecarboximidamide, N-cyano-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N'-propyl- (9CI) (CA INDEX NAME)



RN 344419-76-7 CAPLUS


CN 1-Piperidinecarboximidamide, N'-cyano-N,N,4-trimethyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



RN 344419-77-8 CAPLUS


CN 3-Piperidinamine, N-(5-fluoro-1H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-methyl-N-methyl-1-(1-oxopropyl)- (9CI) (CA INDEX NAME)

10/720,600



RN 384338-43-6 CAPLUS


CN 1-Piperidinecarboxamide, N,N,4-trimethyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



RN 477600-75-2 CAPLUS

CN 3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477600-77-4 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-1-(propylsulfonyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/720,600



RN 477600-78-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-, methyl ester, (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477600-79-6 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-1-(3,3,3-trifluoro-1-oxopropyl)-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477600-80-9 CAPLUS

CN 1-Piperidinecarboxamide, N,N,4-trimethyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/720,600



RN 477600-81-0 CAPLUS

CN Glycine, N-[[ (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477600-82-1 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-N-(5-methyl-1H-pyrrolo[2,3-d]pyrimidin-4-yl)-1-(3,3,3-trifluoro-1-oxopropyl)-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477600-83-2 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-1-(1-oxo-3-butynyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/720,600



RN 477600-86-5 CAPLUS

CN 1-Piperidinecarboximidamide, N-cyano-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N'-propyl-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477600-87-6 CAPLUS

CN 1-Piperidinecarboximidamide, N'-cyano-N,N,4-trimethyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 701913-26-0 CAPLUS

CN 3-Piperidinamine, N-(5-chloro-1H-pyrrolo[2,3-d]pyrimidin-4-yl)-N,4-dimethyl-1-(1-oxopropyl)-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/720,600



RN 701913-27-1 CAPLUS

CN 3-Piperidinamine, N-(5-fluoro-1H-pyrrolo[2,3-d]pyrimidin-4-yl)-N,4-dimethyl-1-(1-oxopropyl)-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 384336-73-6P 384337-90-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(treatment of transplant rejection using pyrrolopyrimidinylamines)

RN 384336-73-6 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-(4-methyl-3-piperidinyl)- (9CI) (CA INDEX NAME)



RN 384337-90-0 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-(phenylmethyl)-3-piperidinyl]- (9CI) (CA INDEX NAME)

10/720,600




RE.CNT 3      THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/720,600

L4 ANSWER 23 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2004:144575 CAPLUS  
DN 140:281028  
TI The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models  
AU Kudlacz, Elizabeth; Perry, Bret; Sawyer, Perry; Conklyn, Maryrose; McCurdy, Sandra; Brissette, William; Flanagan, Mark; Changelian, Paul  
CS Department of Immunology, Pfizer Global Research and Development, Groton, CT, 06340, USA  
SO American Journal of Transplantation (2004), 4(1), 51-57  
CODEN: AJTMBR; ISSN: 1600-6135  
PB Blackwell Publishing Ltd.  
DT Journal  
LA English  
IT 477600-75-2, CP 690550  
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(CP 690550; novel JAK-3 kinase inhibitor CP-690550 as potent immunosuppressive agent)  
RN 477600-75-2 CAPLUS  
CN 3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/720,600

L4 ANSWER 24 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2004:77516 CAPLUS  
DN 141:81446  
TI JAK3 inhibition as a new concept for immune suppression  
AU Borie, Dominic C.; Si, Ming-Sing; Morris, Randall E.; Reitz, Bruce A.;  
Changelian, Paul S.  
CS Transplantation Immunology Laboratory Cardiothoracic Surgery, Stanford  
University School of Medicine, Stanford, CA, 94305-5407, USA  
SO Current Opinion in Investigational Drugs (Thomson Current Drugs) (2003),  
4(11), 1297-1303  
CODEN: COIDAZ; ISSN: 1472-4472  
PB Thomson Current Drugs  
DT Journal; General Review  
LA English  
IT 477600-75-2, CP-690550  
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
(JAK3 inhibition as new concept for immunosuppression in  
transplantation patients)  
RN 477600-75-2 CAPLUS  
CN 3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-  
d]pyrimidin-4-yl-, (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 25 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:864546 CAPLUS  
 DN 140:53024  
 TI Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor  
 AU Changelian, Paul S.; Flanagan, Mark E.; Ball, Douglas J.; Kent, Craig R.; Magnuson, Kelly S.; Martin, William H.; Rizzuti, Bonnie J.; Sawyer, Perry S.; Perry, Bret D.; Brissette, William H.; McCurdy, Sandra P.; Kudlacz, Elizabeth M.; Conklyn, Maryrose J.; Elliott, Eileen A.; Koslov, Erika R.; Fisher, Michael B.; Strelevitz, Timothy J.; Yoon, Kwansik; Whipple, David A.; Sun, Jianmin; Munchhof, Michael J.; Doty, John L.; Casavant, Jeffrey M.; Blumenkopf, Todd A.; Hines, Michael; Brown, Matthew F.; Lillie, Brett M.; Subramanyam, Chakrapani; Chang, Shang-Poa; Milici, Anthony J.; Beckius, Gretchen E.; Moyer, James D.; Su, Chunyan; Woodworth, Thasia G.; Gaweco, Anderson S.; Beals, Chan R.; Littman, Bruce H.; Fisher, Douglas A.; Smith, James F.; Zagouras, Panayiotis; Magna, Holly A.; Saltarelli, Mary J.; Johnson, Kimberly S.; Nelms, Linda F.; Des Etages, Shelley G.; Hayes, Lisa S.; Kawabata, Thomas T.; Finco-Kent, Deborah; Baker, Deanna L.; Larson, Michael; Si, Ming-Sing; Paniagua, Ricardo; Higgins, John; Holm, Bari; Reitz, Bruce; Zhou, Yong-Jie; Morris, Randall E.; O'Shea, John J.; Borie, Dominic C.  
 CS Immunology Group, Dep. Antibacterials and Immunology, Pfizer Global Res. and Dev., Groton, CT, 06340, USA  
 SO Science (Washington, DC, United States) (2003), 302(5646), 875-878  
 CODEN: SCIEAS; ISSN: 0036-8075  
 PB American Association for the Advancement of Science  
 DT Journal  
 LA English  
 IT 477600-75-2, CP 690550  
 RL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor CP-690,550 in relation to inhibition of interleukin-2-induced T-cell proliferation and gene expression)  
 RN 477600-75-2 CAPLUS  
 CN 3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/720,600

L4 ANSWER 26 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2003:454326 CAPLUS  
DN 139:36538  
TI Preparation of a novel crystalline compound useful as inhibitors of  
protein kinases  
IN Flanagan, Mark Edward; Li, Zheng Jane  
PA Pfizer Products Inc., USA  
SO PCT Int. Appl., 20 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003048162	A1	20030612	WO 2002-IB4948	20021125
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2469350	A1	20030612	CA 2002-2469350	20021125
	AU 2002348857	A1	20030617	AU 2002-348857	20021125
	EP 1451192	A1	20040901	EP 2002-781589	20021125
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002014761	A	20041109	BR 2002-14761	20021125
	CN 1596257	A	20050316	CN 2002-823587	20021125
	JP 2005511696	T	20050428	JP 2003-549352	20021125
	NZ 532366	A	20061130	NZ 2002-532366	20021125
	US 2003130292	A1	20030710	US 2002-310078	20021204
	US 6965027	B2	20051115		
	IN 2004DN01095	A	20050401	IN 2004-DN1095	20040423
	ZA 2004004270	A	20050815	ZA 2004-4270	20040531
	NO 2004002721	A	20040628	NO 2004-2721	20040628
	US 2005159434	A1	20050721	US 2005-32990	20050110
PRAI	US 2001-338984P	P	20011206		
	WO 2002-IB4948	W	20021125		
	US 2002-310078	A1	20021204		
OS	CASREACT 139:36538				
IT	477600-73-0				
	RL: RCT (Reactant); RACT (Reactant or reagent) (hydrogenolysis and reaction of, with dioxopyrrolidinyl cyanoacetate; preparation and x-ray diffraction of a novel crystalline compound useful as inhibitors of protein kinases)				
RN	477600-73-0 CAPLUS				
CN	1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[(3R,4R)-4-methyl-1-(phenylmethyl)-3-piperidinyl]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.

10/720,600



IT 540737-29-9P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
(preparation and x-ray diffraction of a novel crystalline compound useful as  
inhibitors of protein kinases)

RN 540737-29-9 CAPLUS


CN 3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-  
d]pyrimidin-4-yl-, (3R,4R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)  
(9CI) (CA INDEX NAME)

CM 1

CRN 477600-75-2

CMF C16 H20 N6 O


Absolute stereochemistry.



CM 2

CRN 77-92-9

CMF C6 H8 O7



IT 477600-75-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation and x-ray diffraction of a novel crystalline compound useful as




10/720,600

inhibitors of protein kinases)

RN 477600-75-2 CAPLUS

CN 3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 477600-74-1P, (3R,4R)-Methyl{(4-methylpiperidin-3-yl)(7H-pyrrolo[2,3-d]pyrimidin-4-yl)}amine


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(reaction of, with dioxopyrrolidinyl cyanoacetate; preparation and x-ray diffraction of a novel crystalline compound useful as inhibitors of protein kinases)

RN 477600-74-1 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[(3R,4R)-4-methyl-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/720,600

L4 ANSWER 27 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:133054 CAPLUS

DN 138:170253

TI Preparation of 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidines as protein tyrosine kinase inhibitors

IN Bold, Guido; Capraro, Hans-Georg; Caravatti, Giorgio; Traxler, Peter

PA Novartis AG, Switz.; Novartis Pharma G.m.b.H.

SO PCT Int. Appl., 95 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003013541	A1	20030220	WO 2002-EP8780	20020806
	WO 2003013541	A8	20040226		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW			
	RW:	AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR			
	CA 2453881	A1	20030220	CA 2002-2453881	20020806
	EP 1416935	A1	20040512	EP 2002-758437	20020806
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
	BR 2002011801	A	20040831	BR 2002-11801	20020806
	HU 200401083	A2	20040928	HU 2004-1083	20020806
	CN 1538847	A	20041020	CN 2002-815351	20020806
	JP 2005501077	T	20050113	JP 2003-518550	20020806
	NZ 530824	A	20050826	NZ 2002-530824	20020806
	ZA 2004000271	A	20041101	ZA 2004-271	20040114
	US 2004242600	A1	20041202	US 2004-485747	20040203
	NO 2004000540	A	20040205	NO 2004-540	20040205
	US 2004248911	A1	20041209	US 2004-783000	20040220
PRAI	GB 2001-19249	A	20010807		
	WO 2002-EP8780	W	20020806		
	US 2004-485747	A2	20040203		
OS	MARPAT 138:170253				
IT	497840-89-8P				
	RL:	PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)			
		(preparation of 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidines as protein tyrosine kinase inhibitors)			
RN	497840-89-8 CAPLUS				
CN	1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(6-methoxy-3-pyridinyl)-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)				




IT 497840-85-4P 497840-86-5P 497840-87-6P  
 497840-88-7P 497840-90-1P 497840-91-2P  
 497840-92-3P 497840-93-4P 497840-94-5P  
 497840-95-6P 497840-96-7P 497840-97-8P  
 497840-98-9P 497840-99-0P 497841-00-6P  
 497841-01-7P 497841-02-8P 497841-03-9P  
 497841-04-0P 497841-05-1P 497841-06-2P  
 497841-07-3P 497841-08-4P 497841-09-5P  
 497841-10-8P 497841-11-9P 497841-12-0P  
 497841-13-1P 497841-14-2P 497841-15-3P  
 497841-16-4P 497841-17-5P 497841-18-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidines as protein tyrosine kinase inhibitors)

RN 497840-85-4 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-1,3-benzodioxol-5-yl-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-86-5 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-1,3-benzodioxol-5-yl-6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)

10/720,600




RN 497840-87-6 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-1,3-benzodioxol-5-yl-6-[4-[(dimethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 497840-88-7 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-1,3-benzodioxol-5-yl-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497840-90-1 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(6-methoxy-3-pyridinyl)-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)

10/720,600




RN 497840-91-2 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(dimethylamino)methyl]phenyl]-N-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 497840-92-3 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)



10/720,600


RN 497840-93-4 CAPLUS

CN 2(1H)-Pyridinone, 5-[[6-[4-(4-morpholinylmethyl)phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497840-94-5 CAPLUS


CN 2(1H)-Pyridinone, 5-[[6-[4-[(dimethylamino)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497840-95-6 CAPLUS


CN 2(1H)-Pyridinone, 5-[[6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)

10/720,600



RN 497840-96-7 CAPLUS


CN 2(1H)-Pyridinone, 5-[[6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497840-97-8 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(6-methoxy-3-pyridinyl)methyl]- (9CI) (CA INDEX NAME)

10/720,600



RN 497840-98-9 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(6-methoxy-3-pyridinyl)methyl]-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 497840-99-0 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(dimethylamino)methyl]phenyl]-N-[(6-methoxy-3-pyridinyl)methyl]- (9CI) (CA INDEX NAME)




10/720,600




RN 497841-00-6 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(2-methoxy-4-pyridinyl)methyl]- (9CI) (CA INDEX NAME)




RN 497841-01-7 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2-methoxy-4-pyridinyl)methyl]-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 497841-02-8 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(dimethylamino)methyl]phenyl]-N-[(2-methoxy-4-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 497841-03-9 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(2-methoxy-4-pyridinyl)methyl]-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



10/720,600


RN 497841-04-0 CAPLUS

CN 2(1H)-Pyridinone, 5-[[[6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 497841-05-1 CAPLUS

CN 2(1H)-Pyridinone, 5-[[[6-[4-[(dimethylamino)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 497841-06-2 CAPLUS

CN 2(1H)-Pyridinone, 5-[[[6-[4-(4-morpholinylmethyl)phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 497841-07-3 CAPLUS

CN 2(1H)-Pyridinone, 4-[[[6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 497841-08-4 CAPLUS

CN 2(1H)-Pyridinone, 4-[[[6-[4-(4-morpholinylmethyl)phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 497841-09-5 CAPLUS


CN 2(1H)-Pyridinone, 4-[[[6-[4-[(dimethylamino)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 497841-10-8 CAPLUS


CN 2(1H)-Pyridinone, 4-[[[6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)

10/720,600




RN 497841-11-9 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(2-methoxy-4-pyridinyl)-6-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 497841-12-0 CAPLUS


CN 2(1H)-Pyridinone, 4-[[6-[4-(4-morpholinylmethyl)phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



10/720,600


RN 497841-13-1 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(2-methoxy-4-pyridinyl)-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 497841-14-2 CAPLUS

CN 2(1H)-Pyridinone, 4-[[6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)




RN 497841-15-3 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-(2-methoxy-4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 497841-16-4 CAPLUS

CN 2(1H)-Pyridinone, 4-[[6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 497841-17-5 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(dimethylamino)methyl]phenyl]-N-(2-methoxy-4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 497841-18-6 CAPLUS

CN 2(1H)-Pyridinone, 4-[[6-[4-[(dimethylamino)methyl]phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)






IT 497841-49-3P 497841-50-6P 497841-51-7P  
497841-52-8P 497841-53-9P 497841-54-0P  
497841-55-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation of 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidines as protein  
tyrosine kinase inhibitors)


RN 497841-49-3 CAPLUS

CN Benzenemethanol, 4-[4-(1,3-benzodioxol-5-ylamino)-1H-pyrrolo[2,3-  
d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)




RN 497841-50-6 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-1,3-benzodioxol-5-yl-6-[4-  
(chloromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 497841-51-7 CAPLUS


CN Benzoic acid, 4-[4-[[6-methoxy-3-pyridinyl)methyl]amino]-1H-pyrrolo[2,3-  
d]pyrimidin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 497841-52-8 CAPLUS  
 CN Benzenemethanol, 4-[4-[(6-methoxy-3-pyridinyl)methyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl)- (9CI) (CA INDEX NAME)




RN 497841-53-9 CAPLUS  
 CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-(chloromethyl)phenyl]-N-[(6-methoxy-3-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 497841-54-0 CAPLUS  
 CN Benzenemethanol, 4-[4-[(2-methoxy-4-pyridinyl)amino]-1H-pyrrolo[2,3-


10/720,600

d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)



RN 497841-55-1 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-(chloromethyl)phenyl]-N-(2-methoxy-4-pyridinyl)- (9CI) (CA INDEX NAME)




RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/720,600

L4 ANSWER 28 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2002:964146 CAPLUS  
DN 138:39187  
TI Preparation of piperidinecarboxylates and related compounds as NMDA NR2B  
receptor antagonists for the treatment or prevention of migraine.  
IN Allen, Christopher; Koblan, Ken S.; Sleeth, Timothy  
PA Merck & Co., Inc., USA  
SO PCT Int. Appl., 185 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002100352	A2	20021219	WO 2002-US21069	20020607
	WO 2002100352	A3	20030327		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2449249	A1	20021219	CA 2002-2449249	20020607
	EP 1399160	A2	20040324	EP 2002-744807	20020607
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2004537526	T	20041216	JP 2003-503178	20020607
	US 2004204341	A1	20041014	US 2003-479923	20031205
PRAI	US 2001-297672P	P	20010612		
	WO 2002-US21069	W	20020607		
IT	455265-87-9P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of piperidinecarboxylates and related compds. as NR2B receptor antagonists for the treatment or prevention of migraine)				
RN	455265-87-9 CAPLUS				
CN	1-Piperidinecarboxylic acid, 4-[(1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)				

10/720,600



10/720,600

L4 ANSWER 29 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2002:927431 CAPLUS  
DN 138:14072  
TI Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and  
the use thereof for the preparation of pyrrolo[2,3-d]pyrimidines as  
protein kinase inhibitors  
IN Wilcox, Glenn Ernest; Koecher, Christian; Vries, Ton; Flanagan, Mark  
Edward; Munchhof, Michael John  
PA Pfizer Products Inc., USA  
SO PCT Int. Appl., 55 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002096909	A1	20021205	WO 2002-IB1905	20020529
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003073719	A1	20030417	US 2002-154699	20020523
	CA 2448281	A1	20021205	CA 2002-2448281	20020529
	EP 1392694	A1	20040303	EP 2002-733058	20020529
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	EE 200300594	A	20040415	EE 2003-594	20020529
	BR 2002009246	A	20040615	BR 2002-9246	20020529
	JP 2004534047	T	20041111	JP 2003-500088	20020529
	NZ 530380	A	20050826	NZ 2002-530380	20020529
	EP 1609781	A1	20051228	EP 2005-15461	20020529
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	CN 1729192	A	20060201	CN 2002-810817	20020529
	EP 1666481	A2	20060607	EP 2005-15454	20020529
	EP 1666481	A3	20061129		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	ZA 2003007982	A	20041014	ZA 2003-7982	20031014
	NO 2003005201	A	20031124	NO 2003-5201	20031124
	BG 108389	A	20050131	BG 2003-108389	20031127
	US 2004229923	A1	20041118	US 2004-869101	20040616
PRAI	US 2001-294775P	P	20010531		
	US 2001-341048P	P	20011206		
	US 2002-154699	A1	20020523		
	EP 2002-733058	A3	20020529		
	WO 2002-IB1905	W	20020529		
OS	MARPAT 138:14072				
IT	477600-75-2P 477600-76-3P 477600-77-4P				
	477600-78-5P 477600-79-6P 477600-80-9P				
	477600-81-0P 477600-82-1P 477600-83-2P				
	477600-84-3P 477600-85-4P 477600-86-5P				
	477600-87-6P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				


10/720,600

(optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and the use thereof for preparation of pyrrolo[2,3-d]pyrimidines as protein kinase inhibitors)

RN 477600-75-2 CAPLUS

CN 3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-, (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477600-76-3 CAPLUS

CN 3-Piperidinamine, 1-acetyl-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-, (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477600-77-4 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-1-(propylsulfonyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477600-78-5 CAPLUS

10/720,600

CN 1-Piperidinecarboxylic acid, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-, methyl ester, (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477600-79-6 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-1-(3,3,3-trifluoro-1-oxopropyl)-, (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477600-80-9 CAPLUS

CN 1-Piperidinecarboxamide, N,N,4-trimethyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477600-81-0 CAPLUS

CN Glycine, N-[[ (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/720,600



RN 477600-82-1 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-N-(5-methyl-1H-pyrrolo[2,3-d]pyrimidin-4-yl)-1-(3,3,3-trifluoro-1-oxopropyl)-, (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477600-83-2 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-1-(1-oxo-3-butynyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477600-84-3 CAPLUS

CN 3-Piperidinamine, N-(5-chloro-1H-pyrrolo[2,3-d]pyrimidin-4-yl)-N,4-dimethyl-1-(3,3,3-trifluoro-1-oxopropyl)-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/720,600



RN 477600-85-4 CAPLUS

CN 3-Piperidinamine, N-(5-fluoro-1H-pyrrolo[2,3-d]pyrimidin-4-yl)-N,4-dimethyl-1-(3,3,3-trifluoro-1-oxopropyl)-, (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477600-86-5 CAPLUS

CN 1-Piperidinecarboximidamide, N-cyano-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N'-propyl-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477600-87-6 CAPLUS

CN 1-Piperidinecarboximidamide, N'-cyano-N,N,4-trimethyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



IT 477600-73-0P 477600-74-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and the use thereof for preparation of pyrrolo[2,3-d]pyrimidines as protein kinase inhibitors)

RN 477600-73-0 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[(3R,4R)-4-methyl-1-(phenylmethyl)-3-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477600-74-1 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[(3R,4R)-4-methyl-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/720,600

10/720,600

L4 ANSWER 30 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2002:676010 CAPLUS  
DN 137:216875  
TI Preparation of N-acyl-4-(heterocyclylaminomethyl)piperidines as NMDA/NR2B antagonists  
IN Claiborne, Christopher F.; Butcher, John W.; Claremon, David A.; Libby, Brian E.; Liverton, Nigel J.; Munson, Peter M.; Nguyen, Kevin T.; Phillips, Brian; Thompson, Wayne; McCauley, John A.  
PA Merck & Co., Inc., USA  
SO PCT Int. Appl., 208 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002068409	A1	20020906	WO 2002-US5226	20020220
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2438895	A1	20020906	CA 2002-2438895	20020220
	US 2002165241	A1	20021107	US 2002-79452	20020220
	US 7053089	B2	20060530		
	EE 200300403	A	20031215	EE 2003-403	20020220
	EP 1379520	A1	20040114	EP 2002-721105	20020220
	EP 1379520	B1	20060426		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	HU 200303258	A2	20040128	HU 2003-3258	20020220
	BR 2002007526	A	20040309	BR 2002-7526	20020220
	CN 1503793	A	20040609	CN 2002-808713	20020220
	JP 2004524314	T	20040812	JP 2002-567923	20020220
	NZ 527365	A	20050826	NZ 2002-527365	20020220
	AT 324371	T	20060515	AT 2002-721105	20020220
	PT 1379520	T	20060831	PT 2002-721105	20020220
	ES 2261658	T3	20061116	ES 2002-2721105	20020220
	US 2004209889	A1	20041021	US 2003-470561	20030729
	ZA 2003006159	A	20040705	ZA 2003-6159	20030808
	BG 108113	A	20050430	BG 2003-108113	20030819
	NO 2003003732	A	20031022	NO 2003-3732	20030822
	IN 2003CN01316	A	20051125	IN 2003-CN1316	20030822
PRAI	US 2001-271100P	P	20010223		
	WO 2002-US5226	W	20020220		

OS MARPAT 137:216875

IT 455265-87-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of  
N-acyl-4-(heterocyclylaminomethyl)piperidine  
s as NMDA/NR2B antagonists)

RN 455265-87-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

10/720,600



RE.CNT 3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/720,600


L4 ANSWER 31 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2002:10480 CAPLUS  
 DN 136:85818  
 TI Preparation of pyrrolo[2,3-d]pyrimidines as immunosuppressive agents  
 IN Blumenkopf, Todd Andrew; Flanagan, Mark Edward; Munchhof, Michael John  
 PA Pfizer Products Inc., USA  
 SO PCT Int. Appl., 86 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002000661	A1	20020103	WO 2001-IB975	20010605
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2412560	A1	20020103	CA 2001-2412560	20010605
	EP 1294724	A1	20030326	EP 2001-934243	20010605
	EP 1294724	B1	20060419		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	HU 200301114	A2	20030828	HU 2003-1114	20010605
	BR 2001011561	A	20030909	BR 2001-11561	20010605
	JP 2004501922	T	20040122	JP 2002-505785	20010605
	EE 200200711	A	20040615	EE 2002-711	20010605
	NZ 522364	A	20040924	NZ 2001-522364	20010605
	AU 784297	B2	20060302	AU 2001-60538	20010605
	AT 323704	T	20060515	AT 2001-934243	20010605
	PT 1294724	T	20060731	PT 2001-934243	20010605
	ES 2257410	T3	20060801	ES 2001-1934243	20010605
	EP 1686130	A1	20060802	EP 2006-7969	20010605
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	TW 243820	B	20051121	TW 2001-90115016	20010620
	US 2002068746	A1	20020606	US 2001-891028	20010625
	US 6696567	B2	20040224		
	IN 2002DN01075	A	20050128	IN 2002-DN1075	20021030
	BG 107236	A	20030930	BG 2002-107236	20021031
	NO 2002006030	A	20021216	NO 2002-6030	20021216
	ZA 2002010275	A	20031219	ZA 2002-10275	20021219
	US 2003220353	A1	20031127	US 2003-463724	20030616
	US 6962993	B2	20051108		
	US 2005197349	A1	20050908	US 2005-112307	20050421
PRAI	US 2000-214287P	P	20000626		
	EP 2001-934243	A3	20010605		
	WO 2001-IB975	W	20010605		
	US 2001-891028	A1	20010625		
	US 2003-463724	A1	20030616		
OS	MARPAT 136:85818				
IT	384336-73-6P 384337-90-0P				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(preparation of pyrrolo[2,3-d]pyrimidines as immunosuppressive agents)				

10/720,600


RN 384336-73-6 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-(4-methyl-3-piperidiny)-  
(9CI) (CA INDEX NAME)



RN 384337-90-0 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-(phenylmethyl)-  
3-piperidiny]- (9CI) (CA INDEX NAME)



IT 384335-17-5P 384335-18-6P 384335-19-7P  
384335-20-0P 384335-21-1P 384335-22-2P  
384335-23-3P 384335-24-4P 384335-25-5P  
384335-26-6P 384335-27-7P 384335-28-8P  
384335-29-9P 384335-30-2P 384335-31-3P  
384335-32-4P 384335-33-5P 384335-34-6P  
384335-35-7P 384335-36-8P 384335-37-9P  
384335-38-0P 384335-39-1P 384335-40-4P  
384335-41-5P 384335-42-6P 384335-43-7P  
384335-44-8P 384335-45-9P 384335-46-0P  
384335-47-1P 384335-48-2P 384335-49-3P  
384335-50-6P 384335-51-7P 384335-52-8P  
384335-53-9P 384335-54-0P 384335-56-2P  
384335-57-3P 384335-58-4P 384335-59-5P  
384335-60-8P 384335-61-9P 384335-62-0P  
384335-63-1P 384335-64-2P 384335-65-3P  
384335-66-4P 384335-67-5P 384335-68-6P  
384335-70-0P 384335-71-1P 384335-72-2P  
384335-73-3P 384335-74-4P 384335-75-5P  
384335-76-6P 384335-77-7P 384335-78-8P  
384335-79-9P 384335-80-2P 384335-81-3P  
384335-82-4P 384335-83-5P 384335-84-6P  
384335-85-7P 384335-86-8P 384335-87-9P  
384335-88-0P 384335-89-1P 384335-90-4P  
384335-91-5P 384335-92-6P 384335-93-7P  
384335-94-8P 384335-95-9P 384335-96-0P



384335-97-1P 384335-98-2P 384335-99-3P  
 384336-00-9P 384336-01-0P 384336-02-1P  
 384336-03-2P 384336-04-3P 384336-05-4P  
 384336-06-5P 384336-07-6P 384336-08-7P  
 384336-09-8P 384336-10-1P 384336-11-2P  
 384336-12-3P 384336-13-4P 384336-14-5P  
 384336-15-6P 384336-16-7P 384336-17-8P  
 384336-18-9P 384336-19-0P 384336-20-3P  
 384336-21-4P 384336-23-6P 384336-24-7P  
 384336-26-9P 384336-28-1P 384336-29-2P  
 384336-30-5P 384336-31-6P 384336-32-7P  
 384336-33-8P 384336-34-9P 384336-35-0P  
 384336-36-1P 384336-37-2P 384336-38-3P  
 384336-39-4P 384336-40-7P 384336-41-8P  
 384336-42-9P 384336-43-0P 384336-44-1P  
 384336-45-2P 384336-46-3P 384336-47-4P  
 384336-48-5P 384336-49-6P 384336-50-9P  
 384336-51-0P 384336-52-1P 384336-53-2P  
 384336-54-3P 384336-55-4P 384336-56-5P  
 384336-57-6P 384336-58-7P 384336-59-8P  
 384336-60-1P 384336-61-2P 384336-62-3P  
 384336-63-4P 384336-64-5P 384336-65-6P  
 384336-66-7P 384336-67-8P 384336-68-9P  
 384336-69-0P 384336-70-3P 384336-71-4P  
 384336-72-5P 384336-74-7P 384336-75-8P  
 384336-76-9P 384336-77-0P 384336-78-1P  
 384336-79-2P 384336-80-5P 384336-81-6P  
 384336-82-7P 384336-83-8P 384336-84-9P  
 384336-85-0P 384336-86-1P 384336-87-2P  
 384336-88-3P 384336-89-4P 384336-90-7P  
 384336-91-8P 384336-92-9P 384336-93-0P  
 384336-94-1P 384336-95-2P 384336-96-3P  
 384336-97-4P 384336-98-5P 384336-99-6P  
 384337-00-2P 384337-01-3P 384337-02-4P  
 384337-03-5P 384337-04-6P 384337-05-7P  
 384337-06-8P 384337-12-6P 384337-13-7P  
 384337-14-8P 384337-15-9P 384337-16-0P  
 384337-17-1P 384337-18-2P 384337-19-3P  
 384337-20-6P 384337-21-7P 384337-22-8P  
 384337-23-9P 384337-24-0P 384337-25-1P  
 384337-26-2P 384337-27-3P 384337-28-4P  
 384337-29-5P 384337-30-8P 384337-31-9P  
 384337-32-0P 384337-33-1P 384337-34-2P  
 384337-35-3P 384337-36-4P 384337-37-5P  
 384337-38-6P 384337-39-7P 384337-40-0P  
 384337-41-1P 384337-42-2P 384337-43-3P  
 384337-44-4P 384337-45-5P 384337-46-6P  
 384337-47-7P 384337-48-8P 384337-49-9P  
 384337-50-2P 384337-51-3P 384337-52-4P  
 384337-53-5P 384337-54-6P 384337-55-7P  
 384337-56-8P 384337-57-9P 384337-58-0P  
 384337-59-1P 384337-60-4P 384337-61-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of pyrrolo[2,3-d]pyrimidines as immunosuppressive agents)

RN 384335-17-5 CAPLUS


CN 3-Piperidinamine, 1-[(4-methoxyphenyl)sulfonyl]-N,4-dimethyl-N-1H-  
 pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)

10/720,600




RN 384335-18-6 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-1-(phenylsulfonyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 384335-19-7 CAPLUS

CN 3-Piperidinamine, 1-[[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]sulfonyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 384335-20-0 CAPLUS

CN Cyclohexanecarboxamide, N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)




RN 384335-21-1 CAPLUS

CN Benzamide, 2-chloro-N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)




RN 384335-22-2 CAPLUS

CN Benzamide, 4-chloro-N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)




RN 384335-23-3 CAPLUS

CN 2-Furancarboxamide, N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)




RN 384335-24-4 CAPLUS

CN Benzamide, 3-methoxy-N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)




RN 384335-25-5 CAPLUS

CN 5-Isoxazolecarboxamide, N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)




RN 384335-26-6 CAPLUS

CN Benzamide, 2,4-difluoro-N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)




RN 384335-27-7 CAPLUS

CN Benzamide, 3-chloro-N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)



RN 384335-28-8 CAPLUS


CN Benzamide, 3-fluoro-N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)



RN 384335-29-9 CAPLUS


CN Benzamide, 2-fluoro-N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)

10/720,600




RN 384335-30-2 CAPLUS

CN Benzamide, 4-fluoro-N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)



RN 384335-31-3 CAPLUS


CN Benzamide, N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)



RN 384335-32-4 CAPLUS


CN Cyclopropanecarboxamide, N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)

10/720,600




RN 384335-33-5 CAPLUS

CN Cyclopentanecarboxamide, N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)



RN 384335-34-6 CAPLUS


CN 3-Piperidinamine, 1-(cyclopentylcarbonyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384335-35-7 CAPLUS


CN 2-Furancarboxamide, tetrahydro-N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)

10/720,600




RN 384335-36-8 CAPLUS

CN 3-Furancarboxamide, tetrahydro-N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)



RN 384335-37-9 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-1-[(tetrahydro-2-furanyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 384335-38-0 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-1-[(tetrahydro-3-furanyl)carbonyl]- (9CI) (CA INDEX NAME)




10/720,600




RN 384335-39-1 CAPLUS

CN Cyclohexanecarboxamide, N-[3-[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-3-oxopropyl]- (9CI) (CA INDEX NAME)




RN 384335-40-4 CAPLUS

CN 3-Piperidinamine, 1-(cyclopropylacetyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 384335-41-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 384335-42-6 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-1-(2-pyrrolidinylcarbonyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384335-43-7 CAPLUS

CN 3-Piperidinamine, 1-[(1-acetyl-2-pyrrolidinyl)carbonyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

10/720,600


RN 384335-44-8 CAPLUS

CN 3-Piperidinamine, 1-(3-furanylcarbonyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 384335-45-9 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-1-(2-pyridinylcarbonyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384335-46-0 CAPLUS


CN 3-Piperidinamine, 1-benzoyl-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384335-47-1 CAPLUS


CN 3-Piperidinamine, N,4-dimethyl-1-(phenylacetyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)

10/720,600



RN 384335-48-2 CAPLUS


CN 3-Piperidinamine, 1-(cyclopropylacetyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 384335-49-3 CAPLUS


CN 1-Piperidinecarboxamide, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 384335-50-6 CAPLUS


10/720,600

CN 1-Piperidinecarboxamide, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N-phenyl- (9CI) (CA INDEX NAME)




RN 384335-51-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-, tetrahydro-3-furanyl ester (9CI) (CA INDEX NAME)



RN 384335-52-8 CAPLUS


CN 3-Piperidinamine, 1-[(1-acetyl-4-piperidiny)carbonyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384335-53-9 CAPLUS


CN 3-Piperidinamine, 1-(cyclopentylacetyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)

10/720,600



RN 384335-54-0 CAPLUS

CN 1-Piperidinecarboxamide, N-cyclohexyl-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)




RN 384335-56-2 CAPLUS

CN 3-Piperidinamine, 1-(3-azetidinylocarbonyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 384335-55-1

CMF C17 H24 N6 O




10/720,600

CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 384335-57-3 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-1-(1-pyrrolidinylcarbonyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384335-58-4 CAPLUS


CN 1-Piperidinecarboxamide, N,4-dimethyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N-phenyl- (9CI) (CA INDEX NAME)



RN 384335-59-5 CAPLUS


CN Morpholine, 4-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME).

10/720,600




RN 384335-60-8 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-(2-pyridinyl)-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 384335-61-9 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-(2-thiazolyl)-3-piperidinyl]- (9CI) (CA INDEX NAME)




RN 384335-62-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N-3-pyridinyl- (9CI) (CA INDEX NAME)




10/720,600




RN 384335-63-1 CAPLUS

CN 1-Piperidinecarboxamide, N-(4-fluorophenyl)-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



RN 384335-64-2 CAPLUS


CN 1-Piperidinecarboxamide, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 384335-65-3 CAPLUS


CN 1-Piperidinecarboxamide, N-(4-methoxyphenyl)-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)

10/720,600




RN 384335-66-4 CAPLUS

CN Benzoic acid, 4-[[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 384335-67-5 CAPLUS


CN 3-Piperidinamine, N,4-dimethyl-1-(1-piperidinylcarbonyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384335-68-6 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-(5-nitro-2-pyridinyl)-3-piperidinyl]- (9CI) (CA INDEX NAME)

10/720,600




RN 384335-70-0 CAPLUS

CN 1-Piperidinecarboxamide, N-(3-fluorophenyl)-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



RN 384335-71-1 CAPLUS


CN 1-Piperidinecarboxamide, N-(2,4-difluorophenyl)-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



RN 384335-72-2 CAPLUS


CN 3-Piperidinamine, N,4-dimethyl-1-(1-pyrrolidinylsulfonyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)

10/720,600




RN 384335-73-3 CAPLUS

CN 1-Piperidinecarboxamide, N-(3-methoxyphenyl)-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



RN 384335-74-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 384335-75-5 CAPLUS

CN L-Proline, 1-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/720,600




RN 384335-76-6 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-(5-nitro-2-thiazolyl)-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 384335-77-7 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 384335-78-8 CAPLUS

CN 3-Pyridinemethanol, 6-[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]- (9CI) (CA INDEX NAME)


CN 3-Piperidinamine, N,4-dimethyl-1-(1-piperidinylsulfonyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl (6CI) (CN INPDB 11414)

CN 1-Piperidinecarboxamide, N-(3-cyanophenyl)-4-methyl-3-(methyl-1H-imidazo[2,3-d]oximinid-4-yl)- (95%) (155 mg, 0.5 mmol)

pyrrolo[2,3-d]pyrimidin-4-ylamino) - (9Cl) (CA INDEX NAME)


CN 1-Piperidinecarboxamide, N-(3,4-difluorophenyl)-4-methyl-3-(methyl-1H-pyrrol-2-yl)-2,2-dioximid-4-yl-3-ylidene-1,2,5-triazole-5-carboxamide

pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9Cl) (CA INDEX NAME)




RN 384335-82-4 CAPLUS

CN Morpholine, 4-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 384335-83-5 CAPLUS


CN 1-Piperidinecarboxamide, N-(4-chlorophenyl)-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



RN 384335-84-6 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-(6-methyl-3-pyridazinyl)-3-piperidinyl]- (9CI) (CA INDEX NAME)

10/720,600




RN 384335-85-7 CAPLUS

CN 1-Piperidinecarboxamide, N-(4-cyanophenyl)-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



RN 384335-86-8 CAPLUS


CN 1-Piperidinecarboxamide, N-[1,1'-biphenyl]-4-yl-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



RN 384335-87-9 CAPLUS


CN 1-Piperidinecarboxamide, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)






RN 384335-88-0 CAPLUS

CN Carbamic acid, methyl[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidiny]sulfonyl]ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 384335-89-1 CAPLUS

CN 3-Piperidinamine, 1-(cyclopropylcarbonyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 384335-90-4 CAPLUS

CN 3-Piperidinamine, 1-(cyclobutylcarbonyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 384335-91-5 CAPLUS

CN 3-Furancarboxamide, tetrahydro-N-methyl-N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)



RN 384335-92-6 CAPLUS


CN Cyclohexanecarboxamide, N-methyl-N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)



RN 384335-93-7 CAPLUS


CN 3-Piperidinamine, 1-[(5,7-dichloro-1H-indol-2-yl)carbonyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)

10/720,600




RN 384335-94-8 CAPLUS

CN Benzoic acid, 4-[[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 384335-95-9 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[1-(2-benzoxazolyl)-4-methyl-3-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 384335-96-0 CAPLUS


CN 3-Piperidinamine, 1-(1H-indol-2-ylcarbonyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



10/720,600


RN 384335-97-1 CAPLUS

CN 3-Piperidinamine, 1-[(5-fluoro-1H-indol-2-yl)carbonyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 384335-98-2 CAPLUS

CN 3-Piperidinamine, 1-[(5-methoxy-3-methyl-2-benzofuranyl)carbonyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384335-99-3 CAPLUS


CN 3-Piperidinamine, 1-[(5-chloro-2-benzofuranyl)carbonyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384336-00-9 CAPLUS


CN 3-Piperidinamine, N,4-dimethyl-1-[(5-nitro-2-benzofuranyl)carbonyl]-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)

10/720,600




RN 384336-01-0 CAPLUS

CN 3-Piperidinamine, 1-[(5-chloro-2,3-dihydro-2-benzofuranyl)carbonyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 384336-02-1 CAPLUS

CN 4-Piperidinol, 1-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 384336-03-2 CAPLUS

CN 3-Piperidinamine, 1-[(5-acetyl-2-benzofuranyl)carbonyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 384336-04-3 CAPLUS

CN 3-Piperidinamine, 1-[(5-acetyl-3-methyl-1H-indol-2-yl)carbonyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 384336-05-4 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[1-(5-chloro-2-benzothiazolyl)-4-methyl-3-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 384336-06-5 CAPLUS

CN Carbamic acid, [3-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]carbonyl]-3-azabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 384336-07-6 CAPLUS

CN 3-Piperidinamine, 1-[3-(4-chlorophenoxy)-1-oxopropyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384336-08-7 CAPLUS


CN 1-Piperidinecarboxamide, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N-2-pyridinyl- (9CI) (CA INDEX NAME)



RN 384336-09-8 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/720,600



● HCl


RN 384336-10-1 CAPLUS

CN 1-Piperidinecarboxamide, N-(5-chloro-2-pyridinyl)-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



RN 384336-11-2 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-1-[(3-oxocyclopentyl)carbonyl]-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 384336-12-3 CAPLUS

CN 3-Piperidinamine, 1-[(3-hydroxycyclopentyl)carbonyl]-N,4-dimethyl-N-1H-




10/720,600

pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 384336-13-4 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-1-[(4-oxocyclohexyl)carbonyl]-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384336-14-5 CAPLUS


CN 3-Piperidinamine, N,4-dimethyl-1-[(3-oxocyclohexyl)carbonyl]-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384336-15-6 CAPLUS


CN 1-Piperidinecarboxamide, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N-(5-nitro-2-pyridinyl)- (9CI) (CA INDEX NAME)

10/720,600




RN 384336-16-7 CAPLUS

CN Benzeneacetic acid, 4-[[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 384336-17-8 CAPLUS

CN 3-Piperidinamine, 1-[(4-amino-1-piperidinyl)carbonyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 384336-18-9 CAPLUS


CN 1-Piperidinecarboxamide, 4-methyl-N-(6-methyl-2-pyridinyl)-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)

10/720,600




RN 384336-19-0 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-1-[(1-methyl-5-oxo-3-pyrrolidinyl)carbonyl]-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384336-20-3 CAPLUS


CN 3-Piperidinamine, N,4-dimethyl-1-[[5-oxo-1-(phenylmethyl)-3-pyrrolidinyl]carbonyl]-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384336-21-4 CAPLUS


CN 1-Piperidinecarboxamide, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

10/720,600




RN 384336-23-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[4-(aminocarbonyl)phenyl]-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



RN 384336-24-7 CAPLUS


CN 1-Piperidinecarboxamide, N-[4-(aminosulfonyl)phenyl]-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



RN 384336-26-9 CAPLUS


CN 1-Piperidinecarboxamide, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)

10/720,600




RN 384336-28-1 CAPLUS

CN 1-Piperidinecarboxamide, N-(5,6-dichloro-2-benzothiazolyl)-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)




RN 384336-29-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N-(4-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 384336-30-5 CAPLUS


CN 3-Piperidinamine, 1-(1-azetidiny carbonyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 384336-31-6 CAPLUS

CN 4-Thiazoleacetic acid, 2-[[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 384336-32-7 CAPLUS

CN 1-Piperidinecarboxamide, N-(4,5-dimethyl-2-thiazolyl)-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)




RN 384336-33-8 CAPLUS

CN 4-Thiazoleacetic acid, 2-[[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-


10/720,600

4-ylamino)-1-piperidiny]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 384336-34-9 CAPLUS

CN 1-Piperidinecarboxamide, N-2-benzothiazolyl-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



RN 384336-35-0 CAPLUS


CN 1-Piperidinecarboxamide, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N-2-thiazolyl- (9CI) (CA INDEX NAME)



RN 384336-36-1 CAPLUS


CN 1-Piperidinecarboxamide, N-[6-[[2-(dimethylamino)ethyl]amino]-3-pyridinyl]-  
4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX  
NAME)

10/720,600




RN 384336-37-2 CAPLUS

CN 1-Piperidineacetamide, N-(4-chlorophenyl)-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



RN 384336-38-3 CAPLUS


CN 1-Piperidineacetamide, N,N,4-trimethyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



RN 384336-39-4 CAPLUS


CN 1-Piperidinecarboxamide, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N-[6-[[2-(1-pyrrolidiny)ethyl]amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)






RN 384336-40-7 CAPLUS

CN Carbamic acid, [2-[[5-[[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]carbonyl]amino]-2-pyridinyl]oxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 384336-41-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[6-(2-aminoethoxy)-3-pyridinyl]-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)




RN 384336-42-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-methyl-N-[4-[(methylamino)sulfonyl]phenyl]-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)




RN 384336-43-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 384336-44-1 CAPLUS


CN 1-Piperidinecarboxamide, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N-(5-methyl-1,3,4-thiadiazol-2-yl)- (9CI) (CA INDEX NAME)



RN 384336-45-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-methyl-N-[4-[(methylamino)sulfonyl]phenyl]-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-, monohydrochloride (9CI) (CA INDEX NAME)


10/720,600



● HCl


RN 384336-46-3 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-(1-phenylethyl)-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 384336-47-4 CAPLUS


CN 3-Piperidinamine, 1-[(3-hydroxy-1-pyrrolidinyl)carbonyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



10/720,600


RN 384336-48-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 384336-49-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[4-[2-(dimethylamino)ethyl]-2-thiazolyl]-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



RN 384336-50-9 CAPLUS


CN 1-Piperidinecarboxamide, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N-[[4-(methylsulfonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



10/720,600


RN 384336-51-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[4-[(acetylamino)sulfonyl]phenyl]-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)




RN 384336-52-1 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-1-(oxophenylacetyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384336-53-2 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-[6-(methylamino)-4-pyrimidinyl]-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 384336-54-3 CAPLUS


10/720,600

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-[6-(1-pyrrolidinyl)-4-pyrimidinyl]-3-piperidinyl]- (9CI) (CA INDEX NAME)




RN 384336-55-4 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-[6-[(phenylmethyl)amino]-4-pyrimidinyl]-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 384336-56-5 CAPLUS


CN 1,2-Ethanediamine, N,N-dimethyl-N'-[6-[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 384336-57-6 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[1-(6-chloro-4-pyrimidinyl)-4-methyl-3-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)

10/720,600




RN 384336-58-7 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[1-[(2-fluorophenyl)methyl]-4-methyl-3-piperidiny]-N-methyl- (9CI) (CA INDEX NAME)



RN 384336-59-8 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[1-(2-chloro-4-pyrimidinyl)-4-methyl-3-piperidiny]-N-methyl- (9CI) (CA INDEX NAME)



RN 384336-60-1 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[1-(4-chloro-2-pyrimidinyl)-4-methyl-3-piperidiny]-N-methyl- (9CI) (CA INDEX NAME)

10/720,600




RN 384336-61-2 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-[2-(methylanino)-4-pyrimidinyl]-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 384336-62-3 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-[4-(1-pyrrolidinyl)-2-pyrimidinyl]-3-piperidinyl]- (9CI) (CA INDEX NAME)




RN 384336-63-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-methyl-N-(3-methyl-5-isoxazolyl)-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)




10/720,600




RN 384336-64-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-methyl-N-(3-methyl-4-isoxazolyl)-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



RN 384336-65-6 CAPLUS


CN 1-Piperidinecarboxamide, 4-methyl-N-(5-methyl-3-isoxazolyl)-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



RN 384336-66-7 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)

10/720,600




RN 384336-67-8 CAPLUS

CN 1-Piperidinecarboxamide, N-3-isoxazolyl-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



RN 384336-68-9 CAPLUS


CN 1-Piperidinepropanamide, N,4-dimethyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



RN 384336-69-0 CAPLUS


CN 2-Propanone, 1-[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]- (9CI) (CA INDEX NAME)

10/720,600




RN 384336-70-3 CAPLUS

CN 1-Piperidineacetic acid, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- $\alpha$ -oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 384336-71-4 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[1-(cyclohexylmethyl)-4-methyl-3-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 384336-72-5 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[1-(5-amino-2-thiazolyl)-4-methyl-3-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)

10/720,600




RN 384336-74-7 CAPLUS

CN 1-Piperidinepropanoic acid, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- $\beta$ -oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 384336-75-8 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-[(phenylsulfonyl)methyl]-3-piperidinyl]- (9CI) (CA INDEX NAME)




RN 384336-76-9 CAPLUS

CN 3-Piperidinamine, 1-(1,2-dioxopropyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 384336-77-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[6-(aminosulfonyl)-3-pyridinyl]-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)




RN 384336-78-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[6-(acetylamino)-3-pyridinyl]-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)




RN 384336-79-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[4-[[[2-(dimethylamino)ethyl]amino]sulfonyl]phenyl]-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)




RN 384336-80-5 CAPLUS

CN 1-Piperidinecarboxamide, N-(6-cyano-3-pyridinyl)-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



RN 384336-81-6 CAPLUS


CN 3-Pyridinesulfonamide, 6-[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-N-2-pyridinyl- (9CI) (CA INDEX NAME)



RN 384336-82-7 CAPLUS


CN 1-Piperidinecarboxamide, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N-[6-(1-pyrrolidinylcarbonyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)

10/720,600




RN 384336-83-8 CAPLUS

CN 3-Piperidinamine, 1-(1H-imidazol-1-ylacetyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384336-84-9 CAPLUS


CN 3-Pyridinecarboxamide, N-methyl-6-[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 384336-85-0 CAPLUS


CN Morpholine, 4-[[6-[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)

10/720,600




RN 384336-86-1 CAPLUS

CN 2-Pyridinecarboxamide, 5-[[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]carbonyl]amino]-N-propyl- (9CI) (CA INDEX NAME)



RN 384336-87-2 CAPLUS

CN 3-Pyridinecarboxamide, 6-[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 384336-88-3 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]- (9CI) (CA INDEX NAME)




10/720,600




RN 384336-89-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N-[4-(1-pyrrolidinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 384336-90-7 CAPLUS


CN 1-Piperidinecarboxamide, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N-[4-(4-morpholinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 384336-91-8 CAPLUS


CN 1-Piperidinecarboxamide, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N-[6-(4-morpholinylcarbonyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)

10/720,600




RN 384336-92-9 CAPLUS

CN 1-Piperidinecarboxamide, N-(1,3-dimethyl-1H-pyrazol-5-yl)-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



RN 384336-93-0 CAPLUS


CN 1-Piperidinecarboxamide, N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



RN 384336-94-1 CAPLUS


CN 1-Piperidinecarboxamide, 4-methyl-N-(3-methyl-5-isothiazolyl)-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)

10/720,600




RN 384336-95-2 CAPLUS

CN Benzoic acid, 4-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 384336-96-3 CAPLUS


CN Pyrrolidine, 1-[[6-[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-3-pyridinyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 384336-97-4 CAPLUS


CN 3-Pyridinesulfonamide, N-methyl-6-[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]- (9CI) (CA INDEX NAME)

10/720,600




RN 384336-98-5 CAPLUS

CN Benzenesulfonamide, 4-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 384336-99-6 CAPLUS


CN Benzenesulfonamide, N-(1,1-dimethylethyl)-4-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 384337-00-2 CAPLUS


CN 3-Piperidinamine, N,4-dimethyl-1-(1H-pyrazol-1-ylacetyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)

10/720,600




RN 384337-01-3 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-(5-nitro-2-benzoxazolyl)-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 384337-02-4 CAPLUS


CN 3-Pyridinesulfonamide, N-(2-hydroxyethyl)-6-[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 384337-03-5 CAPLUS


CN 1-Piperidineacetamide, N,4-dimethyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-α-oxo- (9CI) (CA INDEX NAME)

10/720,600




RN 384337-04-6 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[1-[5-(ethylsulfonyl)-2-benzoxazolyl]-4-methyl-3-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 384337-05-7 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-(5-methyl-2-benzoxazolyl)-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 384337-06-8 CAPLUS


CN 1-Piperidinecarboxamide, N-(6-chloro-3-pyridinyl)-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)

10/720,600




RN 384337-12-6 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-(2-quinolinyl)-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 384337-13-7 CAPLUS


CN 3-Pyridinesulfonamide, 6-[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 384337-14-8 CAPLUS


CN 3-Piperidinamine, N,4-dimethyl-1-(oxo-1-pyrrolidinylacetyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)

10/720,600




RN 384337-15-9 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-(4-methyl-2-benzoxazolyl)-3-piperidiny]- (9CI) (CA INDEX NAME)



RN 384337-16-0 CAPLUS

CN Morpholine, 4-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidiny]oxoacetyl]- (9CI) (CA INDEX NAME)




RN 384337-17-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N-[6-(methylsulfonyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




10/720,600




RN 384337-18-2 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-(6-nitro-2-benzoxazolyl)-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 384337-19-3 CAPLUS


CN 3-Piperidinamine, N,4-dimethyl-1-[(3-methylphenyl)sulfonyl]-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384337-20-6 CAPLUS


CN 3-Piperidinamine, N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-1-[[4-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

10/720,600




RN 384337-21-7 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[1-(2-benzothiazolyl)-4-methyl-3-methyl-3-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 384337-22-8 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[1-(5,7-dimethyl-2-benzoxazolyl)-4-methyl-3-methyl-3-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 384337-23-9 CAPLUS


CN 6-Benzoxazolecarboxylic acid, 2-[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-, methyl ester (9CI) (CA INDEX NAME)

10/720,600




RN 384337-24-0 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-(6-methyl-2-benzoxazolyl)-3-piperidinyl]- (9CI) (CA INDEX NAME)




RN 384337-25-1 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[1-(6-methoxy-2-benzoxazolyl)-4-methyl-3-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 384337-26-2 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-[5-(trifluoromethyl)-2-benzothiazolyl]-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 384337-27-3 CAPLUS


10/720,600

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[1-(5,7-dichloro-2-benzoxazolyl)-4-methyl-3-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 384337-28-4 CAPLUS

CN 3-Piperidinamine, 1-[(6-chloro-3-pyridinyl)sulfonyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384337-29-5 CAPLUS


CN 3-Piperidinamine, 1-[(4-chlorophenyl)sulfonyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384337-30-8 CAPLUS


CN 3-Piperidinamine, 1-[(4-fluorophenyl)sulfonyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)

10/720,600




RN 384337-31-9 CAPLUS

CN 3-Piperidinamine, 1-[(4-cyanophenyl)sulfonyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 384337-32-0 CAPLUS

CN Benzenesulfonyl fluoride, 4-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 384337-33-1 CAPLUS

CN 3-Piperidinamine, 1-[(2-cyanophenyl)sulfonyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 384337-34-2 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-1-(1H-tetrazol-1-yl)acetyl)- (9CI) (CA INDEX NAME)



RN 384337-35-3 CAPLUS


CN 3-Piperidinamine, N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-1-[(2,2,2-trifluoroethyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 384337-36-4 CAPLUS


CN 3-Piperidinamine, 1-[(2,6-difluorophenyl)sulfonyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)

10/720,600




RN 384337-37-5 CAPLUS

CN 3-Piperidinamine, 1-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384337-38-6 CAPLUS


CN 3-Piperidinamine, 1-[(2,4-difluorophenyl)sulfonyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384337-39-7 CAPLUS


CN 3-Piperidinamine, N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-1-[[2-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

10/720,600




RN 384337-40-0 CAPLUS

CN 3-Piperidinamine, 1-[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384337-41-1 CAPLUS

CN 3-Piperidinamine, 1-[(3,5-dichlorophenyl)sulfonyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 384337-42-2 CAPLUS

CN Benzoic acid, 4-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




10/720,600




RN 384337-43-3 CAPLUS

CN 3-Piperidinamine, 1-(3-fluorobenzoyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384337-44-4 CAPLUS


CN 3-Piperidinamine, 1-(4-isothiazolylcarbonyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384337-45-5 CAPLUS


CN 3-Piperidinamine, N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-1-(3-thienylcarbonyl)- (9CI) (CA INDEX NAME)

10/720,600




RN 384337-46-6 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-1-[(5-methyl-1H-pyrazol-3-yl)carbonyl]-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384337-47-7 CAPLUS


CN 3-Piperidinamine, N,4-dimethyl-1-[(5-methyl-3-isoxazolyl)carbonyl]-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384337-48-8 CAPLUS


CN 3-Piperidinamine, N,4-dimethyl-1-[(5-methyl-2-thienyl)carbonyl]-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)

10/720,600




RN 384337-49-9 CAPLUS

CN 3-Piperidinamine, 1-(4-fluorobenzoyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384337-50-2 CAPLUS


CN 3-Piperidinamine, N,4-dimethyl-1-[(3-nitrophenyl)sulfonyl]-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384337-51-3 CAPLUS


CN 3-Piperidinamine, 1-[(3-fluorophenyl)sulfonyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)

10/720,600




RN 384337-52-4 CAPLUS

CN 3-Piperidinamine, 1-(2-fluorobenzoyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384337-53-5 CAPLUS


CN 3-Piperidinamine, 1-[(1,5-dimethyl-1H-pyrazol-3-yl)carbonyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384337-54-6 CAPLUS


CN 3-Piperidinamine, N,4-dimethyl-1-[(2-methyl-4-thiazolyl)carbonyl]-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)

10/720,600




RN 384337-55-7 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-1-(4-thiazolylcarbonyl)- (9CI) (CA INDEX NAME)



RN 384337-56-8 CAPLUS


CN 3-Piperidinamine, N,4-dimethyl-1-[(4-methyl-5-isothiazolyl)carbonyl]-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384337-57-9 CAPLUS


CN 3-Piperidinamine, 1-[(2,2-dimethyl-5-oxo-1,3-dioxolan-4-yl)acetyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)

10/720,600




RN 384337-58-0 CAPLUS

CN Cyclopropaneacetamide, N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyllsulfonyl]ethyl]- (9CI) (CA INDEX NAME)




RN 384337-59-1 CAPLUS

CN Methanesulfonamide, N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyllsulfonyl]ethyl]- (9CI) (CA INDEX NAME)




RN 384337-60-4 CAPLUS

CN Benzonitrile, 4-[[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyllmethyl]- (9CI) (CA INDEX NAME)



RN 384337-61-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-, phenylmethyl ester (9CI) (CA INDEX NAME)



IT 384337-62-6P 384337-63-7P 384337-64-8P  
 384337-65-9P 384337-66-0P 384337-67-1P  
 384337-68-2P 384337-69-3P 384337-70-6P  
 384337-71-7P 384337-72-8P 384337-73-9P  
 384337-74-0P 384337-75-1P 384337-76-2P  
 384337-77-3P 384337-78-4P 384337-79-5P  
 384337-80-8P 384337-81-9P 384337-82-0P  
 384337-83-1P 384337-85-3P 384337-86-4P  
 384337-87-5P 384337-88-6P 384337-89-7P  
 384337-91-1P 384337-92-2P 384337-93-3P  
 384337-94-4P 384337-95-5P 384337-96-6P  
 384337-97-7P 384337-98-8P 384337-99-9P  
 384338-01-6P 384338-04-9P 384338-06-1P  
 384338-08-3P 384338-10-7P 384338-12-9P  
 384338-14-1P 384338-16-3P 384338-17-4P  
 384338-18-5P 384338-29-8P 384338-42-5P  
 384338-43-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of pyrrolo[2,3-d]pyrimidines as immunosuppressive agents)

RN 384337-62-6 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[1-(1H-imidazol-2-ylmethyl)-4-methyl-3-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)

10/720,600




RN 384337-63-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-, (2-chlorophenyl)methyl ester (9CI) (CA INDEX NAME)



RN 384337-64-8 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-[(1-methyl-1H-imidazol-2-yl)methyl]-3-piperidinyl]- (9CI) (CA INDEX NAME)




RN 384337-65-9 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-1-(phenoxyacetyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




10/720,600




RN 384337-66-0 CAPLUS

CN 3-Piperidinamine, 1-[(4-fluorophenoxy)acetyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384337-67-1 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-, 2,2,2-trichloroethyl ester (9CI) (CA INDEX NAME)



RN 384337-68-2 CAPLUS


CN 3-Piperidinamine, 1-[(2-chlorophenoxy)acetyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)

10/720,600




RN 384337-69-3 CAPLUS

CN 3-Piperidinamine, 1-[(3-chlorophenoxy)acetyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384337-70-6 CAPLUS


CN 3-Piperidinamine, N,4-dimethyl-1-[(methanesulfonyl)acetyl]-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384337-71-7 CAPLUS


CN 3-Piperidinamine, N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-1-[(tetrahydro-1,1-dioxido-3-thienyl)acetyl]- (9CI) (CA INDEX NAME)

10/720,600




RN 384337-72-8 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-1-[[ (4-methylphenyl)sulfonyl]acetyl]-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 384337-73-9 CAPLUS

CN 3-Piperidinamine, 1-(hydroxyacetyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 384337-74-0 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-1-(3-nitro-1-oxopropyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 384337-75-1 CAPLUS

CN 3-Piperidinamine, 1-[(2,4-dioxo-5-thiazolidinyl)acetyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 384337-76-2 CAPLUS

CN 3-Piperidinamine, 1-(3-hydroxy-1-oxopropyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 384337-77-3 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-1-[4-[(methylsulfonyl)amino]-1-oxobutyl]-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 384337-78-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)



RN 384337-79-5 CAPLUS


CN 3-Piperidinamine, N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-1-[(3-thiazolidinylsulfonyl)acetyl]- (9CI) (CA INDEX NAME)



RN 384337-80-8 CAPLUS


CN 3-Piperidinamine, 1-[(3,4-dihydroxy-1-pyrrolidinyl)carbonyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)

10/720,600




RN 384337-81-9 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-1-[(2-oxo-4-thiazolidinyl)carbonyl]-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 384337-82-0 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-, 2-propynyl ester (9CI) (CA INDEX NAME)



RN 384337-83-1 CAPLUS


CN 1-Piperidinecarboxamide, N-(2-cyanoethyl)-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)

10/720,600




RN 384337-85-3 CAPLUS

CN 1-Piperidinecarboxamide, N-(cyanomethyl)-N,4-dimethyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



RN 384337-86-4 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 384337-87-5 CAPLUS


CN 1-Piperidinecarboxamide, N-(2-cyanoethyl)-N,4-dimethyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)

10/720,600




RN 384337-88-6 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-[(1-oxido-4-pyridinyl)methyl]-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 384337-89-7 CAPLUS

CN 1-Piperidineacetonitrile, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)




RN 384337-91-1 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[1-(2-furanylmethyl)-4-methyl-3-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)




10/720,600




RN 384337-92-2 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[1-[(4-methoxyphenyl)methyl]-4-methyl-3-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 384337-93-3 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[1-[(4-fluorophenyl)methyl]-4-methyl-3-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 384337-94-4 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-(3-pyridinylmethyl)-3-piperidinyl]- (9CI) (CA INDEX NAME)

10/720,600




RN 384337-95-5 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-(2-thiazolylmethyl)-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 384337-96-6 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-(2-pyridinylmethyl)-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 384337-97-7 CAPLUS


CN Benzonitrile, 3-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

10/720,600




RN 384337-98-8 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[1-[(3-fluorophenyl)methyl]-4-methyl-3-piperidiny]-N-methyl- (9CI) (CA INDEX NAME)



RN 384337-99-9 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[1-[(3-methoxyphenyl)methyl]-4-methyl-3-piperidiny]-N-methyl- (9CI) (CA INDEX NAME)



RN 384338-01-6 CAPLUS


CN Benzoic acid, 3-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidiny]methyl]- (9CI) (CA INDEX NAME)

10/720,600




RN 384338-04-9 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[1-[(2,6-difluorophenyl)methyl]-4-methyl-3-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 384338-06-1 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-(2-phenylethyl)-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 384338-08-3 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[1-[(2,3-difluorophenyl)methyl]-4-methyl-3-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)

10/720,600




RN 384338-10-7 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[1-[(2,4-difluorophenyl)methyl]-4-methyl-3-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 384338-12-9 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-[[4-(methylsulfonyl)phenyl]methyl]-3-piperidinyl]- (9CI) (CA INDEX NAME)




RN 384338-14-1 CAPLUS

CN Piperidine, 1-[[4-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]methyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 384338-16-3 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[1-[(3,5-difluorophenyl)methyl]-4-methyl-3-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 384338-17-4 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[1-[(3-chlorophenyl)methyl]-4-methyl-3-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 384338-18-5 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[1-[(3,5-dichlorophenyl)methyl]-4-methyl-3-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)

10/720,600




RN 384338-29-8 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-1-(3-thiazolidinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 384338-42-5 CAPLUS


CN 1-Piperidinecarboxamide, N,4-dimethyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 384338-43-6 CAPLUS

CN 1-Piperidinecarboxamide, N,N,4-trimethyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)

10/720,600



RE.CNT 5      THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L4 ANSWER 32 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2001:435077 CAPLUS  
 DN 135:46193  
 TI Synthesis of pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases  
 IN Blumenkopf, Todd Andrew; Flanagan, Mark Edward; Munchhof, Michael John  
 PA Pfizer Products Inc., USA  
 SO PCT Int. Appl., 32 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001042246	A2	20010614	WO 2000-IB1742	20001123
	WO 2001042246	A3	20011122		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2393640	A1	20010614	CA 2000-2393640	20001123
	CA 2393640	C	20060905		
	BR 2000016263	A	20020813	BR 2000-16263	20001123
	EP 1235830	A2	20020904	EP 2000-974738	20001123
	EP 1235830	B1	20040102		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	HU 200203503	A2	20030228	HU 2002-3503	20001123
	JP 2003516405	T	20030513	JP 2001-543545	20001123
	EE 200200304	A	20030616	EE 2002-304	20001123
	AT 257157	T	20040115	AT 2000-974738	20001123
	EP 1382339	A1	20040121	EP 2003-24332	20001123
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	NZ 518884	A	20040227	NZ 2000-518884	20001123
	PT 1235830	T	20040430	PT 2000-974738	20001123
	ES 2208433	T3	20040616	ES 2000-974738	20001123
	AU 777911	B2	20041104	AU 2001-12950	20001123
	NZ 528905	A	20050324	NZ 2000-528905	20001123
	TW 248935	B	20060211	TW 2000-89125918	20001205
	US 2001053782	A1	20011220	US 2000-732669	20001208
	US 6627754	B2	20030930		
	ZA 2002004535	A	20030929	ZA 2002-4535	20020606
	NO 2002002738	A	20020607	NO 2002-2738	20020607
	HR 20020509	B1	20050630	HR 2002-509	20020610
	BG 106855	A	20021229	BG 2002-106855	20020620
	HK 1051195	A1	20050729	HK 2003-103456	20030516
	US 2004053947	A1	20040318	US 2003-640227	20030813
	US 6956041	B2	20051018		
	US 2005288313	A1	20051229	US 2005-211217	20050824
	US 7091208	B2	20060815		
	US 2006241131	A1	20061026	US 2006-474233	20060623
PRAI	US 1999-170179P	P	19991210		
	EP 2000-974738	A3	20001123		
	WO 2000-IB1742	W	20001123		
	US 2000-732669	A1	20001208		


10/720,600

US 2003-640227 A3 20030813  
US 2005-211217 A1 20050824  
OS MARPAT 135:46193  
IT 344418-61-7P 344418-63-9P 344418-65-1P  
344418-67-3P 344418-73-1P 344418-75-3P  
344418-77-5P 344418-79-7P 344418-82-2P  
344418-86-6P 344418-88-8P 344418-90-2P  
344418-92-4P 344418-94-6P 344418-96-8P  
344418-98-0P 344419-00-7P 344419-02-9P  
344419-05-2P 344419-07-4P 344419-10-9P  
344419-13-2P 344419-15-4P 344419-17-6P  
344419-66-5P 344419-70-1P 344419-71-2P  
344419-73-4P 344419-74-5P 344419-75-6P  
344419-76-7P 344419-77-8P 384336-48-5P  
384338-43-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(synthesis of pyrrolo[2,3-d]pyrimidine compds. as inhibitors of protein kinases)


RN 344418-61-7 CAPLUS

CN 3-Piperidinamine, 1-acetyl-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-  
(9CI) (CA INDEX NAME)




RN 344418-63-9 CAPLUS

CN 3-Piperidinamine, 1-[(2-aminoethyl)sulfonyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 344418-65-1 CAPLUS

CN 3-Piperidinamine, 1-(ethylsulfonyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 344418-67-3 CAPLUS

CN 3-Piperidinamine, 1-(butylsulfonyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




RN 344418-73-1 CAPLUS

CN Propanamide, N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)




RN 344418-75-3 CAPLUS

CN Carbamic acid, [2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 344418-77-5 CAPLUS

CN Propanamide, 2-methyl-N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)



RN 344418-79-7 CAPLUS


CN 3-Piperidinamine, N-methyl-1-(methylsulfonyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 344418-82-2 CAPLUS


CN 3-Piperidinamine, 1-(ethylsulfonyl)-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)

10/720,600




RN 344418-86-6 CAPLUS

CN 3-Piperidinamine, N-methyl-1-(propylsulfonyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 344418-88-8 CAPLUS


CN 3-Piperidinamine, 1-(butylsulfonyl)-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 344418-90-2 CAPLUS


CN Propanamide, 2,2-dimethyl-N-[2-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]sulfonyl]ethyl]- (9CI) (CA INDEX NAME)

10/720,600




RN 344418-92-4 CAPLUS

CN 3-Piperidinamine, 1-(cyanoacetyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 344418-94-6 CAPLUS


CN Carbamic acid, [3-[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 344418-96-8 CAPLUS


CN 3-Piperidinamine, N,4-dimethyl-1-(propylsulfonyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)

10/720,600




RN 344418-98-0 CAPLUS

CN 3-Piperidinamine, 1-(3-amino-1-oxopropyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 344419-00-7 CAPLUS


CN 3-Piperidinamine, 1-(methoxyacetyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)



RN 344419-02-9 CAPLUS


CN 3-Piperidinamine, 1-[(dimethylamino)acetyl]-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)

10/720,600




RN 344419-05-2 CAPLUS

CN 3-Piperidinamine, N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-1-(3,3,3-trifluoro-1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 344419-07-4 CAPLUS

CN Acetamide, N-[2-[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 344419-10-9 CAPLUS

CN 3-Piperidinamine, 1-(3-ethoxy-1-oxopropyl)-N,4-dimethyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




10/720,600




RN 344419-13-2 CAPLUS

CN 1-Piperidinecarboxamide, N,4-dimethyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



RN 344419-15-4 CAPLUS


CN 1-Piperidinecarboxamide, N,N-diethyl-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



RN 344419-17-6 CAPLUS


CN 3-Piperidinamine, N,4-dimethyl-1-[[2-(methylamino)ethyl]sulfonyl]-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)

10/720,600




RN 344419-66-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-, methyl ester (9CI) (CA INDEX NAME)



RN 344419-70-1 CAPLUS

CN Glycine, N-[[4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 344419-71-2 CAPLUS


CN 3-Piperidinamine, N,4-dimethyl-N-(5-methyl-1H-pyrrolo[2,3-d]pyrimidin-4-yl)-1-(3,3,3-trifluoro-1-oxopropyl)- (9CI) (CA INDEX NAME)

CC1=CN2C(=C1)N(C)C(=N2)C3CC(C)CC3C(=O)CC(F)(F)F

CN 3-Piperidinamine, N,4-dimethyl-1-(1-oxo-3-butynyl)-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl- (9CI) (CA INDEX NAME)




CN 3-Piperidinamine, N-(5-chloro-1H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-methyl-N-methyl-1-(1-oxopropyl)- (9CI) (CA INDEX NAME)




CN 1-Piperidinecarboximidamide, N-cyano-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N'-propyl- (9CI) (CA INDEX NAME)

10/720,600




RN 344419-76-7 CAPLUS

CN 1-Piperidinecarboximidamide, N'-cyano-N,N,4-trimethyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



RN 344419-77-8 CAPLUS


CN 3-Piperidinamine, N-(5-fluoro-1H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-methyl-N-methyl-1-(1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 384336-48-5 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/720,600



RN 384338-43-6 CAPLUS

CN 1-Piperidinecarboxamide, N,N,4-trimethyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)




IT 384336-73-6P 384337-90-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis of pyrrolo[2,3-d]pyrimidine compds. as inhibitors of protein kinases)

RN 384336-73-6 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-(4-methyl-3-piperidinyl)- (9CI) (CA INDEX NAME)



RN 384337-90-0 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[4-methyl-1-(phenylmethyl)-3-piperidinyl]- (9CI) (CA INDEX NAME)

10/720,600




10/720,600

L4 ANSWER 33 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1999:811244 CAPLUS  
 DN 132:49975  
 TI Preparation of pyrrolo[2,3-d]pyrimidines as immunosuppressive agents  
 IN Blumenkopf, Todd Andrew; Flanagan, Mark Edward; Brown, Matthew Frank;  
 Changelian, Paul Steven  
 PA Pfizer Products Inc., USA  
 SO PCT Int. Appl., 59 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9965908	A1	19991223	WO 1999-IB1100	19990614
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2335492	A1	19991223	CA 1999-2335492	19990614
	CA 2335492	C	20050517		
	AU 9939518	A	20000105	AU 1999-39518	19990614
	BR 9911365	A	20010313	BR 1999-11365	19990614
	TR 200003719	T2	20010321	TR 2000-200003719	19990614
	EP 1087970	A1	20010404	EP 1999-922454	19990614
	EP 1087970	B1	20040428		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
	HU 200102574	A2	20011128	HU 2001-2574	19990614
	JP 2002518393	T	20020625	JP 2000-554733	19990614
	TW 505646	B	20021011	TW 1999-88109926	19990614
	CN 1128800	B	20031126	CN 1999-807521	19990614
	AT 265458	T	20040515	AT 1999-922454	19990614
	PT 1087970	T	20040630	PT 1999-922454	19990614
	ES 2219018	T3	20041116	ES 1999-922454	19990614
	ZA 9904004	A	20001218	ZA 1999-4004	19990617
	AP 1021	A	20011109	AP 1999-1584	19990617
	W: BW, GM, GH, KE, MW, SD, UG, ZM, ZW				
	NZ 518444	A	20040430	NZ 2000-518444	20001108
	NO 2000006453	A	20010205	NO 2000-6453	20001218
	NO 318784	B1	20050509		
	HR 2000000885	A1	20011031	HR 2000-885	20001219
	BG 105129	A	20011130	BG 2001-105129	20010108
	US 2002019526	A1	20020214	US 2001-956645	20010919
	US 6610847	B2	20030826		
	HK 1036801	A1	20040416	HK 2001-107744	20011106
	US 2003212273	A1	20031113	US 2003-442807	20030520
	US 6890929	B2	20050510		
	AU 2003234874	A1	20030911	AU 2003-234874	20030813
	NO 2005000202	A	20010910	NO 2005-202	20050113
	US 2005171128	A1	20050804	US 2005-64873	20050223
PRAI	US 1998-89866P	P	19980619		
	US 1998-104787P	P	19981019		
	WO 1999-IB1100	W	19990614		
	US 1999-335121	B1	19990617		
	US 2001-956645	A1	20010919		
	US 2003-442807	A3	20030520		

10/720,600

OS MARPAT 132:49975  
IT 252853-63-7P 252853-90-0P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of pyrrolo[2,3-d]pyrimidines as immunosuppressive agents)  
RN 252853-63-7 CAPLUS  
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 252853-90-0 CAPLUS  
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-1H-indol-5-yl-6-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



10/720,600

L4 ANSWER 34 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1997:632396 CAPLUS

DN 127:293244

TI Preparation of 4-substituted pyrrolopyrimidines as tyrosine kinase inhibitors

IN Buzzetti, Franco; Brasca, Maria Gabriella; Longo, Antonio; Ballinari, Dario

PA Pharmacia & Upjohn S.P.A., Italy

SO Eur. Pat. Appl., 15 pp.

CODEN: EPXXDW

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 795556	A1	19970917	EP 1997-200386	19970211
	R: DE, GB, IT				
	JP 09323995	A	19971216	JP 1997-44207	19970227
PRAI	GB 1996-4361	A	19960229		
OS	MARPAT 127:293244				
IT	197083-88-8P				

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of 4-substituted pyrrolopyrimidines as tyrosine kinase inhibitors)

RN 197083-88-8 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-(1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-  
(9CI) (CA INDEX NAME)



10/720,600

L4 ANSWER 35 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1997:132775 CAPLUS  
DN 126:144288  
TI Preparation of heterocyclic ring-fused pyrimidines for treatment of  
hyperproliferative diseases  
IN Arnold, Lee D.; Moyer, Mikel P.; Sobolov-jaynes, Susan B.  
PA Pfizer Inc., USA; Arnold, Lee D.; Moyer, Mikel P.; Sobolov-Jaynes, Susan  
B.  
SO PCT Int. Appl., 62 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9640142	A1	19961219	WO 1995-US7881	19950607
	W: CA, FI, JP, MX, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2223081	A1	19961219	CA 1995-2223081	19950607
	CA 2223081	C	20010306		
	EP 831829	A1	19980401	EP 1995-924027	19950607
	EP 831829	B1	20030820		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
	JP 3290666	B2	20020610	JP 1997-500390	19950607
	AT 247469	T	20030915	AT 1995-924027	19950607
	PT 831829	T	20031231	PT 1995-924027	19950607
	ES 2203642	T3	20040416	ES 1995-924027	19950607
	CN 1141298	A	19970129	CN 1996-108101	19960605
	NO 9602386	A	19961209	NO 1996-2386	19960606
	AU 9654791	A	19961219	AU 1996-54791	19960606
	ZA 9604725	A	19971208	ZA 1996-4725	19960606
	BR 9602695	A	19981006	BR 1996-2695	19960607
	RU 2136683	C1	19990910	RU 1996-111016	19960607
	FI 9704443	A	19971205	FI 1997-4443	19971205
	US 6395733	B1	20020528	US 1999-423510	19991109
PRAI	EP 1995-924027	A	19950607		
	WO 1995-US7881	A	19950607		

OS MARPAT 126:144288

IT 186519-22-2P 186519-25-5P 186519-27-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic ring-fused pyrimidines for treatment of hyperproliferative diseases)

RN 186519-22-2 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-1H-indol-5-yl-, monohydrochloride (9CI) (CA INDEX NAME)


10/720,600



● HCl


RN 186519-25-5 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-benzo[b]thien-5-yl- (9CI) (CA INDEX NAME)



RN 186519-27-7 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-1H-indazol-5-yl- (9CI) (CA INDEX NAME)



10/720,600


L4 ANSWER 36 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1982:492306 CAPLUS  
DN 97:92306  
TI Pyrrolopyrimidines and their use in production of biologically effective substances  
IN Jacobi, Haireddin; Roth, Hermann Josef; Eger, Kurt; Pichler, Herbert  
PA Troponwerke G.m.b.H. und Co. K.-G., Fed. Rep. Ger.  
SO Ger. Offen., 20 pp.  
CODEN: GWXXBX  
DT Patent  
LA German  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	DE 3036390	A1	19820513	DE 1980-3036390	19800926
PRAI	DE 1980-3036390		19800926		
OS	CASREACT 97:92306				
IT	82703-41-1P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN	82703-41-1 CAPLUS				
CN	1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(2-furanylmethyl)-5,6-dimethyl- (9CI) (CA INDEX NAME)				




10/720,600

L4 ANSWER 37 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1977:994 CAPLUS  
DN 86:994  
TI Effect of 4-substituted pyrrolo[2,3-d]pyrimidines on the tobacco callus growth  
AU Iwamura, Hajime; Kurimoto, Masahiro; Matsubara, Satoshi; Ogawa, Yukiyo; Koshimizu, Koichi; Kumazawa, Zenzaburo  
CS Dep. Food Sci. Technol., Kyoto Univ., Kyoto, Japan  
SO Agricultural and Biological Chemistry (1976), 40(9), 1885-6  
CODEN: ABCHA6; ISSN: 0002-1369  
DT Journal  
LA English  
IT 60972-05-6  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
(cytokinin-like activity of)  
RN 60972-05-6 CAPLUS  
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(2-furanylmethyl)- (9CI) (CA INDEX NAME)



10/720,600


L4 ANSWER 38 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1972:126924 CAPLUS  
DN 76:126924  
TI New series of purine analogs with antimitotic action. Structure activity relations  
AU Marquet, Jean P.; Montagnier, Luc; Gruest, Jacqueline; Bourzat, Jean D.; Andre-Louisfert, Jeannine; Bisagni, Emile  
CS Inst. Radium-Biol., Fac. Sci., Orsay, Fr.  
SO Chimica Therapeutica (1971), 6(6), 427-38  
CODEN: CHTPBA; ISSN: 0009-4374  
DT Journal  
LA French  
IT 35801-01-5P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 35801-01-5 CAPLUS  
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(2-furanylmethyl)-6-methyl- (9CI)  
(CA INDEX NAME)




10/720,600

L4 ANSWER 39 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1962:476026 CAPLUS  
DN 57:76026  
OREF 57:15129f-i,15130a-i  
TI Pyrrolopyrimidine vasodilators  
IN Hitchings, George H.; Ledig, Kurt W.; West, Robert A.  
PA Burroughs Wellcome & Co. (U.S.A.) Inc.  
SO 5 pp.  
DT Patent  
LA Unavailable

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3037980		19620605	US 1960-12675	19600304
PRAI	GB		19550818		
IT	60972-05-6P, 7H-Pyrrolo[2,3-d]pyrimidine, 4-(furfurylamino)- 91092-03-4P, 7H-Pyrrolo[2,3-d]pyrimidine, 4-(2-thenylamino)- 91560-19-9P, 7H-Pyrrolo[2,3-d]pyrimidine, 4-(furfurylamino)-2- methyl- 91843-68-4P, 7H-Pyrrolo[2,3-d]pyrimidine, 4-(methyl-2-pyridylamino)- 93256-72-5P, 7H-Pyrrolo[2,3- d]pyrimidine, 2-methyl-4-(2-thenylamino)- 106598-07-6P, 7H-Pyrrolo[2,3-d]pyrimidine, 2-methyl-4-[(2-pyridylmethyl)amino]- RL: PREP (Preparation) (preparation of)				
RN	60972-05-6 CAPLUS				
CN	1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(2-furanylmethyl)- (9CI) (CA INDEX NAME)				




RN 91092-03-4 CAPLUS  
CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-(2-thenylamino)- (7CI) (CA INDEX NAME)



RN 91560-19-9 CAPLUS


10/720,600

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-(furfurylamino)-2-methyl- (7CI) (CA INDEX NAME)




RN 91843-68-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-(methyl-2-pyridylamino)- (7CI) (CA INDEX NAME)



RN 93256-72-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 2-methyl-4-(2-thenylamino)- (7CI) (CA INDEX NAME)




RN 106598-07-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 2-methyl-4-[(2-pyridylmethyl)amino]- (7CI) (CA INDEX NAME)




10/720,600




10/720,600

L4 ANSWER 40 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1962:46024 CAPLUS  
DN 56:46024  
OREF 56:8712e-i,8713a-c  
TI 2-Alkyl(aryl)- and 2,7-dimethyl-4-substituted amino-pyrrolo[2,3-d]pyrimidines  
AU West, R. A.; Beauchamp, L.  
CS Wellcome Research Labs., Tuckahoe, NY  
SO Journal of Organic Chemistry (1961), 26, 3809-12  
CODEN: JOCEAH; ISSN: 0022-3263  
DT Journal  
LA Unavailable  
OS CASREACT 56:46024  
IT 93256-72-5P, 7H-Pyrrolo[2,3-d]pyrimidine, 2-methyl-4-(2-thenylamino)-  
RL: PREP (Preparation)  
(preparation of)  
RN 93256-72-5 CAPLUS  
CN 7H-Pyrrolo[2,3-d]pyrimidine, 2-methyl-4-(2-thenylamino)- (7CI) (CA INDEX NAME)



10/720,600

L4 ANSWER 41 OF 41 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1960:44692 CAPLUS  
DN 54:44692  
OREF 54:8840e-i,8841a-i,8842a-e  
TI Pyrrolo[2,3-d]pyrimidines  
AU Davoll, J.  
CS Parke, Davis & Co., Ltd., Hounslow, UK  
SO Journal of the Chemical Society (1960) 131-8  
CODEN: JCSOA9; ISSN: 0368-1769  
DT Journal  
LA Unavailable  
OS CASREACT 54:44692  
IT 60972-05-6P, 7H-Pyrrolo[2,3-d]pyrimidine, 4-furfurylamino-  
RL: PREP (Preparation)  
(preparation of)  
RN 60972-05-6 CAPLUS  
CN 1H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(2-furanylmethyl)- (9CI) (CA INDEX  
NAME)



10/720,600

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

156.33

329.09

STN INTERNATIONAL LOGOFF AT 07:48:59 ON 04 MAR 2007